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Summary 
Apart from being the most common malignancy in women worldwide, breast cancer is 
also one of the most extensively investigated human cancers. The breast cancer 
susceptibility genes, BRCA1 and BRCA2 are responsible for less than 10% of breast 
cancer cases. However the genetic basis of the majority of breast cancer has not yet 
been identified. 
Since an acquired genetic instability resulting from the defects in DNA repair is known to 
promote tumorigenesis, a proportion of inherited breast cancers might be attributable to 
mutations in the genes involved in these functions. 
Homologous Recombination Repair (HRR) is an accurate and high fidelity repair 
mechanism, which is mainly responsible for repair of DNA double strand breaks (DSBs). 
There is considerable evidence to suggest that defects in DNA damage repair in particular 
in HRR contribute to breast cancer. 
In the present study we tested the effect of single nucleotide polymorphisms of HRR 
genes on breast cancer susceptibility. We screened a series of 522 breast cancer patients 
and 900 healthy controls for a panel of four polymorphic HRR genes. The rare allele of 
XRCC2 R188H was found to be associated with increased risk of breast cancer (odds 
ratio: 1.32, CI: 0.98,1.79). This allele was also shown to be more associated with lobular 
breast carcinoma (p=0.001). Furthermore there was preliminary evidence of interaction 
between XRCC2 R188H and XRCC3 T241 M, and also between XRCC3 T241 M and 
BRCA2 N372H alleles (both p=0.06). 
Four novel naturally occurring sequence variants of the XRCC3 DNA repair gene were 
also identified. We studied the effect of these sequence variants on the repair ability of the 
XRCC3 protein. A rare XRCC3 variant (D213N), was shown to completely ablate the 
protein function. The association of this variant with cancer susceptibility was studied in a 
group of 1524 patients with common cancer and 1577 healthy individuals. However, no 
association between this variant and cancer susceptibility was found, indicating that 
XRCC3 is unlikely to be a tumour suppressor gene. 
The results from the present study support the hypothesis that normally occurring 
variation in DNA repair genes can influence DNA repair capacity and cancer susceptibility 
in the population. 
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Chapter I. Introduction 
1 Introduction 
1.1 General concepts in cancer 
One of the most important discoveries in cancer biology during recent decades has been 
that tumours arise as a result of cumulative genetic changes in somatic cells. The 
progression of a tumour from normal cell to cancer and finally metastasis is the result of 
the clonal expansion of cells. This uncontrolled expansion may be the result of as little as 
three to seven successive mutations in genes that control cellular proliferation and cell 
death (Miller, 1980, Weinberg, 1989). As the mutation rate is typically less than 10-6 per 
each cell division, the likelihood of a single cell accumulating the requisite number of 
independent mutations to inactivate the cellular defences against tumourigenesis appears 
to be very low (Loeb, 1991). However, there are two general mechanisms that make the 
series of cancer-promoting mutations more likely. Mutations enhancing the cell proliferation 
rate increase the size of the target population of cells in which the next mutation may 
occur, and mutations affecting the stability of the genome increase the overall mutation 
rate (Antonarakis, et aL, 2002, Strachan and Reed, 1999). 
Pathogenic mutations usually occur in the genes controlling the cell cycle, apoptosis and 
genomic integrity. They can also influence proteins which are responsible for cell-to-cell 
contacts, or the factors needed for tumour expansion and invasion into nearby tissues. The 
changes involve alterations or mutations in specific oncogenes, and are generally divided 
into two major categories: those that activate proto-oncogenes, thus promoting cellular 
proliferation or inhibiting cell death; or those that inactivate tumour suppressor genes 
(TSG) whose normal function is to inhibit cell proliferation or promote cell death. 
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Non-mutational DNA alteration such as changes in DNA methylation or genomic imprinting 
may also alter gene expression and could, therefore, potentially be a mechanism that 
disrupts the function of tumour suppressor genes or increases the expression of proto- 
oncogenes. These are called epigenetic changes and defined as heritable alterations in 
gene function that are mediated by factors other than changes in the primary DNA 
sequence (Verma and Srivastava, 2002). 
1.2 Proto"oncogenes and tumour suppressor genes 
The normal activity of a proto-oncogene supports growth of cells, but a gain of function 
(e. g. amplification, point mutation, or transposition to an active chromosome domain) in a 
single allele may result in inappropriate or excessive activity (Park, 2002 and references 
therein). Tumour suppressor gene products, on the other hand, inhibit events leading 
towards cancerous behaviour. They are responsible for controlling the cell cycle 
progression and the induction of apoptosis and for maintaining genomic integrity by 
ensuring accurate replication, repair and segregation of the cell's DNA. Inactivation of both 
alleles of a TSG may leave some of these crucial regulatory functions uncontrolled, and 
thus provide the mutated cell with an overgrowth advantage (Fearon, 2002 and references 
therein). 
Tumour suppressor genes have been categorised into gatekeepers and caretakers. The 
"gatekeepers" refer to genes whose mutation or altered expression affect the normal 
controls of cell division, death or life span, promoting the uncontrolled proliferation of 
cancer cells while "caretakers" are genes whose mutation or disruption do not initiate a 
tumour directly but cause genome instability and increase the frequency of mutations in 
gatekeeper genes. Genes involved in DNA repair and genome integrity that are 
responsible for the fidelity of information transfer are classified in this latter group (Kinzler 
and Vogelstein, 1997). 
The germline alterations related to inherited cancer susceptibility are frequently found in 
tumour suppressor genes, and only on a few occasions such as multiple endocrine 
neoplasia type 1, hereditary papillary renal carcinoma and familial melanoma (e. g. RET, 
CDK4 and MET) have they been found in proto-oncogenes (Mulligan, et al., 1993, 
Schmidt, et al., 1997, Zuo, eta!., 1996). Conversely, cancer-associated somatic mutations 
are found in genes belonging to both categories. 
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1.3 The cell cycle 
The cell cycle is an ordered set of events, culminating in cell growth and division into two 
daughter cells. Cells need to replicate their genome and double their cell mass. This 
requires precise replication and segregation of chromosomes and equal distribution of 
other cell components. The cell cycle consists of several phases (figure 1). In the first 
phase (G1) the cell grows and becomes larger. When it has reached a certain size it enters 
the (S) phase, in which DNA-synthesis takes place. The cell duplicates its hereditary 
material (DNA-replication) and a copy of each chromosome is formed. During the next 
phase (G2) the cell checks that DNA-replication is completed before the cell cycle 
proceeds to the next step. During (M) phase the pairs of chromosomes are separated 
(mitosis) and the cell divides into two daughter cells. After division, the cells resume G1 
and the cell cycle is completed. In G1 checks of whether the previous cycle was error free 
take place before cells proceed to another division. For all living eukaryotic organisms it is 
essential that the different phases of the cell cycle are precisely coordinated. The phases 
must be followed in correct order, and one phase must be completed before the next 
phase can begin. Errors in this coordination may lead to chromosomal alterations, 
rearrangement or unequal distribution of genetic material between the two daughter cells. 
This type of chromosome alteration is often seen in cancer cells (Clurman and Roberts, 
2002). 
Figure 1: The cell cycle 
In the next sections the breast cancer environmental and genetic risk factors are explained, 
we then discuss the homologous recombination repair (HRR) pathway of double strand 
breaks and the evidence linking DNA repair and breast cancer susceptibility. 
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1.4 Breast Cancer 
1.4.1 Normal development of mammary glands 
The ductal system of the adult human breast consists of 15-25 lactiferous ducts opening at 
the nipple (figure 2). Lobule formation in the female breast occurs within 1-2 years after the 
onset of the first menstrual period. Full differentiation of the mammary gland is a gradual 
process, which takes years to complete. The breast of nulliparous women contains more 
undifferentiated structures while in pre-menopausal parous women the predominant 
structure is the most differentiated form. Full lobular differentiation only occurs in parous 
women, especially in those experiencing full term pregnancy at a young age. After 
menopause the breast undergoes regression in both nulliparous and parous women 
manifested as an increase in the undifferentiated structures. 
Lobular 
Lobule 
cells 
ý"d 1 Duct cells 
Duct 
Ducts 
Areola 
Lobules - Nipple 
Fatty connective tissue 
Figure 2: Schematic picture of terminal ductulobular unit of female breast. 
Each lobular unit opens into terminal ducts which form lactiferous ducts and subsequently open at the nipple. 
In breast cancer, mammary cells proliferate abnormally. The diagnosis of breast cancer is 
based on histological examination of breast tissue. Breast cancer may arise in the 
intermediate-sized ducts or terminal ducts and lobules. The cancer may either be invasive 
(infiltrating ductal carcinoma, infiltrating lobular carcinoma) or in situ. 
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1.4.2 In situ breast carcinoma 
In situ breast carcinoma (CIS) is a transitional phase in the evolution of invasive 
malignancy from normal breast tissue. There are two histological forms of CIS. Ductal 
carcinoma in situ (DCIS), also known as intraductal carcinoma or non-invasive ductal 
carcinoma, does not invade the surrounding stroma. Lobular carcinoma in situ (LCIS) is 
characterized by clusters of analplastic small cells of high nuclear grade that lie within the 
lobules (Frykberg, 1999). LCIS is considered as a pre-malignant stage with a substantially 
higher risk of subsequent development of carcinoma (Allred, et al., 2001). 
1.4.3 Invasive breast carcinoma 
Infiltrating (invasive) ductal carcinoma (IDC) of unspecified type is the most common type 
of breast cancer, accounting for nearly 75% of the cases (Berg and Hutter, 1995). It is 
characterized by stony hardness at palpation which microscopically shows invasion to 
surrounding stroma and fat. These tumours commonly metastasise to bone, lung, liver, and 
axillary lymph nodes and have a poor prognosis. Other rare types of ductal carcinoma 
include medullary, tubular, mucinous and papillary carcinoma, which have a lower 
incidence of nodal involvement and better prognosis. 
The second common type of breast cancer is infiltrating (invasive) lobular carcinoma (ILC) 
accounting for about 10% of breast tumours. It is characterized by ill-defined thickening in 
the breast, and is microscopically composed of small cells in a linear arrangement with a 
tendency to grow around ducts and lobules. ILC has the same probability to metastasise 
as IDC though invading preferentially to meninges, serosal surfaces, and retroperitoneum. 
Most undifferentiated structure in the breast has been found to be the site of origin of 
ductal carcinomas. Although differentiated lobular structures have been found to give rise 
to tumours but they are less aggressive (Russo, et al., 2000). 
1.4.4 Staging 
Tumour staging is used to assess the extent of the breast cancer. In the tumour node 
metastasis (TNM) staging system, the extent of the disease is determined based on clinical 
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and pathological assessment of the tumour, local lymph nodes and presence of distant 
metastasis. The status of tumour can be sub-classified according to the size of tumour 
from T; s (carcinoma in situ) to T4 where tumour size is more than 5 cm and has invaded the 
chest wall or skin. Lymph node involvement is also sub-classified from No (no regional 
lymph node involvement) to N3 (Ipsilateral internal mammary node involvement). Absence 
of metastasis is classified as Mo while distant metastasis is Mi (Sainsbury, et al., 2000). 
Based on this classification breast cancer is staged from I to IV, where stage I is a small 
locally invasive tumour without lymph node involvement, stage II is a small or medium- 
sized tumour with or without nodal metastases, stage III cancer is a locally advanced 
cancer, usually with axillary node metastases, and stage IV cancer has already 
metastasised to distant sites (Anderson, et al., 1996). 
1.4.5 Incidence 
Breast cancer is the most common cancer in women worldwide. Over one million new 
cases occur each year worldwide, comprising about 25 per cent of all female malignancies 
(Ferlay, et al., 2001). This proportion is higher in women in western, developed countries. 
The highest age-adjusted incidence rate is reported for North America, being 86.3 per 100 
000 women per year, while the lowest rate, reported in China, is only 11.8 (Parkin, 1998). 
In England and Wales, 33100 new breast cancer cases were registered in 1997 which 
account for almost 30 per cent of all cancers in women (National Statistics UK, 2000). One 
in 9 women will develop breast cancer at some time in their life in the UK. Breast cancer in 
men is rare with around 250 cases each year in the UK (National Statistics UK, 2000). In 
England and Wales, 11,574 women and 80 men died from breast cancer in 2001 (National 
Statistics UK, 2002), and in the UK, where the mortality is highest in the world, 17 per cent 
of all female cancer deaths was due to breast cancer by year 2000 (General Register 
Office for Northern Ireland, 2001, General Register Office for Scotland, 2001, National 
Statistics UK, 2001). 
The high rates of breast cancer incidence and mortality in industrialised, Western nations 
and lower rates for less industrialised and Asian nations are considered to mirror 
differences in factors important in the aetiology of the disease such as parity and hormonal, 
environmental and dietary exposures. 
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1.4.6 Classification 
The majority of breast cancer patients can be classified as sporadic cases, in which the 
individual is the only one in her family with breast cancer for two generations (Claus, et al., 
1991, Newman, et al., 1988). On the contrary, familial cases imply to individuals that have 
one or more first-degree relatives with breast cancer (Lynch, et al., 1994). Familial breast 
cancer is different from hereditary breast cancer in which family history suggests a highly 
penetrant major gene for breast cancer, characterized by early age of onset, high 
incidence of bilateral disease and association with other tumours (Claus, et al., 1991, 
Kelsey and Gammon, 1991, Newman, et al., 1998). 
1.4.7 Risk Factors 
Breast cancer is a complex, multifactorial disease involving interaction between genetic 
and non-genetic (environmental) factors for its development. Although the aetiology of 
breast cancer is not fully understood, several inherent and other factors can indicate an 
increased risk (Table 1). 
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Factor Increased/Decreased Risk 
Female gender 100 fold compared to males 
Age Double every 10 years until menopause 
Diet High intake of unsaturated fat increases the risk 
High intake of soy products decreases the risk 
Obesity Postmenopausal obesity (BMI >35 kg/m2) doubles the risk 
Alcohol consumption Daily use of alcohol increases the risk 
Family history of breast cancer A first degree relative with breast cancer 
before the age of 50 doubles the risk 
Cancer in other breast 3 to 5-fold cancer risk in contra lateral breast 
Previous atypical hyperplasia 4 to 5-fold risk 
Endometrial and ovarian cancer 1.5 to 2-fold risk 
Age at menarche Age below 12 years increases the risk 
Age at menopause Late age increases the risk 
Nulliparity Increases the risk 
Age at first full-term pregnancy High age at first delivery increases the risk 
Lactation Lactation over 24 months decreases the risk 
Oral contraceptives Current use of OCPs increases the risk, 
the risk disappears 10 years after cessation of OCPs 
Menopausal hormone use Over 5 years of use increases the risk, 
(HRT) Excess risk disappears 5 years after cessation of oestrogen. 
Adding progestin to oestrogen still increases the risk 
Geographical location Living in developed country increases risk 
Exposure to ionising radiation Abnormal exposure in female after age 10 increases risk by 3 fold 
Table 1: Environmental factors and their effect on risk of breast cancer. 
OCP: oral contraceptive pills; HRT: hormone replacement therapy; BMI: body mass index. Adopted 
from (Broeders and Verbeek, 1997, Colditz and Rosner, 2000, Collaborative Group on Hormonal 
Factors in Breast Cancer, 1996,1997, Lopez-Otin and Diamandis, 1998, Mettlin, 1992). 
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1.4.7.1 Age 
The incidence of breast cancer, as that of almost any cancer, increases with advancing 
age. Eighty per cent of cases occur in post-menopausal women. Breast cancer is 
extremely rare in women in their teens or early twenties and uncommon in women under 
35. After this age the risk begins to increase, rising sharply after the menopause. The 
estimated risk of developing it for each of the other age groups has been calculated as 
follows (Cancer research UK, 2001): 
U 
U 
LL- 
Age 
Figure 3: Frequency of breast cancer among women in the UK. 
Adopted from Cancer research UK, breast cancer fact sheet, 2001. 
1.4.7.2 Reproductive factors 
Recent studies have revealed the relationship between endogenous hormone levels and 
breast cancer risk (Dorgan, et al., 1997, Kabuto, et al., 2000, Key and Verkasalo, 1999). 
The serum levels of at least oestrone, oestradiol, oestriol, androstenedione, testosterone, 
dehydroepiandrostenone, progesterone, sex-hormone-binding globulin, and prolactin have 
been considered as important in this context (Bernstein and Ross, 1993). Lifetime 
exposure to endogenous sex hormones is determined by several variables including timing 
12 
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of menarche, age at first full term pregnancy, number of pregnancies, and age at 
menopause. These variables have therefore all been studied in relation to breast cancer 
risk (Feigelson and Henderson, 1996). 
The increased breast cancer risk associated with early age at menarche (<12 years) 
(Apter, et al., 1989, Bernstein and Ross, 1993, Henderson, et al., 1985, Kelsey, et al., 
1993), could probably be due to prolonged exposure of breast epithelium to estrogens and 
higher oestrogen levels for several years after menarche in women with early menarche 
(Apter, et al., 1989, Henderson, et al., 1985). Similarly, later age at menopause increases 
the number of ovulatory cycles, and may therefore lead to increased risk. For every one- 
year increase in the age at menopause, the risk of breast cancer increases by 
approximately three percent (Collaborative Group on Hormonal Factors in Breast Cancer, 
1996). 
Higher parity and early age at first birth have both been associated with decreased lifetime 
incidence of breast cancer (Chie, et al., 2000, Kelsey, 1993, Pathak, et al., 2000). Women 
having their first child before the age of 20 have about half of the risk compared to those 
having their first child after the age of 30. The mechanism of the protective effect of parity 
is not completely understood but it probably due to early full differentiation of mammary 
gland cells, making them less susceptible to carcinogenic transformations (Russo, et al., 
2000). Also prolonged lactation has been associated with decreased risk (Lipworth, et al., 
2000). Many of the above mentioned hormone related factors have recently been shown to 
be more strongly associated with oestrogen receptor (ER) and progesterone receptor (PR) 
positive than negative breast cancers (Enger, et al., 2000, Huang, et al., 2000). 
1.4.7.3 Body size 
Obesity has been related to both higher endogenous oestrogen levels and increased risk 
of breast cancer in postmenopausal women who have most of their circulating oestrogen 
derived from conversion of androgen to oestrogen in adipose tissue (Hunter and Willett, 
1993). Another theory suggests a more important role for the localisation of body fat 
measured as waist-to-hip ratio (Hall, et al., 2000, Mannisto, et al., 1996). 
13 
Chapter 1- Introduction 
1.4.7.4 Exogenous oestrogen 
Since sex hormones have become widely used by women, concern has been raised about 
their safety. It has not usually been possible to study the effects of single hormones; many 
are used either in combination or consecutively in the same patient. Therefore, risks are 
generally assessed in relation to the therapeutic goal of the treatment, i. e., oral 
contraception or hormone replacement therapy (HRT). 
The results from studies on the role of oral contraceptives in breast cancer have been 
controversial. However, a recent meta-analysis using data from 54 studies concluded that 
current use of oral contraceptives poses a slight (24%) increase in the risk, which 
disappears 10 years after the cessation of use (Collaborative Group on Hormonal Factors 
in Breast Cancer, 1996). The data from 51 studies indicated that risk of having breast 
cancer is slightly increased in women using HRT (Collaborative Group on Hormonal 
Factors in Breast Cancer, 1997). A 35% increase in the risk was seen for women who have 
used HRT for 5 years or longer, which is consistent with the effect of delay in the 
menopause. The increase in risk largely disappears 5 years after terminating the use of 
hormones. The combined oestrogen-progestin regimen is associated with greater 
increases in the risk than oestrogen alone (Schairer, et al., 2000). In some studies, breast 
cancer in women who have ever used HRT tend to be less advanced at diagnosis and 
biologically less aggressive than those in never users (Holli, et al., 1998). The overall 
mortality among HRT users has been shown to be lower but the benefit diminishes with 
longer duration of use (Grodstein, et al., 1997). 
1.4.7.5 Smoking 
The studies on smoking and breast cancer susceptibility have given rise to controversial 
results, and the risk has at its best been only weakly associated with cigarette smoking 
(Palmer and Rosenberg, 1993). However, statistically significant effects have been seen 
for early age at starting, and for heavy, current, and passive smoking (Wartenberg, et al., 
2000). 
14 
Chapter 1- Introduction 
1.4.7.6 Alcohol intake 
Alcohol has been described as being one of the most constant enhancers of breast cancer 
risk. In a recent analysis pooling six cohort studies, alcohol was shown to increase breast 
cancer risk linearly with alcohol consumption from 1 to 5 drinks/ day (Smith-Warner, et al., 
1998). However only a 15% increase in the risk was found in a study of alcoholic women 
(Kuper, et al., 2000). 
1.4.7.7 Diet 
The human diet contains a great variety of natural carcinogens and anticarcinogens 
(Sugimura, 2000). Many of these may act through the generation of oxygen radicals, which 
in turn may lead to DNA damage. Accordingly, a high intake of fat, especially 
polyunsaturated fatty acids, has been shown to increase breast cancer risk (Bartsch, et al., 
1999, Nair, et al., 1999). 
1.4.7.8 Ionising radiation 
Ionising radiation has been shown to markedly increase breast cancer risk among young 
women who already received mantle radiation for Hodgkin's lymphoma (Bhatia, et al., 
1996). Also high incidence of breast cancer is seen in atomic bomb survivors in Japan 
(Tokunaga, et al., 1994). It has also been shown that radiotherapy for an existing breast 
cancer increases the incidence of cancer in the contralateral breast (Boice, et al., 1992). 
1.4.7.9 Family history 
The most prominent and therefore one of the best studied risk factors is a family history of 
breast cancer. Over 130 years ago, French physician Paul Broca (1866) reported multiple 
cases of breast cancer in a family. Since then multiple epidemiological studies have shown 
positive association between breast cancer and family history. The risk conferred by having 
a relative with breast cancer varies according to the closeness of kinship, number of 
affected relatives and age at which the relatives affected (Claus, et al., 1990, Slattery and 
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Kerber, 1993). Having a first degree relative (mother, sister, and daughter) with breast 
cancer can increase a woman's risk of breast cancer by two fold. This risk is greater if the 
relative's age of breast cancer development is lower. Having more than one close relative 
with breast cancer is associated with even higher risk (Pharoah, et al., 1997 and 
references therein). Ovarian cancer is also frequent in relatives of familial breast cancer 
patients (Go, et al., 1983). Breast cancer families also show an early age of onset, 
increased incidence of bilateral disease, and, occasionally, the occurrence of male breast 
cancer. This familial clustering and also twin studies are suggestive of inherited 
susceptibility for familial cases (Peto and Mack, 2000). Hereditary breast cancer accounts 
for 5-10% of all cases of breast cancer (Broeders and Verbeek, 1997, Lynch, et al., 1994). 
First evidence for an autosomal dominant breast cancer susceptibility gene with age- 
related penetrance was provided in 1984 (Williams and Anderson, 1984). This hereditary 
trait has been shown in several different studies ever since (Go, et al., 1983, Iselius, et al., 
1992, Lindblom, et al., 1993, Newman, et al., 1988). 
Studies to find genetic basis of breast cancer resulted in isolation of the first breast cancer 
susceptibility gene BRCA1 in 1994 (Miki, et al., 1994) followed by identification of BRCA2 
in 1995 (Wooster, et al., 1995). Germline mutations in both BRCAI and BRCA2 genes 
confer an increased risk of breast and ovarian cancer; the risk is particularly high for 
BRCA1 mutation carriers. In families with multiple affected members, female BRCA1 or 
BRCA2 mutation carriers have an approximately 80% chance of developing breast or 
ovarian cancer by the age of 70 (Ford, et al., 1998). 
1.4.8 Predisposing genes 
1.4.8.1 BRCAI 
BRCA1 is a large gene located on chromosome 17g12-q21 (Hall, et al., 1990). With 22 
coding exons, it encodes a 220-kilodalton nuclear protein (Miki, et al., 1994). Exon 11 
constitutes more than 60% of the coding region (Miki, et al., 1994). Depending on the 
population under study, germline mutations in BRCA1 account for 15-45% of hereditary 
breast cancer cases, and 80% of families with both breast and/or ovarian cancers (Couch, 
et al., 1997, Easton, et al., 1993, Narod, et al., 1995). Female mutation carriers of BRCAI 
also have 60%-80% lifetime risk of developing breast cancer (Easton, et al., 1993, 
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Struewing, et al., 1996) and 20%-40% lifetime risk of developing ovarian cancer (Easton, et 
al., 1995, Struewing, et al., 1996). Some studies have reported variation in BRCA1 breast 
and ovarian cancer risks with mutation position, suggesting that mutations toward the 3' 
end of the gene are associated with lower ovarian cancer risks (Gayther, et al., 1995). The 
median age of diagnosis in BRCA1 mutation carriers is 42 years which is significantly lower 
than the median age for unselected western European and US women (Easton, et al., 
1994). 
1.4.8.2 BRCA2 
BRCA2 is located on chromosome 13q12-13 (Wooster, et al., 1994). It has 27 coding 
exons with exons 10 and 11 being the largest, and encodes a 384-kilodalton nuclear 
protein. Germline mutations of BRCA2 account for 37% of familial breast cancer. However, 
only 15% of breast and/or ovarian cancers are due to mutations in BRCA2 (Ford, et al., 
1998). There is evidence for an increased risk of several other cancers, including prostate 
cancer, pancreatic cancer, gall-bladder and bile-duct cancer, stomach cancer, and 
malignant melanoma in carriers of BRCA2 mutation (Breast Cancer Linkage Consortium, 
1999). A recent study has reported that 2.3% of early-onset prostate cancers are due to 
BRCA2 mutations (Edwards, et al., 2003). The lifetime breast cancer risk for carriers of 
BRCA2 mutation is 60%-85% (Easton, et al., 1997) and lifetime ovarian cancer risk is 10%- 
20% (Easton, et al., 1997, Ford, et al., 1998). It has been reported that families with a high 
proportion of ovarian cancers, relative to the frequency of breast cancer, tended to have 
mutations located within a 3.3-kb region in exon 11 (Gayther, et al., 1997, Thompson and 
Easton, 2001). Men with germline mutations in BRCA2 have 6% lifetime risk of developing 
breast cancer which is 100 fold greater than the baseline risk of the male population. 
1.4.8.3 Other Breast cancer susceptibility genes 
Although estimation from early studies was that familial early-onset female breast cancers 
could be due to mutations in BRCA1 and BRCA2 in 50% and 35% Of cases respectively, 
later studies confirmed that the breast cancer predisposition in a majority (67%) of families 
with less than six cases of female breast cancer and no ovarian cancer is not due to 
BRCA1 or BRCA2 mutations (Ford, et al., 1998, Huusko, et al., 1998, Rebbeck, et al., 
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1996, Schubert, et al., 1997, Serova, et al., 1997, Vehmanen, et al., 1997a, Vehmanen, et 
al., 1997b). In Britain, only 16% of the early-onset breast cancer patients are carriers of 
these mutations (Peto, et al., 1999). Additionally BRCAI and BRCA2 are not mutated in 
sporadic breast cancer cases. 
Germline mutations in the TP53, ATM, PTEN, STK1I/LKB1, and CHEK2 genes have been 
reported to predispose individuals to breast cancer (Boardman, et al., 1998, Lobaccaro, et 
al., 1993, Malkin, et al., 1990, Meijers-Heijboer, et al., 2002, Srivastava, et al., 1990, Swift, 
et al., 1987, Tsou, et al., 1997, Wooster, et al., 1992). However these cases are very rare 
and are usually part of a multi-cancer and/or developmental abnormality syndrome (lau, et 
al., 2001). Overall, mutation in these known susceptibility genes account for 15-25% of 
familial risk and less than 5% of all cases of breast cancer (Easton, 1999, Nathanson, et 
al., 2001). 
1.4.8.3.1 Ataxia telangiectasia mutant (ATM) 
Ataxia telangiectasia is an autosomal recessive disorder resulting from germline mutations 
in the ATM gene. It has a complex phenotype; cerebellar ataxia, neuromuscular 
degeneration, dilated ocular and facial small blood vessels (telangiectasia), 
immunodeficiency, chromosomal instability, and a substantially increased incidence of 
some cancers (Meyn, 1997, Morrell, et al., 1986, Savitsky, et al., 1995). Estimated 
frequency of the disorder is about 1 per 40,000-100,000 live births (Pippard, et al., 1988, 
Swift, et al., 1986). Lymphocytic leukaemia and non-Hodgkin's lymphoma (100% life time 
risk) appear to be the commonest forms of cancer, but solid tumours in various organs 
including breast and ovary are also associated with ataxia-telangiectasia (Hecht and 
Hecht, 1990, Meyn, 1997). Heterozygous carriers of ATM have 3-4 fold higher risk of 
developing breast cancer. Unaffected member of AT families have increased risk of breast 
cancer with increased risk varying from 1.5-9 (Nathanson and Weber, 2001). In one 
mutation analysis of 82 breast cancer patients with early onset disease (<45 years) who 
had been exposed to low dose radiation, increased rate of mutation was observed (Broeks, 
et al., 2000). However, several other mutation analysis studies show that there is no 
difference between frequency of mutation in young breast cancer patients (<40 years) and 
control group (Chen, et al., 1998, FitzGerald, et al., 1997, Izatt, et al., 1999, Shayeghi, et 
al., 1998). These data suggest that mutations of ATM gene have a small role in breast 
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cancer development with population attributable risk of only 1-2% (Nathanson and Weber, 
2001, Olsen, et al., 2001). It has recently been suggested that missense mutations of ATM 
may be implicated in breast cancer susceptibility. In agreement with this, an intronic ATM 
mutation has shown to have a dominant negative effect in the presence of a wild type copy 
of ATM (Chenevix-Trench, et al., 2002). 
1.4.8.3.2 TP53 
The most frequent point mutations in breast tumours are TP53 mutations, however TP53 
mutation occurs in only 20-40% of breast tumours (Greenblatt, et al., 1996, Ingvarsson, 
2001). Despite the high frequency of somatic mutation of TP53, germline mutations of this 
gene are rare in familial breast cancer and are only seen in Li-Fraumeni syndrome, a rare 
syndrome of familial clustering of brain tumour, sarcoma, childhood leukaemia, adrenal 
carcinoma and breast cancer. Penetrance of developing breast cancer is 50% by age of 30 
and 90% by age of 70 (Li, 1990, Malkin, et al., 1990). Approximately 50% of Li-Fraumeni 
families show mutations in TP53 gene (Brugieres, et al., 1993, Malkin, et al., 1992). A 
single nucleotide polymorphism in TP53 has also reported to slightly increase the risk of 
breast cancer (Dunning, et al., 1999). 
1.4.8.3.3 CHEK2 
Cell-cycle checkpoint kinase 2 (CHEK2) mediates the cellular response to DNA damage, 
leading to cell-cycle arrest at G1 (Chehab, et al., 2000). CHEK2 is phosphorylated by ATM 
in response to DNA damage, and phosphorylate p53 and BRCA1, which are involved in 
cell-cycle control, apoptosis, and DNA repair (Also see section 1.7.1 and Fig. 5). Germline 
mutations of CHEK2 genes have reported in Li- Fraumeni syndrome and variant LFS, a 
combination of multicancer phenotypes that fails to meet the stringent criteria for classic 
LFS (Bell, et al., 1999, Lee, et al., 2001, Vahteristo, et al., 2001). 
It has recently been found that the 1100deIC variant in CHEK2 which is carried by -1% of 
the population confers a 1.7-fold increased risk and thus acts as low penetrance breast 
cancer susceptibility gene (Meijers-Heijboer, et al., 2002, Vahteristo, et al., 2002). Two 
independent studies have reported a higher frequency of this mutation in non- 
BRCA1/BRCA2 familial breast cancer cases relative to healthy controls (Meijers-Heijboer, 
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et al., 2002, Vahteristo, et al., 2002). A recent study also reported presence of the 
1100deIC in 18% of families with hereditary breast and colorectal cancer which is 
significantly higher than the frequency of this mutation in families with only breast cancer 
cases (Meijers-Heijboer, et al., 2003). 
1.4.8.3.4 PTEN 
Mutations in phosphatase and tensin homolog (PTEN) are associated with a rare 
autosomal dominant disorder, Cowden syndrome which is responsible for hamartomas, 
adenomas and follicular carcinoma of thyroid, adenocarcinoma of gastrointestinal tract and 
20-50% increased in lifetime risk of breast cancer (reviewed in Arver, et al., 2000). PTEN 
mutations are absent or quite rare in sporadic or familial breast cancer without other 
components of Cowden syndrome and it is suggested that the role of this gene in 
development of breast cancer is quite small (Arver, et al., 2000). 
1.4.8.3.5 STKI11LKBI 
The STK11/LKB1, a tumour suppressor gene which is associated with most cases of 
Peutz-Jegher syndrome was identified after it was observed that chromosome 19p was 
missing in intestinal hamartoma (Hemminki, et al., 1997). Apart from gastrointestinal 
hamartomatous polyps, melanocytic spots of the lips, buccal mucosa and digits, this 
autosomal dominant syndrome is characterised by a 5-fold increased risk of early-onset 
breast cancer (Tomlinson and Houlston, 1997). No somatic or germline mutations of 
STK11/LKB1 have been found in breast cancer patients and the contribution of mutations 
of STK11/LKB1 to breast cancer is very small (Arver, et al., 2000). 
Since 75-85% of familial cases and 95% of breast cancer overall can not be explained by 
the above mentioned susceptibility genes, and family history still remains a strong 
predictive factor in patients with no detectable mutation in these genes (Claus, et al., 
1998), other unknown loci with different penetrances should be involved. Multiple 
approaches are now being used to identify these additional breast cancer susceptibility 
genes (Nathanson and Weber, 2001). In one model based on high-penetrance 
susceptibility loci like BRCA1 and BRCA2, genetic linkage studies are being performed on 
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families with multiple cases of breast cancer. Based on this model, it is proposed that at 
least one other major breast cancer susceptibility gene exist (Phelan, et al., 1996, Serova, 
et al., 1997). Positive linkage was observed at the chromosome region 8p12-p22 in two 
German breast cancer families (Seitz, et al., 1997), but was not confirmed in a larger study 
(Rahman, et al., 2000). In a study of Finnish, Swedish and Icelandic breast cancer families, 
another plausible breast cancer susceptibility locus at chromosome 13g21 was identified 
(Kainu, et al., 2000), however the finding was not confirmed by other studies (Du, et al., 
2002, Thompson, et al., 2002). As genetic linkage studies have had limited success in 
identifying new breast cancer susceptibility genes, another model has been proposed in 
which multiple common, low penetrance alleles confer the risk in the majority of the cases. 
1.4.8.4 Low penetrance candidate genes 
Low-penetrance genes are defined as sequence variants or polymorphisms that might be 
associated with a slightly elevated risk for breast cancer. However, due to their frequent 
occurrence, these alterations might confer a much higher attributable cancer risk in the 
general population than rare mutations in high-penetrance genes (Nathanson and Weber, 
2001). In table 2 some characteristics of high penetrance mutations are compared with low 
penetrance polymorphisms. 
Characteristic High penetrance mutations Low penetrance polymorphisms 
Gene frequency Uncommon Common (>1%) 
Penetrance High Low 
Relative risk High Low 
Population attributable risk Low High 
Role of environment Modest Essential 
Study setting Family Population 
Study type Linkage analysis Case-control study 
Table 2: Comparison of characteristics of high penetrance mutations and single nucleotide 
polymorphisms. 
Adapted from (Caporaso and Goldstein, 1995). 
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1.4.9 Single Nucleotide Polymorphisms (SNPs) 
The most common polymorphisms in the human genome are single base-pair variants, 
also called single nucleotide polymorphisms (SNPs) which constitute about 90% of human 
genetic variations (Collins, et al., 1998). A SNP is a stable substitution of a single base with 
a frequency of more than 1% in at least one population (Taylor, et al., 2001). More than 
2X106 SNPs have been identified so far (Marth, et al., 2001). The overall frequency of 
SNPs throughout the genome is estimated to be one in every 1-2 kilobase pairs 
(Sachidanandam, et al., 2001, Venter, et al., 2001). These variations in DNA sequence 
influence individual characteristics such as physical appearance, susceptibility to diseases 
and response to treatments. Based on the position of SNPs in the human genome they 
have been classified as those that occur within coding region of genes and those that fall in 
non-coding regions. Depending on whether a coding SNP leads to an amino-acid 
substitution or not, they are classified as non-synonymous (change in amino-acid) and 
synonymous (no change in amino-acid). The former group can also be sub-classified into 
non-conservative and conservative groups (Risch, 2000). Non-synonymous SNPs are 
potentially important because they lead to amino-acid changes which may have functional 
effects and phenotypic outcomes (Risch, 2000). It is estimated that 60000-250000 SNPs 
fall in the category of non-synonymous coding SNPs (Risch, 2000,2001). Non-coding 
SNPs are also separated into those occur in the 5' untranslated region (UTR), 3' 
untranslated region and other non-coding SNPs. A SNP in the 5' promoter region could 
alter the rate of transcription or it may increase or decrease gene expression either by 
affecting mRNA stability when occurring in a gene's 3' untranslated region. 
There are many less common single nucleotide variants that do not have sufficiently high 
frequency to meet the definition of a SNP; however they may have significant biological or 
clinical importance (Taylor, et al., 2001). 
Based on the biological plausibility, candidate low-penetrance genes are usually chosen 
from among the genes in which even a subtle change could have an effect on the 
biochemical pathways that influence carcinogenesis. For example, the genes involved in 
carcinogen and steroid hormone metabolism, cell cycle control, DNA damage recognition 
and repair, apoptosis and immune surveillance have been hypothesized as candidates for 
low-penetrance cancer susceptibility genes (Nathanson and Weber, 2001). Due to the rare 
appearance of low-penetrance alleles in cancer families, linkage analysis has low power to 
identify these genes (Houlston and Tomlinson, 2000). Either population-based association 
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studies or the evaluation of low-penetrance genes as modifiers of high-penetrance genes 
are currently the two most suitable approaches. 
1.4.10 The role of environmental factors 
Since 1775 when the first link was established between environmental exposures to coal 
tar and the development of scrotal cancer (Waldron, 1983), epidemiological studies have 
uncovered the essential role of environmental determinants in the development of cancer. 
However in many settings, tumours develop in only a fraction of the population exposed to 
an established human carcinogen. This could be due to inter-individual variations in genes 
whose products metabolise carcinogens or involve in repair of DNA damage. One subject 
may be10-200 times more sensitive than another (Venitt, 1994) and may therefore develop 
cancer, while others at the same level of exposure will not. Therefore carcinogenic risk of 
many exogenous or endogenous exposures may be modified by common genetic 
polymorphisms in different genetic pathways. On the other hand a genetic susceptibility 
gene may only be activated in the presence of a certain level of environmental exposure. 
Understanding how these low-penetrance genetic factors interact with the environment is 
of great importance in understanding tumour biology, determination of the population at 
risk and possibly in cancer prevention. 
1.4.11 Association Study 
Although a linkage analysis approach has been used successfully to map simple 
Mendelian diseases, it has not yielded consistent evidence for mapping complex disease 
genes. It has been suggested that linkage analysis may have less power for weak effect 
genes compared to case control studies (Risch and Merikangas, 1996). 
An association study or case-control study is the study of the genetic influences on a 
complex trait by generating hypotheses about candidate genes that might have a role in 
the aetiology of the disease. In this type of study the correlation between genetic variants 
and the trait is assessed on a population scale. Allele frequencies in cases (i. e., breast 
cancer patients) compared to of control, unaffected patients. However, a potential problem 
with case-control studies is population stratification, in which both disease risk and 
frequency of polymorphism/mutation vary among ethnic groups. Matching cases to controls 
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on ethnic background is one way of avoiding the problem of population stratification bias. 
However, determination of ethnicity is not always easy, particularly in a large-scale 
epidemiologic study. Another way to overcome the problem of population stratification is by 
using family based case-control studies. Two main forms of this study have been 
introduced; the case-parent study and case-sib study. The case-parent study compares the 
number of heterozygous parents who transmit one allele with the number of heterozygous 
parents who transmit the other allele to the affected offspring. In practice the use of this 
approach is limited to diseases that occur at young enough ages that parents of the cases 
are alive. In a Sib-case study the frequency of transmitted allele is compared between 
affected and non-affected siblings. The Sib-case study is used for diseases with variable 
age of onset for which parents of affected offspring are more likely not to be alive. Family- 
based case-control studies are valid on the assumption that parental alleles are transmitted 
with equal and independent probability in the population (Ewens and Spielman, 2001). 
1.5 DNA damage and carcinogenesis 
DNA is exposed to a variety of different damaging agents, which can be of either 
exogenous or endogenous origin. Wide range of damage to the DNA is the result of such 
exposures (Hoeijmakers, 2001a) which can subsequently disrupt the integrity of the 
genome. Monitoring these damages and maintaining integrity of the genes without 
significant alteration is an important function of a cell. In addition to efficient DNA repair, 
correct activation of cell cycle checkpoints is also of great importance for maintaining 
genome integrity. Normal cells can arrest the cell cycle following a damage occurs to DNA, 
whereas failure of cancerous cell to arrest their cell cycle because of defective checkpoints 
may allow replication of damaged DNA (Vogelstein and Kinzler, 1998). 
Deficiencies in DNA damage signalling and repair pathways are fundamental to the 
aetiology of most human cancers. Genomic instability, caused by a wide range of 
molecular and/or chromosomal alterations in neoplastic cells, is observed in most of 
human cancer (Cooper DN, in Genetic basis of human cancer, 1998) and is suggestive of 
sustained genetic damage in all cancer cells (Coleman and Tsongalis, 1999). 
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1.6 DNA repair in mammalian cells 
Several DNA repair pathways have been identified in mammalian cells (Fig. 4). These 
include Base excision repair (BER), Nucleotide excision repair (NER), Mismatch repair 
(MMR), Homologous recombination repair (HRR) and Non-homologous end-joining repair 
(NHEJ). On the whole, each of these repair pathways recognises and repairs one 
particular form of DNA damage, however they are overlapping in repairing DNA damages 
(Hoeijmakers, 2001b). The severity of DNA damage, or the context in which damage 
occurs (e. g. during DNA replication), will often dictate a repair strategy that places survival 
first and incurs genetic change (Friedberg, 1995). 
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Figure 4: DNA damage and repair pathways. 
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DNA-damaging agents (top), examples of DNA lesions (middle), and the relevant repair mechanisms 
(bottom). The essential genes involved in each DNA repair pathway have been shown below the 
corresponding titles. HR, homologous recombination; NHEJ nonhomologous end-joining; TCR, transcription- 
coupled repair; BER, base excision repair; MMR, mismatch repair. Adapted from Hoeijmakers (2001), 
(Khanna and Jackson, 2001), (Svejstrup, 2002). 
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1.7 Chromosomal instability disorders that predispose to cancer 
The consequences of loss of repair capacity are seen in a number of human syndromes 
and mutant cell lines (Table 3). These disorders show hypersensitivity to ionising radiation 
and some other environmental agents and often have multiple symptoms, including cancer 
proneness, neurological disorders, and immune dysfunction. 
Gene Defect Hereditary syndrome Cancer 
ATM DBS Ataxia telangiectasia Lymphoma, Leukaemia, Breast 
MREIIA DBS AT-like disorder Lymphoma 
NBS1 DBS Nijmegene breakage syndrome Lymphoma 
BRCAI HR Familial breast cancer 1 Breast, Ovarian, Prostate, Colon 
BRCA2 HR Familial breast cancer 2 Breast (female, male), Ovarian, Prostate, Pancreas 
RECQL2 HR Werner syndrome Sarcomas 
RECQL3 HR Bloom syndrome Common cancers 
RECQL4 HR Rothmund-Thomson syndrome Osteosarcoma 
CHEK1 CCC Not reported Colorectal and endometrial cancer 
CHEK2 CCC Li-Fraumeni syndrome Breast, Sarcoma, Brain, Leukaemia 
TP53 CCC Li-Fraumeni syndrome Breast, Sarcoma, Brain, Leukaemia 
MSH2 MMR HNPCC Colon, rectum, Endometrium, Ovarian, Urinary organs 
MLH1 MMR HNPCC Colon, rectum, Endometrium, Ovarian, Urinary organs 
XPA-XPG NER Xeroderma pigmentosum Skin 
RB CCC Familial retinoblastoma Retinoblastoma, Osteosarcoma 
P16 CCC Familial melanoma Melanoma, Pancreas 
Table 3: Genes involved in human chromosomal instability disorder with cancer predisposition. 
Abbreviations: CCC, cell cycle control; DSB, double-strand break repair, HR, homologous recombination 
repair, MMR, mismatch repair; NER, nucleotide excision break repair; NR, not reported; TCR, transcription 
coupled repair. Adapted from (Bartek and Lukas, 2001), Hoeijmakers (2001), Svejstrup JQ (2002). 
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1.7.1 Ataxia telangictasia (AT) 
Ataxia-telangiectasia is the best described of the radiosensitivity disorders. Cells derived 
from AT patients are hypersensitive to DSB-inducing agents (Gatti, 2001). Compared to 
normal cells, an elevated frequency of chromosomal aberrations is found both 
spontaneously and after irradiation of ataxia-telangiecasia cells that might be the result of 
deficiency in repair of DSBs by HR or NHEJ pathway (Jeggo, et al., 1998, Levitt and 
Hickson, 2002, Thompson and Schild, 2002). Chen, et a! (1999) also demonstrated that 
assembly of RAD51 foci in response to DSBs is defective in AT cells. A similar observation 
has been made by Morrison, et al (2000) in ATM-/- chicken DT40 cells. Another striking 
feature of ataxia-telangiectasia cells is that they fail to suppress DNA synthesis in response 
to ionising radiation (Painter, 1986). Several studies have also shown that ATM directly 
phosphorylates BRCA1 on several sites (Cortez, et al., 1999, Gatei, et al., 2000). BRCA1 
is also phosphorylated by CHEK2, which acts downstream to the ATM (Lee, et al., 2000). 
The activation of CHEK2 following induction of DSB is dependent on ATM (Matsuoka, et 
al., 2000). The NBS1 protein, which is a part of NBS11MRE111RAD50 complex in HRR 
pathway, is also phosphorylated by ATM on several sites in response to DSBs (Wu, et al., 
2000, also see section 1.7.1 and Fig. 5). Activated ATM phosphorylates p53 on Ser15. 
Together these phosphorylations will eventually lead to cell cycle arrest and activation of 
the cellular pathway for repair of DNA damage (Figure 5). 
1.7.2 Nijmegen breakage syndrome (NBS) and ataxia-telangiectasia like 
disorder (ATLD) 
Apart from AT, there are two other phenotypically very similar chromosome breakage 
syndromes. Germline mutations in MRE1IA give rise to an AT-like disorder (ATLD) 
(Stewart, et al., 1999), whereas defects in NBSI result in Nijmegen breakage syndrome 
(NBS) (Carney, et aL, 1998, Varon, et al., 1998). The clinical features of these two 
syndromes overlap, sharing the traits of cancer predisposition, immunodeficiency, 
hypersensitivity to radiation as well as chromosomal instability (Hoeijmakers, 2001b). 
Additionally, cells derived from affected individuals show very similar phenotypes which are 
also similar to that of ataxia-telangiectasia (Antoccia, et aL, 1997, Nove, et aL, 1986, 
Petrini, 2000, Taalman, et al., 1983). This can be explained by the interacting roles of 
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these three proteins in the DSB pathway and the S-phase checkpoint control. MRE11, 
RAD50 and NBS1 form a nuclear complex, which is found in post irradiation cells at sites 
of DSBs (Gamey, et at, 1998, Maser, et at, 1997) and is essential for normal cellular 
response to DSBs. ATM phosphorylates NBS1 on Ser343 in response to DNA damage, 
which is an event required for activation of NBS1/MRE111RAD50 complex (Zhao, et al., 
2000). 
DSB 
ýý 
i It 
Apoptosis Cell cycle arrest DNA repair 
Figure 5: A schematic representation of the DNA DSB signaling pathway. 
Modified from Khanna and Jackson (2001). 
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1.7.3 Bloom's syndrome, Werner syndrome and Rothmund-Thomson 
syndrome 
Other chromosomal instability disorders with cancer proneness are Bloom syndrome, 
Werner syndrome and Rothmund-Thomson syndrome. These syndromes result from 
mutations in RECQ helicase family of genes that unwind DNA (Mohaghegh, et al., 2001). 
Bloom syndrome results from a defective BLM gene and predisposes to a range of early 
onset cancers which are common in the population. Genetic instability is seen as high 
levels of spontaneously-occurring chromosomal aberrations and sister chromatid 
exchanges in cells of Bloom syndrome patients (Thompson and Schild, 2002); 
chromosomal sensitivity to X-rays has been found especially in cells in the G2 phase of 
growth (Aurias, etal., 1985, Kuhn, 1980). 
Werner syndrome is a premature aging syndrome. Frequency of sarcomas is high in 
Werner syndrome but other types of cancer including meningiomas, melanomas and 
thyroid cancer have also been reported (Thompson and Schild, 2002 and references 
therein). Werner patients cells show increased spontaneous genomic instability (van 
Brabant, et al., 2000) but not increased in number of sister chromatid exchange (Shen and 
Loeb, 2001). There are some evidence that show WRN protein is involved in both HR and 
NHEJ repair (Thompson and Schild, 2002and references therein). 
Osteogenic sarcoma is the most common type of cancer in Rothmund-Thomson 
syndrome. Cells of Rothmund-Thomson syndrome show increase genomic instability 
including trisomy and chromosomal rearrangements. RECQL4 gene is mutated in this 
syndrome. The product of this gene is possibly involved in both HR and NHEJ repair 
(Thompson and Schild, 2002 and references therein). 
1.7.4 Fanconi's anaemia 
Fanconi's anaemia is a cancer-prone disorder, most commonly presenting with acute 
myeloid leukaemia (15,000-fold increased risk), although solid tumours are also found. 
Fanconi's anaemia cells show high levels of chromosomal aberrations and are 
hypersensitive to DNA cross-linking agents. It is an autosomal recessive disorder resulting 
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from mutations in one of eight genes called FANC genes (Joenje and Patel, 2001). It has 
been recently shown one of these genes, FANCD1, is infact the BRCA2 (Howlett, et al., 
2002). Sequence analysis of BRCA2 in FANCD1 patients revealed two truncating BRCA2 
mutations. Carrying two mutations in BRCA2 has already been shown to cause embryonic 
lethality in mice (Connor, et al., 1997), however mice with mild (hypomorphic) mutations 
can survive to adulthood and show phenotypes such as small gonads, skeletal defects, 
and sensitivity to DNA cross linking-agents that can be seen in Fanconi's anaemia as well 
(Yu, et al., 2000). Therefore it has been proposed that hypomorphic BRCA2 mutations can 
cause Fanconi's anaemia. Studies have also shown that FANCD2 colocalise with BRCA1 
to focal sites after DNA damage (Garcia-Higuera, et al., 2001, reviewed in Thompson and 
Schild, 2002). Both FANCD2 and BRCA1 proteins are phosphorylated by ATM (Taniguchi, 
et al., 2002). 
Although these chromosomal instability disorders are rarely found in the population, 
studying the genetic basis of these disorders has established a link between DNA damage, 
genetic instability and cancer susceptibility. Most of mutant cells of the above-mentioned 
genes also show some degrees of cellular hypersensitivity to ionising radiation that can 
cause DNA double strand breaks and is a finding in cells from breast cancer patients as 
well. The link between cellular hypersensitivity to ionising radiation, DSBs and breast 
cancer is discussed in section 1.9 in more detail. 
1.8 Repairing Double strand breaks 
For the cell, double-strand breaks (DSB) are probably the most deleterious form of DNA 
damage because the genetic information in both strands of DNA molecules may be lost. 
DSB may arise from ionizing radiation (IR) such as X-rays, free radicals, chemicals, or 
during replication of single-strand breaks (SSB) (Khanna and Jackson, 2001). Because of 
the chromosomal fragmentation, translocations and deletions that can result from DSBs, 
repair of these lesions is important to prevent genome instability and the possibility of 
carcinogenesis (Kanaar, et at, 1998). The presence of unrepaired DSB is sensed by a 
DNA damage response system and results in pausing of the cell cycle. Depending on the 
severity of the damage, cells may either arrest the cell cycle until the damage is repaired, 
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or if the damage is irreparable, proceed to apoptosis. A single DSB is sufficient to kill a cell 
if it inactivates an essential gene or triggers apoptosis (Rich, eta!., 2000). 
There are two distinct and complementary mechanisms for DSB repair: homologous 
recombination (HR) and non-homologous end-joining (NHEJ) (Haber, 2000, Karran, 2000). 
When an intact DNA copy is available, HR can be carried out by using the homologous 
sequence from sister chromatid as a template to repair the damage. Otherwise, cells utilize 
the more error-prone NHEJ in which the two broken ends of DNA will be joined (See figure 
6). It was presumed until recently that HR was the main repair pathway in yeast and NHEJ 
repair was the most predominant DSBs repair pathway in mammals, but emerging 
evidence indicates that HR, has a major role in repair of DNA DSBs in mammalian cells as 
well (Haber, 2000, Liang, et al., 1998). 
It has been proposed that Ku70 protein acts as a switch between the two DSB pathways 
(Goedecke, et al., 1999). When present, Ku70 targets DSB for NHEJ by binding to DNA 
ends and attracting other factors, including MRE1 1. However, the absence of Ku70 allows 
participation of DNA ends together with MRE1 1 in the meiotic HR pathway. In HR, the DNA 
ends are first resected in the 5' to 3' direction by the exonuclease activity of the 
RAD50/MRE11/NBS1 complex (Paull and Gellert, 1998). Several proteins (Rad5l, Rad52, 
Rad54, Rpa, BRCA1, BRCA2, XRCC2, and XRCC3) facilitate the identification and correct 
positioning of the DNA end with the homologous sister chromatid sequence. The 3' single- 
stranded tails invade the DNA double helix of the intact molecule, which is used as a 
template for DNA polymerase to restore information lost at the site of break (See figure 6). 
Following branch migration and ligation, Holliday junctions are resolved by resolvases to 
yield two intact DNA molecules (Khanna and Jackson, 2001). This mechanism provides a 
high fidelity and accurate repair of DSB. In contrast, NHEJ does not require an undamaged 
template: here, the two DNA ends are simply attached together using the end-binding 
Ku70/80 complex and DNA-PKcs, followed by ligation by a DNA ligase IV/XRCC4 
heterodimer (Haber, 2000, Hoeijmakers, 2001b, Karran, 2000, Khanna and Jackson, 
2001). There are studies that show mutations in some of the genes involved in DSB 
detection and repair give rise to cancer or cancer-predisposing syndromes (Meijers- 
Heijboer, et al., 2002, Meyn, 1997, Venkitaraman, 2002). 
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Figure 6: Repair of double strand breaks. 
(A) double-strand break is rejoined end-to-end. (B) A double-strand break is repaired with the help of a 
homologous undamaged DNA (shown in orange). Strand invasion allows re-synthesis on complementary 
sequence, followed by a resolution of the strands and rejoining. 
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1.8.1 Genes involved in Homologous Recombination Repair 
1.8.1.1 Rad5l 
Our understanding of the genes involved in HR comes mainly from studies of bacteria and 
yeast. In bacteria, RecA is the key recombination protein which catalyses DNA strand 
exchange (Eggleston and West, 1996). In yeast and humans the homologues of RecA 
have been identified as Rad5l and HsRad51 which show more than 50% amino acid 
similarity with RecA. The human Rad5l gene product plays a central role in the process of 
homologous recombination. Rad5l has been shown to bind DNA and thereby unwind the 
double helix, an early step in the recombination process (Benson, et al., 1994). Rad5l 
forms filaments at site of DSBs and promotes search for homology, homologous pairing 
and strand transfer (Baumann, et al., 1996, Benson, eta!., 1994). Studies have shown that 
exposing cells to ionizing radiation and some other DNA damaging agents can induce the 
formation of subnuclear foci of Rad5l, the number and intensity of Rad5l nuclear foci are 
markedly increased by dose and duration of exposure to DNA damaging agents such as 
gamma irradiation (Haaf, et al., 1995). The formation of these foci are not a consequence 
of increased cellular level of Rad5l protein as its protein level remains unchanged before 
and after exposure to gamma irradiation (Bishop, eta!., 1998). The presence of Rad5l foci 
has also been shown in cells undergoing recombination during the S and G2 phases of 
meiosis (Bishop, 1994, Tashiro, et aL, 1996). These data suggests that Rad5l is part of 
homologous recombination repair pathway. 
The Rad5l gene in yeast is not essential for cell survival, but absence of Rad5l in 
vertebrates and mammals results in early embryonic lethality (Lim and Hasty, 1996, 
Tsuzuki, et al., 1996). Rad5l Knockout embryos arrest early in development but progress 
further if there is also a mutation in the gene encoding the tumour suppressor p53 (TP53), 
possibly because of a reduction in programmed cell death. This may suggest that Rad5l in 
mammals has functions in addition to recombination and repair, indicating a role in 
maintaining genome stability (Lim and Hasty, 1996). In another study deletion of Rad5l in 
a chicken cell line resulted in accumulation of cells in G2 and M stages of the cell cycle, 
and also accumulation of chromosomal breaks and early cell death, suggesting an 
important role for Rad5l during replication (Sonoda, et aL, 1998). 
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1.8.1.2 Other genes involved in HRR 
In addition to Rad5l, other proteins, including Rpa (Replication Protein A), Rad52, Rad54 
and five paralogues* of Rad5l are required for homologous pairing and strand exchange 
between homologous chromosomes. Rad5l paralogues are XRCC2, XRCC3, Rad51B 
(Rad5lLl), Rad51C (Rad5lL2) and Rad5lD (Rad5lL3). 
Rpa is a single stranded binding protein and is required for efficient DNA strand exchange. 
It has been suggested that Rpa acts by removing secondary structure from single stranded 
DNA and providing a platform for Rad5l to act at the damaged site. It promotes efficient 
formation of Rad5l nuclear filaments (Sugiyama, et aL, 1997). 
Rad52 also interacts with Rad5l, facilitates loading of Rad5l onto Rpa-bound single 
stranded DNA, and is required for the strand exchange activity of Rad5l (Benson, et al., 
1998, Park, et al., 1996). Deletion of Rad52 in mouse and chicken does not cause 
embryonic lethality and mutant cell lines do not show increased sensitivity to DNA 
damaging agents (Rijkers, eta!., 1998, Yamaguchi-lwai, eta!., 1998). 
Rad54 belongs to a family of DNA-dependent ATPases. It interacts with Rad5land 
facilitates the strand exchange activity of Rad5l in vitro. Homozygous deletion of Rad54 in 
mouse and chicken is tolerated, and results in increased cellular radiosensitivity and 
decreased homologous recombination (Bezzubova, et aL, 1997, Essers, eta!., 1997). 
1.8.1.3 Rad5l paralogues 
Rad5l paralogues (XRCC2, XRCC3, Rad51B, Rad51C, and Rad51D) share 20 to 30% 
sequence identity with Rad5l and to each other. The homology is mainly clustered around 
two ATP biding domains, Walker Boxes A and B (Liu, et al., 1998, Thacker, 1999, 
Thompson and Schild, 2001, Walker, et al., 1982). The XRCC2 and XRCC3 (X-Ray Repair 
Cross Complementing) genes were identified on the basis of their ability to complement the 
sensitivity of mutant Chinese hamster ovary cell lines, irsl and irslSF (Fuller and Painter, 
* Paralogues are genes that arose through duplication of an ancestral gene and acquired new functions 
(Thompson LH, 2001). 
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1988, Jones, et al., 1987), to ionizing radiation and some DNA damaging agents. Other 
members of Rad5l family, Rad51B, Rad51C, Rad51D were identified by searching 
sequence database for Rad51-like sequences (Albala, et aL, 1997, Dosanjh, et al., 1998, 
Pittman, eta!., 1998). 
Cells deficient in XRCC2 and XRCC3 (irsl and irslSF respectively) show 2-3 fold increase 
in sensitivity to ionising radiation and ultraviolet light and are extremely (60-100 fold) 
sensitive to the DNA cross linking agent Mitomycin-C (Jones, et al., 1987, Tebbs, et al., 
1995, Thacker, et al., 1995). These cell lines also show an increase in the number of 
spontaneous and radiation-induced chromosomal breaks compared to the wild type cell 
lines V79 (XRCC2 proficient) and AA8 (XRCC3 proficient) (Cui, et al., 1999, Fuller and 
Painter, 1988, Tebbs, et a!., 1995). The chromosomal instability of the deficient cell lines is 
complemented by transferring part of human chromosome 7 or 14 (containing XRCC2 and 
XRCC3 respectively) (Cui, et a1., 1999). Transfection of deficient cell lines with XRCC2 and 
XRCC3 cDNA showed similar results (Bishop, et al., 1998, Liu, et al., 1998, O'Regan, et 
al., 2001). Further studies showed that Rad5l focus formation after exposure to ionising 
radiation and DNA damaging agents is defective in irsl and irslSF cell lines and is 
rescued by expression of XRCC2 and XRCC3, suggestive of requirement of XRCC2 and 
XRCC3 for Rad5l function (Bishop, et al., 1998, O'Regan, et al., 2001). More importantly, 
irs1 and irslSF cell lines showed respectively 100 fold and 25 fold reductions in the level of 
homologous recombination (Johnson, et al., 1999, Pierce, et al., 1999). These findings 
suggest that the XRCC2 and XRCC3 genes are responsible for maintaining chromosome 
stability and are required for the repair of DNA breaks by homologous recombination (Cui, 
et aL, 1999, Liu, et al., 1998). 
Earlier studies suggested that XRCC3 interacts with Rad5l (Bishop, et a!., 1998, Liu, et al., 
1998) and also that Rad5l paralogues interact with each other in a single large complex 
(Schild, et al., 2000). However, recent findings indicate that at least two separate 
complexes exist, in which XRCC2 interacts with Rad51 B, Rad51 C and Rad51 D in one 
complex and XRCC3 interacts with Rad51 C in a separate complex. The interaction 
between XRCC3 and Rad5l could not be confirmed (Liu, et al., 2002, Masson, et al., 2001, 
Wiese, et al., 2002). 
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Targeted disruption of XRCC2 in mouse results in embryonic lethality from mid gestation 
onward. Knockout mice also exhibit developmental abnormalities and neurological defects 
if they survive to later stages of gestation (Deans, et al., 2000). Embryonic lethality has 
also been reported after disruption of Rad51 B and Rad51 D (Pittman and Schimenti, 2000, 
Shu, et al., 1999). These findings indicate that genes involved in HRR are crucial for early 
embryonic survival and development possibly because of their role in repairing DNA 
damage in proliferating cells of the embryo (Deans, et al., 2000). However, despite the 
importance of Rad5l paralogues, their precise function is not yet known, and it is thought 
that they act as accessory proteins for Rad5l filament assembly and recognition of DSB 
(Masson, et al., 2001). 
1.8.1.4 BRCA genes and HRR 
One of the most exciting recent findings has been the involvement of the products of breast 
cancer susceptibility genes in DNA repair. Cells deficient in BRCA1 or BRCA2 
spontaneously show a variety of chromosome aberrations (Moynahan, et aL, 2001a, 
Moynahan, et a!., 2001b, Patel, et al., 1998, Yu, et a!., 2000) indicating that BRCA genes 
are essential for maintaining chromosome structure (Venkitaraman, 2002). 
Both BRCAI and BRCA2 interact with Rad5l (Chen, et al., 1999, Mizuta, et a!., 1997, 
Scully, et a!., 1997, Sharan, et aL, 1997) and colocalise with Rad5l in Rad5l foci (Scully 
and Livingston, 2000) even in the S phase of untreated cells (Chen, et al., 1999). Cells 
deficient in BRCA1 and BRCA2 are also defective in Rad5l focus formation 
(Bhattacharyya, et a!., 2000, Huber, et al., 2001, Yu, et a!., 2000, Yuan, et al., 1999). A 
recent model suggest that BRCA2 works directly to regulate the availability and activity of 
RAD51 in binding to ssDNA which is important in homologous pairing and strand exchange 
(Venkitaraman, 2002). 
BRCA1 is phosphorylated by ATM which is primary sensor of radiation-induced DSB 
(Cortez, et a!., 1999). This phosphorylation suggests that BRCA1 could act as an 
intermediate factor between DNA damage recognition and repair (Thompson and Schild, 
2002). Additionally it is known that BRCA1 interacts with the MRE11/RAD50/NBS1 protein 
complex after exposure to ionising radiation (Zhong, et al., 1999). There is also some 
evidence that show homologous recombination is less efficient in BRCAI deficient cell 
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lines (Moynahan, et al., 1999). BRCA1 and BRCA2 deficiency result in early embryonic 
lethality (Connor, et al., 1997, Gowen, et al., 1996, Hakem, et al., 1996, Sharan, et al., 
1997) suggesting that they are required for normal cell proliferation during embryogenesis 
(Welcsh, et al., 2000). BRCA1 and BRCA2 deficient cell lines exhibit a mild sensitivity to 
ionising radiation and severe sensitivity to cross-liking agents (Bhattacharyya, et aL, 2000, 
Moynahan, et aL, 2001 a, Moynahan, et al., 2001b, Yu, et al., 2000). In human BRCA1 
deficient cells, increased sensitivity to cell killing by gamma rays and reduced repair of 
DNA double strand breaks can be partially corrected by the introduction of the normal 
gene, while mutant BRCA1 genes fail to restore these defects (Scully, et al., 1999). 
1.9 Breast cancer and DNA repair 
Although hereditary breast cancer only constitutes a small fraction of the total number of 
cases, study of genes mutated in hereditary cases may provide clues for genetic basis of 
sporadic breast cancer. As mentioned above, there are many reports that show genes 
which are involved in maintaining genome integrity are mutated in some cases of breast 
cancer and account for a proportion of hereditary cases. Below some other evidence that 
links breast cancer to defects in DNA repair capacity are discussed. 
1.9.1 Breast cancer is linked to ionizing radiation exposure 
Clearly, ionising radiation (a major cause of double strand breaks) is an important 
environmental risk factor for breast cancer. The evidence of the breast carcinogenic effect 
of radiation is supported by studies on Japanese atomic bomb survivors (Tokunaga, et al., 
1994). Other studies on women treated with radiotherapy for non-malignant conditions 
such as thymus enlargement and tuberculosis also showed increased rate of breast cancer 
(Hildreth, et al., 1989, Hrubec, et al., 1989). Using mantle irradiation for treatment of 
Hodgkin's lymphoma in girls has also been shown to increase the risk of developing breast 
cancer (Bhatia, et al., 1996). Furthermore there is some evidence that using radiation for 
treatment of existing breast cancer can increase the risk of cancer in contralateral breast 
by 3% (Boice, et al., 1992). 
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The idea that radiation-induced chromosomal breaks correlates with increased risk of 
breast cancer is also supported by animal studies. In one study, a significantly higher rate 
of radiation-induced mammary carcinoma was observed in BALB/c mice compared to 
C57BU6 mice. The difference was correlated with radiation-induced genomic instability in 
mammary tissue. After 16 population doublings, irradiated mammary cells from BALB/c 
mice showed significantly more chromatid breaks than C57BU6 mice (Ponnaiya, et al., 
1997). 
Studies have shown that spontaneous chromosome aberrations and sister chromatid 
exchanges, as markers of chromosomal instability, are statistically higher in cells of breast 
cancer patents and their healthy relatives compared to control individuals (Dhillon, et at, 
1995, Roy, of at, 2001). The correlation between chromosomal radiosensitivity and breast 
cancer has also been extensively studied. In a large study, 135 women with single breast 
cancer were compared to 105 controls with no history of breast cancer. The number of 
radiation-induced chromatid breaks in lymphocytes was significantly higher in the breast 
cancer group than the control group (Scott, et at, 1999). Three similar studies with 
relatively small numbers of breast cancer also reported an increase in median number of 
radiation-induced lymphocyte chromatid breaks in cases vs. controls (Helzlsouer, et al., 
1996, Parshad, et at, 1996, Patel, et at, 1997). Another study on bilateral breast cancer 
patients also showed that radiation induces a greater number of lymphocyte chromatid 
breaks in bilateral breast cancers compared to controls (Buchholz and Wu, 2001). 
1.9.2 Chromosomal radio-sensitivity in breast cancer patients is a genetic 
trait 
Further evidence that chromosomal radio-sensitivity is genetically controlled was provided 
by two studies. The first study reported that first-degree healthy relatives of breast cancer 
patients are 7 times more likely to have suboptimal DNA repair than the control group and 
their risk of developing breast cancer is 2.7 times higher (Patel, et al., 1997). Another study 
also showed that 62% of first-degree relatives of radiosensitive breast cancer patients were 
radiosensitive, compared to 7% in first-degree relatives of less sensitive breast cancer 
patients (Roberts, et at, 1999). The authors suggested that chromosomal radio-sensitivity 
is a marker for low penetrance predisposing genes in majority of breast cancer cases. 
They also suggested genes involved in processing of DNA damage (polymorphisms in 
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XRCC DNA repair genes) as candidate low penetrance genes (Roberts, eta!., 1999, Scott, 
et al., 1999). Reduced repair capacity of DNA repair among relatives of breast cancer 
patients (in comparison to the normal population) leads us to the conclusion that DNA 
repair capacity is a genetic trait (Helzlsouer, et aL, 1995, Helzlsouer, et al., 1996) and 
deficient DNA repair capacity may play an important role in the development of breast 
cancer. 
1.9.3 Mutations in some genes involved in genome stability predispose to 
breast cancer 
Mutations in TP53, a tumour suppressor gene whose role has been described as 'guardian 
of the genome' are associated with breast cancer in Li-Fraumeni syndrome (Faille, et al., 
1994, Malkin, et al., 1990). Also germline mutations in CHEK2, cell cycle checkpoint have 
found in Li-Fraumeni syndrome families with multiple breast cancer cases (Bell, et al., 
1999). Mutant alleles of ATM, a gene that is involved in signalling DNA damage also linked 
to breast cancer (Athma, et aL, 1996, Easton, 1994). Two major breast susceptibility genes 
BRCAI and BRCA2 have recently been shown to be involved in DNA repair. Specifically, 
both BRCA1 and BRCA2 co-localise with Rad5l following radiation-induced double strand 
breaks (Scully, et aL, 1997, Sharan, et aL, 1997). In addition BRCA1 has been shown to 
associate with Rad50-Mrel1-p95 in order to direct a cellular response to ionising radiation 
(Zhong, et al., 1999). Homozygous mutations of BRCA1, BRCA2 and ATM result in 
radiosensitive phenotype (Morimatsu, eta!., 1998, Sharan, et aL, 1997). 
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1.10 Outline of present study 
Despite active efforts, the existence of additional major high-penetrance cancer 
susceptibility genes with similar harmful effects, as has been observed for BRCA1 and 
BRCA2, remains questionable. As defects in DNA repair and cell cycle control are known 
to promote carcinogenesis, a proportion of inherited breast cancers might be attributable to 
mutations in the genes involved in these mechanisms. Cellular sensitivity of breast cancer 
patients to ionizing radiation (a known DNA damaging agent), susceptibility to breast 
cancer in chromosomal instability disorders such as Ataxia telangiectasia and participation 
of BRCAIand BRCA2 in repair of DNA damage by homologous recombination are some 
clues that suggest genes involved in processing and repair of DNA damage could play a 
role in genetic susceptibility to breast cancer. In particular single nucleotide polymorphisms 
of these genes that may have small effects on the function of the repair machinery are of 
interest. Therefore, we wanted to assess the role of single nucleotide polymorphisms of 
some of the central genes involved in the homologous recombination repair of double 
strand DNA damage in breast cancer. Furthermore, the tracking of genes important for 
tumorigenesis in sporadic disease might also open up new perspectives into familial breast 
cancer. 
Another interesting area in the study of single nucleotide polymorphism is whether 
sequence variance as small as a SNP could really decrease the DNA repair capacity? In 
this study we tried to answer this question as well. 
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2. Materials and Methods 
2.1. Subjects and controls 
Cancer patients and control individuals were recruited as follows: 
2.1.1. Patients 
Nine hundred and fifteen unrelated breast cancer patients were recruited from surgical 
outpatient clinics at the Royal Hallamshire Hospital, Sheffield, UK between November 1998 
and June 2001. 
Sixty seven paraffin-embedded breast tumour tissues from the above-mentioned unrelated 
breast cancer patients were also used for mutation detection. 
A total of 187 individuals from breast cancer families were recruited from Sweden. High 
risk breast cancer families denote families with history of breast cancer in at least three 15t 
degree relatives whereas low risk breast cancer families were defined as families with 2 or 
less 1St degree relative or history of breast cancer in their 2nd degree relatives. 
A total of 156 unrelated prostate cancer cases were recruited from urology clinics at the 
Royal Hallamshire Hospital, Sheffield, between 2001 and 2002. 
One hundred and thirty one unrelated colorectal cancer patients were recruited from those 
receiving surgery in Sheffield or neighbouring hospitals. 
Ninety eight unrelated bladder cancer cases were recruited from urology clinics at the 
Royal Hallamshire Hospital, Sheffield, between 1991 and 1996. 
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Thirty seven individuals from multi-case cancer families were recruited from regional 
oncology clinics at Weston Park Hospital, Sheffield. Multi-case cancer families address to 
families with history of a cancer in at least three Ist or 2nd degree relatives. 
The diagnosis of cancer was confirmed for all above-mentioned patients by histopathologic 
examination of their cancer tissues by a histopathologist. 
2.1.2. Controls 
Individuals for control groups were recruited from the healthy population as follows: 
Eight hundred and forty healthy women attending mammography screening in Sheffield 
Breast Screening Service were recruited between 2000 and 2002. Inclusion criteria for this 
group was limited those women whose mammogram showed no evidence of a breast 
lesion. 
Four hundred anonymous healthy women were recruited from amongst blood donors in 
Sheffield during 1996. 
Three hundred and thirty eight anonymous healthy men were also recruited from amongst 
blood donors in Sheffield. 
2.1.3. Ethical approval 
Ethical committee approval was obtained from South Sheffield Research Ethics Committee 
and informed written consent was obtained from all subjects (See appendix 1). 
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2.2. Materials 
2.2.1. General Laboratory equipment and reagents 
2.2.1.1. General Items 
All chemicals used in the preparation of buffers and solutions purchased from Sigma- 
Aldrich or BDH Merck unless otherwise stated. Solvents were purchased from Fisher 
Scientific Ltd. 
Deionised water for rinsing glassware was obtained by passing tap water through a 
reverse osmosis system. Water used for preparation of standard solutions and buffers was 
purified using Purite water system (Purite Ltd. ). 
Where required, solutions and equipment were sterilized by autoclaving at 20IbTnch2 for 20 
minutes before use (Boxer Laboratory Equipment). 
All glassware was washed in RBS 25TH general purpose surfactant (Medline Scientific 
Ltd. ), rinsed several times in tap water and finally in de-ionised water. It was then dried in a 
hot air oven at 80°C. Items requiring sterilisation were then autoclaved. 
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2.2.1.2. Plastic and disposable equipment 
Plastic and Disposable Items were purchased from the following suppliers: 
Item Supplier 
5ml plastic pipettes Corning Incoporated 
10 ml plastic pipettes Corning Incoporated 
100,20N1,200j1 and 1 ml pipette tips Sarstedt Ltd. 
Filtered 10AJ, 20Ad, 200N1 and 1mlpipette tips Starlab GMBH 
0.5ml, 1.5 ml and 2ml eppendorf tubes Sarstedt Ltd. 
15 ml centrifuge tubes Iwakai Ltd. 
6 well tissue culture plates Greiner Labortechnik 
25 Cm2 tissue culture flasks Nalge Nund Ltd 
75 Cm2 tissue culture flasks Nalge Nund Ltd 
100 mm tissue culture dishes Sarstedt Ltd. 
2ml, 5ml, 10ml Syringes Becton Dickinson & Company 
Sterile disposable Scalpels Swann - Morton 
96 well PCR plates Advance Biotechnologies Ltd. 
Thin walled PCR tubes Intermountain Scientific Corporation 
1.2ml Cryovials Nalgene Ltd. 
PCR flat cap strips Advance Biotechnologies Ltd. 
Syringe driven filter unit 0.22µm Millipore 
15ml Falcon@ 2059 polypropylene tubes Becton Dickinson 
Genepulser@ electroporation cuvette 0.4cm BioRad 
Centrifugal filter tube, 5000 NMWL Millipore 
Rehydration tray BioRad Laboratories Ltd. 
Table 1: Plastic and disposable equipment 
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2.2.1.3. General Laboratory Equipment 
General laboratory instruments and machinery was supplied by the following suppliers. 
Supplier 
Ice Machine Scotsman Ice System Ltd. 
P2, P10, P200 and P1000 Pipettes Finpipette 
P10 and P50 Multi channel Pipettes Status 
Electric Pipette Jencons Scientific Ltd. 
Coe Incubator Sanyo, Gallenkamp plc. 
Sterile containment II safety cabinet Walker Safety Cabinet Ltd. 
Hereaus Centrifuge Sanyo 
UV spectrophotometer Eppendorf 
PCR machines MWG 
TaqMan Analyser Applied Biosystems 
Water bath Grant Instruments Ltd. 
Vortex Scientific Industries Inc. 
Heating block Grant Instruments Ltd. 
Light Microscope Olympus 
Power Pac Bio-Rad Laboratories Ltd. 
Wet blotter Bio-Rad Laboratories Ltd. 
SSCP tank Bio-Rad Laboratories Ltd. 
Mini horizontal electrophoresis tank Bio-Rad Laboratories Ltd. 
Vertical electrophoresis tank-Mini Protean II Bio-Rad Laboratories Ltd. 
Midi horizontal electrophoresis tank Hybrid Ltd. 
UV Transilluminator UVP Inc. 
800W Microwave Panasonic 
Hotplate Magnetic Stirrer Chemlab 
PH meter Denever Instruments 
Electroporator Bio-Rad Laboratories Ltd. 
Orbital incubator Gallenkamp 
Orbital shaker Stuart Scientific 
ABI 7200 sequence detector Applied Biosystems 
ABI 377 sequencer Applied Biosystems 
Balance Toledo 
Protean II XL vertical electrophoresis tank BioRad Laboratories Ltd. 
Protean IEF system 
For 2-D with immobilized pH gradients 
BioRad Laboratories Ltd. 
Table 2: General laboratory equipment 
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2.2.1.4. Miscellaneous disposable laboratory equipment 
Para film -M' laboratory film 
Aluminium foil 
Paper tissue 
Autoclave tape 
Latex examination gloves 
American National Can Ltd. 
Terinex Ltd. 
Kimberly-Clark Corporation 
Rexam Medical Packaging 
Ansell Medical 
Table 3: Miscellaneous disposable laboratory equipment 
2.2.1.5. Cell Lines 
Cell Line Origin Growth Medium 
Irs1 SF Chinese Hamster Ovary DMEM 
AA8 Chinese Hamster Ovary DMEM 
SW480 Human Colorectal Carcinoma DMEM 
LM217E Human skin fibroblast DMEM 
Table 4: Cell line used for cell culture studies 
AA8 and irsl SF cell lines were kind gifts of Dr. Larry Thomson and SW480 was purchased 
from ATCC (American Type Culture Collection). LM217E was kind gift of Dr, John 
Murnane. 
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2.3. Methods 
2.3.1. DNA extraction 
2.3.1.1. Extracting DNA from whole blood 
"Solution A: 0.3M Sucrose, 7mM Tris base, 5mM MgCl2 7H20,1% Triton X-100, pH: 8.0 
autoclaved and stored at room temperature. 
"Solution B: 0.3 M Tris base, 76mM EDTA, 0.15M NaCl, 100 ml 10% SDS in 1 final volume of 
litre, pH: 8.0, autoclaved and stored at room temperature. 
10-20mis of frozen blood samples (in EDTA blood tubes), were thawed on ice and 
transferred to 50 ml Falcon tubes. The volume was made up to 45 ml with 1X solution A, 
gently mixed by inversion. The tubes were centrifuged (Hereaus) at 2000X g for 20 
minutes with the centrifuge set at 4°C. The supernatant was carefully removed, leaving 
behind approximately 10 ml of diluted blood containing nuclei, cell walls, etc. A further 40 
ml of 1X solution A was added to the tube, the contents mixed gently, and again 
centrifuged at 2000X g. After centrifugation the supernatant was completely removed, care 
being taken not to disturb the cellular pellet. Two ml of blood solution B was added to the 
pellet, and the pellet was disrupted by aspiration with a pipette several times. The 
resuspended pellet was transferred to a 15ml falcon tube, 500 ýtl of 5M sodium perchlorate 
was added and the lysates were mixed on a rotary wheel for 10 minutes at room 
temperature. The samples were then incubated at 65°C for 25 minutes in a water bath with 
occasional inversion. Two ml of cold chloroform (-20°C) was added to each tube and the 
samples were then mixed for 10 minutes on a rotary wheel at room temperature. The 
samples were then centrifuged at 2000X g in a bench-top centrifuge for 5 minutes. The 
aqueous phase (containing DNA) was transferred to new 15ml Falcon tubes, care being 
taken not to disturb the interface containing denatured proteins. Twice volume of cold (- 
20°C) absolute ethanol was added and the tubes were inverted gently to precipitate the 
DNA. The DNA was recovered by spooling on a sterile pipette. The DNA pellets were air 
dried and the DNA then resuspended in 500 µl of sterile water and left at 4°C overnight to 
dissolve. All samples were quantified by UV spectrophotometery at 260nm. 
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2.3.1.2. Extracting DNA from Paraffin-embedded tissue 
Paraffin embedded breast tumour tissues were cut into 5 micron sections on a Reichert 
Jung 2035 rotary microtome using a fresh sterile blades and transferred into 2 ml 
eppendorf tubes. To remove the paraffin from tissue samples, 1.2 ml of xylene was added 
to each tube and vortexed vigorously. Samples were centrifuged at 8000X g for 5 minutes. 
The supernatant was removed and 1.2 ml of 96% ethanol was added to the pellet and 
mixed to remove the residual xylene. Samples were centrifuged at 8000X g for 5 minutes 
again and the ethanol was removed carefully by pipetting. Another 1.2 ml of 96% ethanol 
was added, mixed and centrifuged for 5 minutes again to ensure removal of traces of 
xylene. The ethanol was removed and the tubes were incubated at 37°C for 10-15 minutes 
until the ethanol had evaporated. The breast tissues prepared by this procedure were 
used for DNA extraction by QlAamp® DNA Mini Kit (QIAGEN). In this procedure the tissue 
was resuspended in a lysis buffer containing Proteinase K and incubated at 56°C in a 
shaking incubator (Stuart Scientific) overnight until the tissue was completely lysed. The 
rest of DNA extraction procedure involved binding of DNA onto a silica-gel-membrane and 
several washing steps to wash away protein and other contaminants. The DNA was eluted 
with an elution buffer. All DNA samples were quantified and kept at -20°C until use. 
2.3.2. DNA quantification 
In order to quantify extracted DNA, 1 pi of DNA sample was mixed with 99pl sterile 
deionised water and mixed thoroughly. The concentration of the double strands (ds) DNA 
was determined using a UV spectrophotometer (Eppendorf) by measuring the absorbance 
of UV light at 26OnM. An optical density of 1.0 was assumed to correspond to 50Ng/NI 
DNA. 
2.3.3. Polymerase Chain Reaction (PCR) 
200 final reaction volume using 1.1X PCR mastermix (ABgene) contains: 
1.25 units Taq DNA polymerase, 75mM Tris-HCI (pH: 8.8), 20mM Ammonium Sulphate, 1.5mM 
Magnesium Chloride, 0.01 % (v/v) Tween 20,0.2mM each of dATP, dCPT, dGTP and dTTP. 
All PCR reactions were prepared in a sterile cabinet in a dedicated area kept solely for that 
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purpose. Sample cross-contamination was avoided by using filter tips and sterilising the 
set-up area between users by ultra-violet irradiation. For PCR, Aliquots of 18µI of 1.1X 
PCR master mix (Abgene) were added to aliquots of 1µl of genomic DNA (100 ng) and 6- 
10* pmol of each forward and reverse primer. A negative control was always included, 
using 1 ELI ddH2O in place of the template DNA to detect any possible contamination of 
reaction components. Reactions were overlaid with 20µI of mineral oil. Charged PCR 
tubes were then cycled in a DNA thermocycler (MWG) for 40 cycles, following an initial 
denaturing step of 3 minutes at 95°C. Each cycle consisted of 35 seconds at 95°C, 25 
seconds at 52-61°C* and 25 seconds at 72°C. A final extension step of 72°C for 10 
minutes was included to allow complete extension of the PCR product. 
2.3.4. Agarose gel electrophoresis 
"Agarose: Low melting temperature agarose was purchased from BioWhittaker Molecular 
Applications and used for agarose gel electrophoresis. 
"1X TAE: 30mM Tris base, 20mM glacial acetic acid and 2 ml 0.5M EDTA in 1 litre of water 
(pH: 8.0). 
*Loading dye: 0.25% Bromophenol blue, 0.25% xylene cyanol and 30% glycerol in water. 
"Ethidium Bromide: Tablets of Ethidium bromide were supplied by Sigma. One tablet (100mg) 
was dissolved in 40ml of ddH2O in a dark bottle and kept at room temperature. 
"100bp Molecular Weight Marker was supplied by Life Technologies Ltd and stored at 4°C until 
use. 
Low melting agarose gel was dissolved in 1X TAE at a concentration of 1.5% in a 
microwave oven (Panasonic) until the solution was clear. The solution was allowed to cool 
to about 55°C, and then ethidium bromide was added to 0.025 µg/ml. The solution was 
poured onto a pre-prepared electrophoresis tray (BioRad) containing desired combs and 
allowed to set at room temperature. The comb was removed and the gel was transferred 
into an electrophoresis tank (BioRad) containing 1X TAE running buffer and the same 
concentration of ethidium bromide as the gel. DNA samples were mixed with loading dye 
and then loaded into the wells. Electrophoresis was performed at 70-100 volts for 30-60 
minutes depending on the gel size. The electrophoresis was carried out at room 
* Vary between different experiments, see relevant section. 
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temperature until the tracking dye was approximately 3/4 the way across the gel. The gel 
was removed from electrophoresis tank and bands were visualized on UV- Transilluminator 
(UVP Inc. ). The sizes of DNA fragments were estimated by comparison to 100bp DNA size 
marker (Gibco BRL) run on the same gel. 
2.3.5. Genotyping techniques 
2.3.5.1. PCR- Single Stranded Conformation Polymorphism for XRCC3 
"SSCP loading dye: 95% deionised formamide, 0.05% Bromophenol blue, 0.05% xylene cyanol 
and 0.1% NaOH. 
"Acrylamide was purchased as 30% acrylogel solution from BDH Merck and kept at 4°C until 
use. 
"1X TBE: 70mM Tris base, 80mM Boric acid and 5 ml of 0.5M EDTA in 1 litre water (pH: 8.0). 
"Ammonium per sulphate (APS) was prepared fresh at 0.25% concentration each time and kept 
at 4°C. 
*Fixer solution: 10% absolute ethanol and 0.5% acetic acid in ddH2O, used for fixing gels. 
*Silver nitrate was purchased from BDH Merck. To make a working concentration, 1g silver 
nitrate was dissolved in 1 litre of ddH2O in a dark bottle, kept in room temperature and used for 
silver staining of 6-8 gels. 
*Developer solution: 1.5% Sodium hydroxide and 0.75 ml of 37% formaldehyde. 
*Sodium bicarbonate prepared at 0.75% concentration in ddH2O and used for final fixation of 
gels after silver staining. 
PCR-SSCP was used to screen for XRCC3 exon 7 polymorphism, essentially as described 
by Orieta et al (1989) and explained in section 2.4.2. PCR was carried out as described in 
section 2.3.3. For SSCP, 1 µl of aliquot of the PCR product was withdrawn and diluted with 
10µI of loading dye. The diluted PCR products were denatured by heating to 95°C for 5 
minutes, then rapidly cooled on ice, and 8µI of the product was then loaded in each well of 
an SSCP gel (12% acrylamide, 0.5X TBE, 160µI 0.25% fresh Ammonium Per Sulphate, 
and 50µI TEMED). Samples were electrophoresed for 3000 volt/hours overnight at room 
temperature in 1X TBE running buffer. Constant temperature was maintained using 
circulation of tap water. After electrophoreses, gels were transferred to a plastic container 
and fixed by shaking in fixer solution for 15 minutes. Gels were then washed with water 
and placed in 0.1% silver nitrate solution on a shaker for 20 minutes, washed with water 
twice and then placed in developer solution on a shaker for 25-35 minutes until the bands 
were visible. Gels were then placed in 0.75% sodium bicarbonate for 5 minutes and then 
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transferred into plastic bags, sealed and photographed. 
2.3.5.2. Restriction Fragment Length Polymorphism (RFLP) analysis of the D213N 
variant 
Genomic DNA was amplified for XRCC3 exon 7 using primers and conditions which were 
described in section 2.3.3. The restriction digest was carried out by mixing 7pl of PCR 
product with 1 pl of Bovine Serum Albumin, 1 pi Buffer and 10 units Hin tI (Promega) 
overlaid under 20pl of mineral oil. The Mixture was then incubated at 37°C for 2 hours. Gel 
electrophoresis was carried out by loading 10pl of the digested PCR product onto a 1.5% 
agarose gel. 
2.3.5.3. Fluorescent 5' exonuclease assay (TagManTM) 
The mechanism of 5' exonuclease assay has been explained in section 2.4.3. All probes 
and primers for TagManTm genotyping were designed using Primer Express software 
v. 1.5 (Applied Biosystems) according to the manufacturer's protocol. Using a constant 
concentration of FAM probe and different concentrations of TET probe, the emission of 
FAM and TET was measured by use of the Sequence detector 7200 (Applied Biosystems) 
and the concentration of FAM and TET probes at which the same amount of fluorescence 
is emitted by each probe was calculated. The required concentration of the primers was 
also optimised in a similar fashion by using a constant concentration of the forward primer 
and different concentrations of the reverse primer. To find the samples which are used as 
controls a total of 48 random samples were selected. Using the optimised concentration of 
probes, primers and PCR mastermix a PCR reaction was set. The samples were amplified 
and analysed by the Sequence detector 7200 under allelic discrimination mode. Once 
samples with different genotypes (wild type, heterozygous, homozygous) were identified, 
they used in the following TaqMan screening of the same SNP as controls. The first 24 
wells of each 96 well plates were used as controls in which no template DNA and samples 
with wild type, heterozygous and homozygous genotypes were loaded (6 wells per each 
control). PCR amplification was performed using 12.5pl of 2X PCR master mix (Applied 
Biosystems or Eurogentec), 20ng genomic DNA template, 50-300nM forward and 300- 
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900nM reverse primers, 25-5OnM FAM-labelled probe and 50-150nM TET-labelled probe 
in a final volume of 25pl. The cycling conditions were 50°C for 2 minutes, 95°C for 10 
minutes, followed by 40 cycles of 95°C for 15 seconds and 61-63°C for 1 minute. 
2.3.6. Sequencing 
2.3.6.1. Preparation of PCR product for sequencing 
All samples for sequencing were PCR amplified in a 5Opl reaction. The PCR reaction was 
checked by running out a5 pi aliquot of the reaction product on a 2% agarose gel. After 
confirming that the reaction had worked and verifying the product was at the correct size, 
the remaining 45pl of PCR product was loaded onto a 1.5% agarose gel and 
electrophoresed at 50 volts for one hour at room temperature. The correct bands were 
visualised on UV- transilluminator, excised using a sterile scalpel blade, weighed and put in 
1.5 ml eppendorf tubes. The DNA was extracted from the agarose gel using a Qiagen gel 
extraction kit according to the manufacturer's instructions. This involves melting the 
agarose gel, binding the amplified DNA product onto a silica matrix, washing off 
unincorporated primers, partially amplified products and other reagents, and then finally 
eluting the purified product into sterile water. All samples were then stored at 4°C until use. 
2.3.6.2. Sequencing reaction 
Samples of amplified genomic DNA which were extracted and purified as above were used 
for preparing the sequencing reaction with the SequiTherm EXCELTM ii DNA Sequencing 
Kit (Epicentre Technologies) as described originally by Steffens et al (1995). Reagents in 
the kit were gently thawed on ice and vortexed prior to use. All steps were performed on 
ice. First 7.2µI of 3.5x SequiTherm EXCEL TM Ii sequencing buffer was mixed with 1-2 
pmoles of each labelled primers and 1µl of sample DNA (100ng/ tl). The reaction volume 
was adjusted to 16µI with deionized H2O and then 1µl of SequiTherm EXCELTM II DNA 
polymerase was added. The reaction was mixed well by pipetting, and 4µI of the reaction 
mix was added to each well containing 2µI of termination mixes (A, C, G and T). The 
reactions were mixed well, overlaid with 30µI of mineral oil and amplified using a DNA 
56 
Chapter 2- Materials and Methods 
thermocycler (MWG) for 35 cycles at: 30 seconds of 95°C, 15 seconds at 50°C and I 
minute at 70°C. The samples were then mixed with 3pI of loading buffer included in the 
SequiTherm EXCELTMII DNA Sequencing Kit-LC (Epicentre Technologies) and denatured 
at 96 °C for 3 minutes prior to electrophoresis, which was performed with the Li-Cor IR2 
4200-S DNA Analysis system (Li-Cor Inc. ). Of each sample, an aliquot of 0.5-1 pI was 
loaded on to a 6% Long Range gel by Dr Ian Brock (Institute for Cancer Studies) and run 
at 1500 V for 7-9 hours, depending of the length of the analyzed fragment. The data were 
analyzed using the AlignlRTM and BaselmagIRTM softwares (Li-Cor Inc. ). Sequences were 
analysed using the Sequencher software 4.1 (Gene code corporation). 
2.3.7. Extracting RNA from mammalian cells 
XRCC3 RNA was extracted from LM217E cell line using the RNeasy kit (QIAGEN) 
according to the manufacturer instructions. The extraction is based on binding of total RNA 
to a silica-gel-based membrane and washing steps to wash away cell debris and other 
molecules followed by elution of total RNA with an elution buffer. DNase treatment of the 
extracted RNA was performed to ensure that any residual amounts of DNA were removed. 
Using the RNase-Free DNase (Promega), 8pI of extracted RNA was mixed with 1 pi of 1 OX 
reaction buffer and 1 NI of RNase-Free DNase and incubated at 37°C for 30 minutes. Then 
1 NI of DNase stop solution was added and the reaction incubated at 65°C for 10 minutes 
to inactivate the DNase and terminate the reaction. 
2.3.8. RT"PCR 
RT- PCR was performed using 12.5pi of 2X PCR master mix ( ABgene), 10 pmol of each 
forward and reverse primers designed from human XRCC3 cDNA (See chapter 4, Table 
1), 2pI of extracted RNA, 0.5NI of reverse transcriptase (AB gene) and 8NI water in total 
volume of 25pl. The amplification conditions consisted of 30 minutes of incubation at 47°C 
followed by 2 minutes at 94°C and 40 cycles of 35 sec at 95°C, 35 sec at 57°C and one 
minute at 72°C. A final step of 10 minute at 72°C was also applied as final extension. A 
negative control (excluding reverse transcriptase) was used for each sample to determine 
whether any PCR products originated from contaminating DNA. A 5pl of the amplified 
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product was loaded on a 1.5% agarose gel and the band was compared to the DNA size 
marker to ensure that the right size product has been amplified. 
2.3.9. Cloning of the XRCC3 cDNA 
"PCR2.1-TOPO kit and pcDNA3.11V5-His© TOPO® TA Expression kit were purchased from 
Invitrogen and were used for cloning XRCC3 exon 7 and XRCC3 cDNA respectively. They 
contained SOC medium, competent cells and sequencing primers as well as plasmids and salt 
solution. 
"Luria- Bertani (LB) medium was made by dissolving 25g of LB broth (Merck) in 1 litre of water. 
pH was adjusted to 7 with 5N NaOH. The medium was autoclaved at 15lb/inch2 for 20 minutes 
and kept at room temperature. 
"LB agar was made by dissolving 25g of LB broth in 1 litre of water. 15g agar was added and 
dissolved before autoclaving. 
Cloning of human XRCC3 cDNA was performed using pcDNA3.1/V5-HisIO TOP06 TA 
Expression kit (Invitrogen, See section 2.4.5). Human XRCC3 cDNA was amplified by RT- 
PCR as described in sections 2.3.7 and 2.3.8. The cloning reaction was prepared using 
3µI of fresh PCR product, 1ttl salt solution (1.2M NaCl; 0.06 M MgCI2) and 1µI of TOPO® 
vector in final volume of 5µI. The reaction was gently mixed and incubated at room 
temperature for 5 minutes and then incubated on ice. 
2.3.9.1. Transformation of vector into competent cell 
One vial of One Shop® TOP010 chemically competent E. coli was gently thawed on ice. 
Two microliters of cloning reaction was added into the vial of competent cells and 
incubated on ice for 15 minutes. The reaction was then heat shocked at 42°C for 30 
seconds and immediately transferred to ice. 250µI of room temperature SOC medium was 
added to the cells and incubated in the orbital incubator (200 rpm horizontally) at 37°C for 
1 hour. The transformation reaction was spread on two pre-warmed culture plates (LB agar 
containing 50µg/ml Ampicillin) and incubated at 37°C overnight. Ten colonies were picked 
next day and transferred in 10 separate tubes containing 5 ml of LB medium and 50µg/ml 
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Ampicillin. Tubes were incubated in orbital incubator (200 rpm horizontally) at 37°C 
overnight. 
2.3.9.2. Extraction of plasmid 
Overnight E. coli Cultures were removed from incubator and centrifuged at 3000X g for 10 
minutes at room temperature. The supernatant was discarded and plasmid was extracted 
from E. coli cells using QlAprep spin Miniprep kit (QIAGEN) according to manufacturer 
instructions. This method is based on alkaline lysis of the bacterial cells followed by 
adsorption of DNA onto silica in the presence of high salt, several washes and elution of 
DNA in water. All transformants were analysed for the correct orientation of the PCR 
product by sequencing (see sequencing section 2.3.6). 
2.3.10. Site-directed mutagenesis 
1 OX PCR reaction for site directed mutagenesis (Stratagene) contains: 
100mM Kcl, 100mM (NH4)2SO4,200mM Tris-Hcl (pH 8.8), 20mM MgSO4,1% Triton X-100 and 
1 mg/ml nuclease-free bovine serum albumin 
The QuickChangeTM site directed mutagenesis kit (Stratagene) was used for in vitro re- 
creation of desired mutations in the XRCC3 gene (See chapter 4). A pair of complementary 
mutagenic primers containing the desired base pair change at the site of the mutation was 
designed for each mutation according to the guidelines proposed by Stratagene. Then a 
mutagenic PCR reaction mix was prepared for each desired mutation in thin-walled tubes 
using 5µI of 1 OX reaction buffer, 2µI of ds plasmid containing XRCC3 cDNA prepared as 
described above, 1.25µI (125ng) of each mutagenic oligonucleotide primer and 1 FBI of 
dNTP mix and adjusted to 50µI with ddH2O. Then 1µl of Pfu Turbo DNA polymerase 
(2.5U/pl) was added. The reaction mixes were overlaid with 30µI of mineral oil and 
mutagenic polymerase chain reaction was carried out in the DNA thermocycler (MWG) at 
95°C for 30 sec as a denaturing step followed by 12 cycles of 95°C for 30 sec, 55°C for 1 
minute and 68°C for 13 minutes. Following temperature cycling, the reactions were placed 
on ice for 2 minutes to cool them to <37°C. To digest the parental wild type plasmid and to 
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select for mutant plasmid, each post-PCR reaction was mixed with 1µI of Dpn I 
endonuclease. The reactions were mixed gently and thoroughly by pipetting, centrifuged 
for 1 minute and incubated at 37°C for 1 hour to digest. 
To transform the mutant plasmids, XL1-Blue supercompetent cells (Stratagene) were 
gently thawed on ice. For each sample reaction, 50µI of the supercompetent cells was 
aliquoted into prechilled Falcon 2059 polypropylene tubes and mixed with 1. tl of Dpn I- 
treated plasmid. As an additional control for verification of efficacy of transformation of 
supercompetent cells, 1µl of pUC18 control plasmid (0. ing/µl, Stratagene) was added to 
50µI of supecompetent cells in a separate falcon tube and mixed. All reactions were 
incubated on ice for 30 minutes, and then heat shocked at 42°C for 45 seconds followed 
by 2 minutes incubation on ice. 500µI of preheated (42°C) SOC medium was added to 
each reaction and the transformation reactions were incubated at 37°C in a shaking 
incubator (225 rpm) for 1 hour. 250µI of each transformation reaction was then plated on 
agar plates (two plates per each sample) containing 50µg/ml Ampicillin. Also 500 pUC18 
control (in 200µI SOC medium) was plated on an agar plate containing the same amount 
of Ampicillin. All plates were incubated at 37°C overnight. The next day the plates were 
removed from incubator. The numbers of colonies in pUC18 control plates were more than 
250 indicating the transformation was successful. Five colonies were picked for each 
sample, cultured in 10ml of broth containing 50µg/ml Ampicillin in 20ml tubes and 
incubated at 37°C overnight in an orbital incubator (200rpm, Gallenkamp). Samples (5 per 
each mutant) were taken out of incubator the next morning and were centrifuged at 3000X 
g for 10 minutes at room temperature. Supernatants were discarded and plasmids were 
extracted from the bacterial pellets using Qiaprep spin Miniprep (QIAGEN) according to the 
manufacturer's instructions. All created mutations were confirmed by direct sequencing 
using the XRCC3 primers (See section 2.3.6 and also chapter 4 table 1). 
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2.3.11. Tissue culture 
Phosphate Buffered Saline (PBS) was prepared by dissolving one tablet (Oxoid Ltd. ) in 100ml 
istilled water and was autoclaved before use. 
Dimethyl Sulphoxide (DMSO) was supplied by BDH Merck, prepared at 10% (v/v) in tissue 
ulture media and used for freezing cells. 
Tissue culture media: Dulbecco's modified eagle's medium (DMEM) supplemented with 4.5g/L 
glucose and L-Glutamine was purchased from BioWhittaker Ltd. and stored at 4°C until use. 
II tissue culture media was supplemented with 9% foetal calf serum and checked for sterility 
efore use. 
Foetal Calf Serum (FCS) was purchased from Helena BioSciences, aliquoted in 50ml tubes 
nd stored at -20°C until use. 
Non-essential Amino Acids was purchased from BioWhittaker Ltd. and stored at 4°C until use. 
Presept was supplied by Johnson and Johnson Medical. One tablet of Presept containing 
0% Sodium Dichloroisocyanurate was dissolved in 1 litre of sterilised water and kept in room 
amperature. 
Trypsin was purchased as a 2.5% solution from Gibco BRL and prepared at 1: 20 trypsin in 
terile PBS and stored at - 20°C until use. Versene/EDTA (ethyelenediamine tetra-acetic acid) was supplied by BDH Merck. 0.2g EDTA 
/as dissolved in 1litre of PBS, aliquoted in 1Oml bottles, autoclaved at 1 Olb/inch2 for 10 minutes 
nd stored at -20°C until use. 
Geneticin (G418 sulphate) was purchased from Invitrogen, Dissolved in fully supplemented 
rowth medium to make a stock concentration of 100mg/ml, filtered using a 0.22 micron filter 
nd kept in 4°C prior to use. The stock made fresh each time and any surplus after use was 
"Lipofectamine reagent was purchase from Invitrogen and kept at 4°C until use. 
All tissue culture procedures were carried out under sterile conditions in a containment 
level 2 laboratory cabinet in order to prevent any microbial contamination. All cell lines 
were maintained in a 37°C, 5% C02, humidified atmosphere incubator. All references to 
cells incubated at 37°C within this thesis were cultured under these conditions. Cells were 
routinely passaged at about 80-90% confluence, every 3-4 days. 
2.3.11.1. Freezing cells 
For freezing, 1X107 cells were resuspended in 10ml of culture media and centrifuged at 
500Xg. The culture media was removed and cells were slowly resuspended in freezing 
medium (10% DMSO, 20% FCS, 70% DMEM), care being taken to have a uniform 
distribution of cells in the medium. The cell suspension was then transferred into 1.2 ml 
cryovial tubes and stored at -80°C overnight before transfer to liquid nitrogen. 
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2.3.11.2. Thawing cells 
Cryovials of frozen cells were transferred to a 37°C water bath, for rapid thawing to limit 
the toxicity of the DMSO. Once thawed, cells were centrifuged at 400X g to remove any 
traces of DMSO, then resuspended in culture medium and transferred to a 25 cm2 culture 
flask. 
2.3.12. DNA transfection into mammalian cells 
2.3.12.1. Electroporation 
Chinese Hamster Ovary (CHO), XRCC3 deficient cell lines (irslSF) were cultured in 75 
cm2 tissue culture flasks until they became confluent. They were then washed, trypsinized 
and counted. Approximately 15X 106 cells were centrifuged and resuspended in 1 ml of 
PBS. Approximately 15{ßg of plasmids (in 50pl of ddH2O) carrying wild type or mutant DNA 
were mixed with 750p1 of resuspended cells (in PBS) and transferred into pre-chilled 
0.4cm electroporation cuvettes. Electroporation was carried out with the Bio-Rad Gene 
Pulser at 400 V and 125 pF. The cells were incubated on ice for 10 minutes before and 
after electroporation. 200pI of post-electroporation cells for each transfection were then 
plated onto 100mm culture dishes and incubated at 37°C for two days before addition of 
antibiotic selection media. 
2.3.12.2. LipofectamineTM treatment 
Chinese Hamster Ovary (CHO), XRCC3 proficient cell lines (AA8) and human colorectal 
carcinoma cell line (SW480) were cultured in 100mm tissue culture dishes until became 
90% confluent. One microlitre of extracted plasmid for human XRCC3 D213N and wild type 
human XRCC3 (see section 2.3.9.2) was added to 199NI of serum-free medium in 
separate tubes (marked A). In other tubes (marked B) 20NI of Lipofectamine was added to 
200pl of serum-free medium. The contents of tubes A and B were mixed together and 
incubated at room temperature for 30 minutes before use. The same mixture without any 
plasmid was prepared as a control and incubated at room temperature along with the other 
tubes. 
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Culture medium was removed from the cells and they were washed with serum-free 
medium. The mixture containing plasmid and Lipofectamin was added to 1.6ml of serum- 
free medium, which was then added to the cells and incubated at 37°C for 5 hours. After 5 
hours the transfection mixture was removed and 10ml of normal medium containing 9% 
foetal calf serum was added and incubated at 37°C overnight. Transfectants were used for 
drug selection as described in section 2.3.13. 
2.3.13. Drug selection 
A total of 5x105 cells were seeded onto 100mm plates and incubated at 37°C overnight 
until the cells adhered to the plates. The plates were removed from the incubator the next 
day, washed with PBS, and fresh culture medium containing 100 pg/ml of G418 sulphate 
was added. The plates were incubated at 37°C for 10-12 days until drug-resistant colonies 
formed. Three to six separate clones for each construct (depending on constructs) were 
picked, expanded and tested in cellular toxicity assays. 
2.3.14. Determination of expression of transfected XRCC3 constructs 
2.3.14.1. Extraction of mRNA from mammalian cell lines. 
Poly-A+ mRNA was extracted from mammalian cell lines using OligotexTM Direct mRNA Kit 
(QIAGEN) according to the manufacturer's instructions. The extraction is based on binding 
of polyadenylated RNA (poly-A tail mRNA) to a dT oligomer (dC1oT3o) linked to the surface 
of polystyrene-latex particles and washing away other non-polyadenylated molecules. 
Then the poly-A+ mRNA is eluted from its binding by destabilizing the dT: A hybrid using an 
elution buffer provided in the kit. The extracted mRNA stored in -20°C. 
2.3.14.2. RT"PCR 
RT- PCR was performed using the same method and primers as described in section 
2.3.8 and chapter 4, table 1. A negative control (excluding reverse transcriptase) was used 
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for each sample to eliminate the possibility that any PCR products originated from 
contaminating DNA. 
2.3.15. Western blotting 
2.3.15.1. Extracting Protein from Mammalian cell lines 
"RIPA buffer: 1% Nonidet P-40,0.5% Sodium deoxycholate, 0.1% SDS in PBS stored at 4°C. 
"Phenyl Methyl Sulfonyl Fluride (PMSF) was purchased from Calbiochem- Novabiochem 
Corporation, dissolved in Isoprapanol (57mM) in concentration of 10 mg/ml and stored at -20°C. 
*Protein electrolysis (sample) buffer: 1ml glycerol, 0.5ml ß-mercaptoethanol, 3ml 10% SDS, 
1.25ml 1M Tris-base pH 6.7,1 mq Bromophenol Blue and stored at -20°C. 
Chinese Hamster Ovary cell lines irs1SF and AA8 were cultured in 100 mm tissue culture 
dishes until they reached 80-90% confluence. The culture medium was removed and the 
cells were washed with PBS twice to remove all traces of growth medium. 1 ml of trypsin 
was added to each dish and cells were incubated at 37°C for 3 minutes for detachment. 
5ml fresh culture medium were added to cells and gently mixed. The contents of each dish 
were transferred to a fresh 15ml centrifuge tube and centrifuged at 1000X g for 4 minutes. 
Supernatants were discarded and cell pellets were resuspended in PBS and pelleted again 
by centrifuging under the same conditions. PBS was discarded and 200µI of ice cold (4°C) 
RIPA buffer and 2µl of PMSF were added to the cells and mixed gently but thoroughly by 
pipetting. The contents of the tube were transferred to a fresh 1.5 ml eppendorf tube, 
incubated on ice for 30 minutes and centrifuged at 14000Xg in a bench-top microfuge at 
4°C for 10 minutes to pellet out cell debris. The supernatants (containing protein) were 
removed, care being taken not to disturb the pellets. One microliter of the protein extract 
was mixed with 199µl of PBS and used for protein quantification, and the rest of extracted 
protein was mixed with 100µI of electrophoresis buffer, placed as aliquots of 304I into 
several 0.5ml tubes and stored at -70 °C until use. 
2.3.15.2. Protein quantification 
Proteins extracted from mammalian cell lines were quantified prior to use in western blot. 
CoomassieTM plus-200 protein assay kit (PIERCE) was used for protein quantification. First 
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BSA standard (25000µg/ [, I) was diluted in different concentrations of 1,5,10,15,20 and 
25µg/pl, and 90µI of each diluted BSA was loaded into miniplate wells. They were used as 
controls to compare the absorbance of sample proteins with the standards. Then 150µI of 
each extracted protein sample (diluted 1: 200 in PBS) was mixed with 150µI Coomassie 
reagent. The mixture was aliquoted into 3 wells of a miniplate, 90µI in each well for each 
sample. The absorbance was read at 595nm using an Anthos Denley 2001 plate reader 
(ANTHOS). The absorbance values from the spectrophotometery report were then entered into 
excel file where the values for the samples were compared with the values of the standards 
and the protein concentration for each sample were calculated graphically. 
2.3.15.3. SDS Poly Acrylamide Gel Electrophoresis 
*Ammonium Persulphate was prepared fresh at a concentration of 10% in ddH2O and stored at 
4°C. 
"TEMED: was purchased from Sigma and stored at room temperature. 
"Acrylamide: 30% acrylogel solution was supplied by BDH Merck and kept at 4°C until use. 
*Molecular weight marker: Pre-stained protein marker was purchased from Bio-Rad and kept at - 
200C until use. 
01OX TGS (Running) buffer: 30g Tris-base, 144g Glycine, 10g SDS adjust up to 1000cc with 
ddH2O, autoclaved and stored at room temperature. 
"Sodium Dodecyl Sulphate (SDS) was purchased from Sigma. 10g of SDS dissolved in 100ml of 
ddH2O on a heating stirrer and kept at room temperature. 
"To make 5% upper stacking gel: 0.83 ml of 30% acrylamide, 0.63 ml of Tris base pH: 6.8,50ýtl 
10% of SDS, 50µI of 10% APS, 5µI of TEMED (to be added last) in final volume of 50 ml. 
*To make 8% SDS-PAGE gel: 2.6 ml of 30% acrylamide, 3.75 ml of Tris base pH: 8.8,100µI 
10% of SIDS, 1 00µI of 10% APS, 8µI of TEMED (to be added last) in final volume of 10 ml. 
Equivalent amounts of each protein sample (varying between 20 to 30µI depending on the 
samples), diluted in protein electrophoresis buffer, were heated to 10011C for 5 minutes in a 
heating block. They were then loaded onto the 5% upper stacking gel which concentrates the 
proteins prior to entering the 8% lower resolving SDS-PAGE gel which separate the proteins 
according to their size. Gels were run at 150 volts at constant voltage for 1.5 hours along with 
10[tl of pre-stained high molecular weight protein marker (BioRad). Electrophoresis was 
stopped when the dye front was about 1 cm from the bottom of the gel. 
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2.3.15.4. Blotting to PVDF membrane 
"Towbin (transfer) buffer: 20mM Tris-base, 0.2M Glycine, 200ml Methanol adjust up to 1000cc 
with H20, autoclaved and stored at 4°C. 
*PBS-T; Phosphate Buffered Saline plus 0.1% Tween- 20, stored at room temperature. 
"Blocking Solution: 5% dried low fat skimmed milk (Marvel) in PBS-T, stored at 4°C. 
*Filter paper: 3mm filter papers were supplied by Bio-Rad. 
"lmmun-BIotTM PVDF (polyvinylidene difluoride) membrane (0.2µm thick) was purchased from 
Bio-Rad and used for transfer of protein from gel. 
After electrophoresis the gel was removed from the gel cassette and placed in cold (4°C) 
transfer buffer for 10 minutes to equilibrate. The transfer membrane (Polyvinylidene 
Difluoride (PVDF) membrane, Bio-Rad) was soaked in 100% methanol for 2 minutes and 
then soaked in cold (4°C) transfer buffer for 10 minutes. Filter papers (BioRad) were also 
soaked in cold (4°C) transfer buffer for 2 minutes. The transfer cassette (Bio-Rad) was 
assembled according to the manufacturer's instructions and the gel was sandwiched 
between filter papers and PVDF membrane making sure the gel was correctly oriented, 
care was taken to avoid air bubbles between gel, transfer membrane and filter papers (See 
section 2.4.4). The protein transfer was performed at 10 volts for 30 minutes. After transfer 
was completed the PVDF membrane was incubated in blocking solution on a rocking 
platform in the cold room (4°C) overnight. 
2.3.15.5. Immunoblotting 
The PVDF membrane was removed from the blocking solution and washed with PBS-T 3 
times for a minimum of 5 minutes each. Then it was placed in primary anti-XRCC3 
antibody (Santa Cruz Biotechnology) diluted (1: 200) in blocking solution (3% non-fat milk in 
PBS-T), and incubated at 4°C on rocking platform for one hour. The membrane was then 
washed with PBS-T 3 times for a minimum of 5 minutes each to remove unbound antibody. 
The membrane was then incubated with Anti-goat IgG/horseradish peroxidase conjugate 
secondary antibody (Santa Cruz Biotechnology) diluted (1: 5000) in blocking solution (3% 
non-fat milk in PBS-T) at 4°C on rocking platform for one hour. The membrane was then 
washed 4 times with PBS-T for minimum of 10 minutes each. 
66 
Chapter 2- Materials and Methods 
2.3.15.6. Detection 
The XRCC3 protein was detected using the western blotting detection reagent ECL 
(Amersham pharmacia biotech) according to the instruction stated by the manufacturer. 
The membrane was taken out of PBS-T and excess PBS-T was drained off with Kimwipe 
(Fort James Ltd. ). The membrane was placed on cling film and the ECL reagent was 
added to the top of the membrane with a pipette, making sure that all parts of the 
membrane were covered by ECL. After one minute, excess ECL was drained and 
membrane was dried using Kimwipe. The membrane was then placed in thin plastic wrap, 
placed in a film cassette and was exposed to X-Ray film (Kodak) in the dark for 15 
minutes. 
2.3.15.7. Developing of X-Ray films 
Exposed X-Ray films were developed in the dark, by immersing in X-Ray developer 
(Kodak; diluted according to the enclosed instruction) for 2 minutes. Films were washed 
with tap water, then "fixed" by placing in X-Ray fixer (Kodak; diluted according to the 
enclosed instruction) for 5 minutes. Films were rinsed in tap water for 5 minutes and 
allowed to air dry. 
2.3.16. Two-Dimension gel electrophoresis 
*Sample buffer: 8M Urea, 2% CHAPS, 50mM DTT, 0.2% Bio-Lyte, 0.001% Bromophenol Blue. 
The buffer was distributed into small aliquots and kept at -20°C until use. 
*Equilibration buffer: 10ml Glycerol, 12.5 ml of 1.5 mM Tris (pH: 8), 18g Urea and 1g SDS made 
up to 50ml with ddH2O. 
'Equilibration buffer I: 400mg DTT was added to 20ml of Equilibration buffer. 
*Equilibration buffer II: 400mg lodoacetamide was added to 20ml Equilibration buffer. 
'Immobilized pH gradient (IPG) gel strips were bought from BioRad and kept at -20°C until use. 
*To make 100ml of 14% SDS Acrylamide gel: 46.5ml of 30% Acrylamide, 25ml of 1.5mM Tris pH: 
8.8,1 ml Of 10% SDS, 0.5ml of 10% fresh APS, 27m! of ddH2O and 50pl of TEMED. 
Proteins were extracted from irslSF (XRCC3 deficient) and transfected XRCC3 D213N 
irs1SF cells as explained in section 2.3.15.1. Total protein were quantified as described in 
section 2.3.15.2 and equal amount of protein for each of the two cell lines was loaded into 
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5K Dalton Centrifugal filter tubes and centrifuged at 12000Xg for 20 minutes to filter larger 
proteins. 
Sample buffer was added to 30pg of protein to reach the final volume of 300pl for each 
sample. The whole volume (300pl) of each sample was loaded as a line in channels of a 
rehydration tray. Next, using forceps, the coversheets of IPG strips (17cm, pH: 3-100) were 
peeled off and the stripes were placed down onto the samples, care being taken not to 
induce any air bubble between strip and sample which may interfere with the even 
distribution of sample in the strip. Each strip was overlaid with 2-3ml of mineral oil along 
the length of the strip. Strips were rehydrated under active conditions using Protean® IEF 
cell at 50 volts for 12-16 hours at room temperature and at 40000 volt-hours afterward 
according to the manufacturer's instructions (Also see section 2.4.7). When the Isoelectric 
Focusing was finished, the strips were taken off the tray and placed in equilibration buffer I 
and II for ten minutes each and then loaded onto a 14% pre-prepared SDS polyacrylamide 
gel and fixed in place with melted 1% agarose. The gel cast was mounted in the 
electrophoresis tank where electrophoresis was performed at 16 mA/gel for 30 minutes 
and 24mA/gel for 5 hours. After electrophoresis was completed the gels were removed 
from the tanks and silver staining was performed using Owl silver staining kit according to 
the manufacturer's instructions (Owl Separation Systems). When required, western blotting 
was performed on gels after electrophoresis was finished as described at sections 
2.3.15.4-7. 
2.3.17. Drug sensitivity tests 
"Camptothecin was supplied by Sigma as powder. Stock concentration of 25mM in DMSO was 
prepared and kept at -20°C. 
"Mitomycin-C was supplied by Sigma, Stock concentration of 3µM in DMEM was made and 
kept at-20°C. 
"Thymidine was purchased from Sigma. Stock concentration of 100mM was made and kept at - 20°C until use. 
Cell survival assays were performed by exposing cells from individual variant or wild type 
clones to the DNA cross-linking agent Mitomycin-C (MMC), Topo isomerase I inhibitor 
Camptothecine (CPT) and Thymidine. A total of 500 cells for each clone were seeded into 
100 mm dishes in 1Oml medium containing 100 pg/ml of G418, and incubated at 37°C 
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overnight. Desired concentrations of MMC (0-100 nM), CPT (0-75 nM) and Thymidine (0- 
10 NM) were added and plates were incubated for 10-12 days at 37°C. Plating efficiency 
was assessed in triplicate for each clone. Colonies were stained with Methylene blue (0.4% 
methyline blue in 50% methanol) and counted. Cell survival curves were obtained by 
plotting the survival percentage of each clone against concentration of the drug. Survival 
percentage was corrected for plating efficiency in the absence of the drug. 
2.3.18. Statistical analysis 
The results of all genotyping were entered into Excel file 2000 (Microsoft). Statistical 
significance of difference between case and control groups was performed using 
calculation of Odds ratio and 95% Confidence Interval (See section 3.2.6 for detail of 
statistical tests). 
The cell survival percentage resulting from drug sensitivity tests were entered into Excel 
2000, means and standard deviations were calculated for each drug concentration. The 
result of cell survival and their standard deviations were then entered into Cricket Graph 
(Computer associates) and were used for generating drug sensitivity graphs (See chapter 
4). 
69 
Chapter 2- Materials and Methods 
2.4. Mechanism of some techniques used in this study 
2.4.1. Polymerase Chain Reaction 
The polymerase chain reaction (PCR) is a rapid procedure for the in vitro enzymatic 
amplification of a specific segment of DNA, using two oligonucleotide primers that hybridize 
to opposite strands, and flank the target DNA (Taylor, 1992; Saiki eta!., 1988). A repetitive 
series of cycles involving template denaturation, primer annealing and the extension of the 
annealed primers by a heat stable DNA polymerase results in the exponential 
accumulation of the specific fragment. Three stages are involved (a) Denaturation in which 
the double stranded DNA is separated into single strand DNA by heating. (b) Annealing in 
which the primers anneal to flanking regions of the target sequence and (c) Extension in 
which the annealed primers are extended by the Taq DNA polymerase enzyme. In the next 
cycle the DNA is denatured, and fresh primers bind to repeat the process. 
PCR is central to a wide range of molecular biology techniques, including mutation 
detection, sequencing and in vitro site directed mutagensis. 
2.4.2. Single Strand Conformation Polymorphism analysis 
SSCP is a PCR base technique which is widely used for the detection of sequence 
variation in DNA such as mutations or normally occurring DNA polymorphisms (Orieta et 
al., 1989a, 1989b). The technique is based on the principle that the mobility of double- 
stranded DNA of a given length in gel electrophoresis is relatively independent of 
nucleotide sequence. In contrast, the mobility of single strands can vary considerably as a 
result of only small changes in nucleotide sequence. Therefore molecules differing by as 
little as a single base change may form different conformations relative to the wild type 
sequence and migrate differently in a non-denaturing polyacrylamide gel, resulting in band 
shifts (Fig. 1). 
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Figure 1: Schematic view of mechanism of single stranded conformation polymorphism. 
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2.4.3.5' Nuclease assay (TagMan®) 
TagMane is a mutation detection method which is used for the detection of specific, known 
mutations or polymorphisms. It is based on hybridization of fluorogenic probes, specifically 
designed for each allele, to the template DNA during PCR. The probes are labeled with 
different fluorescent reporter dyes, generally FAM (6-carboxy-fluorescein) and TET (6-carboxy- 
4,7,2', 7'-tetrachloro-fluoroscein) at the 5' end and with a quencher called TAMRA (6-carboxy- 
N, N, N', N'-tetramethyl-rhodamine) at its 3' end. When the probe is intact, the proximity of the 
reporter dye to the quencher dye results in suppression of the reporter fluorescence. During 
PCR, forward and reverse primers hybridize to a specific sequence of the target DNA. The 
TagMan'm probe hybridizes to a target sequence within the PCR product. The 5' nuclease 
activity of Taq polymerase cleaves the TagMan"m probe if it is matched to the template DNA; 
the reporter dye and quencher dye are separated upon cleavage, resulting in increased 
fluorescence of the reporter which is detected by a detector after amplification is completed 
(Fig. 2). In a case of mismatch between the probe and target sequence, caused by mutation or 
polymorphism in one or both alleles, the probe is displaced but is not cleaved and no 
fluorescence is detected. A substantial increase in just one fluorescent signal indicates 
homozygosity, while similar increase in both signals indicates heterozygosity for the specific 
alleles. 
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Figure 2: Schematic representation of 5' nuclease assay (TaqMan) 
A; showing hybridization of probe to target sequence during PCR, B; Strand displacement by Taq 
Polymerase, C; cleavage of fluorescent bounded probe and D; completion of PCR. R, Reporter; Q, 
quencher; arrow, Taq polymerase; Red dot, polymorphic base. 
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2.4.4. Western blot 
Sufficiently separated proteins in an SDS-PAGE can be transferred to a solid membrane 
for western blot analysis. For this procedure, an electric current is applied to the gel so that 
the separated proteins transfer through the gel and onto the membrane in the same pattern 
as they separate on the SDS-PAGE (Fig. 3). 
Cathode 
Gel holder -------- 
Filter paper 
Gel 
PVDF membrane 
Filter paper 
Gel holder -------- 
Anode 
Figure 3: Schematic Representation of protein transfer for western blotting. 
All sites on the membrane which do not contain blotted protein from the gel can then be 
non-specifically blocked so that antibody will not non-specifically bind to them, causing a 
false positive result. To detect the protein blotted on the membrane, a primary antibody is 
added at an appropriate dilution and incubated with the membrane. The primary antibodies 
will bind to its specific protein while excess antibodies will be washed away at the end of 
the incubation. In order to detect the antibodies which have bound, anti-immunoglobulin 
antibodies (called secondary antibody) coupled to a reporter group such as the enzyme 
alkaline phosphatase are added. Finally after excess second antibody is washed free of 
the blot, a substrate is added which will precipitate upon reaction with the conjugate 
resulting in a visible band where the primary antibody bound to the protein. 
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2.4.5. Cloning 
The pcDNA3.1N5-His© TOPO® plasmid vector is a linearized vector with single 3' 
thymidine (T) overhangs for TA cloning and Topoisomerase I which is covalently bound to 
the vector. The PCR product which has been amplified using Taq polymerase has a single 
deoxyadenosine (A) residue at its 3' end. Binding of the T overhangs from the vector and 
the A overhangs from the PCR product allows ligation of PCR insert with the vector. 
4ýý 
A B 
Figure 4: Vector map of pcDNA3.1 and pcDNA23.1 
Vector map for pcDNA3.1/V5-His©TOPO° TA vector (A) and for pCR 2.1-TOPO° vector (B) 
showing multiple cloning site and their restriction digest sites. 
2.4.6. Site-directed mutagenesis 
In vitro site-directed mutagenesis is a PCR-based technique which is used for studying 
protein structure-function relationships and gene expression. There are several 
approaches to this technique. In QuickChangeTM site directed mutagenesis kit, High-fidelity 
Pfu-turbo° polymerase which is a non-displacement DNA polymerase is used. It will extend 
synthesis directly from each of the mutant primers. Thus, mutant primers become part of 
replicated plasmid. Treatment of DNA after PCR with the restriction enzyme, Dpnl, 
selectively destroys the parental (non-mutated) DNA while leaving the newly mutated DNA 
intact. This selectivity is ensured because the parental DNA has been methylated when 
cloned in bacteria (E. coli strain which is used for transformation is Dam+, meaning it 
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contains methylating enzyme). DpnI will only digest methylated DNA. Since the PCR- 
amplified (mutated) DNA has not been used to transform bacteria, it remains unmethylated 
and is not digested. 
Target in the gene inserted in the plasmid 
Annealing mutagenic primers containing 
Desired mutation to the denatured plasmid 
1 
PCR using Pfu Turbo incorporate mutagenic 
Primers in newly generated plasmid containing 
Desired mutations 
1 
Dpni digests the parental plasmid and leave 
the newly generated plasmid containing desired 
mutations 
Primers in newly generated plasmid containing 
Desired mutations 
Figure 5: Schematic representation of different steps of "in vitro site-directed mutagenesis" 
Adopted from protocol manual Stratagene. 
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2.4.7. Two-Dimensional Electrophoresis for Proteomics 
Proteome analysis is a direct measurement of proteins in terms of their presence and 
relative abundance [Wilkins et al. 1996]. 2-D polyacrylamide gel electrophoresis (2-D 
PAGE) is a method by which it is possible to separate and analyse hundreds of proteins in 
a single gel. Proteins are first separated on the basis of their Isoelectric Points (pl), the pH 
at which a protein carries no charge and will not migrate in an electrical field. The second- 
dimension electrophoresis will separate proteins depending on their molecular weight. By 
silver or coomassie staining proteins can be visualised. 
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Figure 6: Schematic representation of mechanism of 2-D electrophoresis for proteomics 
Adopted from protocol manual BioRad. 
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3. The association between HRR gene 
polymorphisms and breast cancer susceptibility 
3.1. Introduction 
Despite extensive efforts, the search for highly-penetrant breast cancer susceptibility 
genes other than BRCA1 and BRCA2 has not been successful so far. Only 5% of breast 
cancer cases are related to mutations in BRCA1, BRCA2 and few other high-penetrance 
genes. Although these mutations are very rare in the population, they confer a high risk of 
developing breast cancer among carriers. Whilst research is still being done to find other 
high-penetrance breast cancer susceptibility loci, common genetic variants or 
polymorphisms have been proposed as low-penetrant alleles for susceptibility to breast 
cancer. They are more frequent in the population therefore they could contribute to a larger 
proportion of breast cancer cases. Inter-individual's response to the environment or 
susceptibility to diseases may be linked to the presence of DNA sequence variations within 
critical genes. Therefore subtle change(s) in protein production or function resulting from 
SNPs in gene(s) whose products are important in cancer prevention could ultimately lead 
to carcinogenesis through the activation/ inactivation of a certain cellular pathways. SNPs 
in genes involved in oestrogen hormone metabolism, carcinogen metabolism, DNA 
damage recognition and repair, cell cycle controls, immune surveillance and apoptosis are 
among the candidates. 
The mammalian genome is regularly exposed to a variety of toxins, from both the external 
and internal environment, and thus is subjected to DNA damage that can cause genetic 
instability. There is also some evidence that an acquired genetic instability is fundamental 
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to tumour development An accumulation of DNA damage causes the disruption of normal 
cellular functions and enables the clonal expansion of abnormal cells to form a tumour. 
Defects in DNA repair mechanisms are known to be responsible for inherited cancer-prone 
syndromes such as Xeroderma Pigmentosum and hereditary non-polyposis colon cancer 
(HNPCC) (Fishel, et al., 1993, Robbins, et al., 1974). Therefore DNA repair genes have a 
critical role in protecting cells from carcinogenesis (Mohrenweiser and Jones, 1998). 
Exposure to ionizing radiation has been identified as a risk factor for breast cancer. 
Ionizing radiation exposure damages DNA in many ways, including the induction of DNA 
double strand breaks. Improper or inefficient repair of DSBs can result in the accumulation 
of chromosomal translocations, deletions, insertions and other gene rearrangements which 
can subsequently lead to carcinogenesis (Elliott and Jasin, 2002, Jeggo, 1998, Pastink, et 
at, 2001). Hypersensitivity to ionizing radiation and defective DNA repair has been 
reported in breast cancer patients and their healthy relatives compared to healthy 
individuals without any family history of breast cancer (Helzlsouer, eta!., 1996, Kovacs and 
Almendral, 1987, Parshad, et at, 1996, Patel, et at, 1997, Roberts, et al., 1999, Scott, et 
a!., 1999). Also higher levels of radiation-induced cellular G2 delay have been observed in 
breast cancer patients and healthy women with family history of breast cancer (Lavin, et 
a1., 1992) Hu JJ, 1999). These studies provide evidence that cellular and chromosomal 
radiosensitivity resulting from deficiencies in DNA repair is inherited in breast cancer 
patients and their families. In addition, the products of the breast cancer susceptibility 
genes BRCA1 and BRCA2 are involved in the homologous recombination DNA repair 
pathway, which repairs DNA double-strand breaks (Karran, 2000). BRCA1 and BRCA2 
deficient cell lines and knockout mice are defective in homologous recombination repair 
and show radiation hypersensitivity (Moynahan, et at, 2001, Ponnaiya, et at, 1997). Since 
in the absence of BRCA1 and BRCA2 mutations, a family history of breast cancer 
constitutes a significant risk factor (Lynch, et al., 1989, Spitz and Bondy, 1993), and 
considering that DNA repair deficiency in breast cancer families Is inherited (Price, et al., 
1997, Roberts, et al., 1999), it has been proposed that DNA repair genes (particularly 
those responsible for repairing DSBs) could be low-penetrance candidate genes for breast 
cancer susceptibility (Mohrenweiser and Jones, 1998, Price, et at, 1997, Roberts, et at, 
1999). 
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As described in section 1.8.1.3, RAD51 and five other homologous genes (RAD51B 
(RAD51 L1), RAD51 C (RAD51 L2), RAD51D (RAD51 L3), XRCC2 and XRCC3) have been 
identified in human and are involved in the HRR pathway of DSB repair. XRCC2 and 
XRCC3 mutant cells show moderate hypersensitivity to ionizing and UV radiation but 
extreme sensitivity to DNA cross-linking drugs such as Mitomycin C and cisplatin (Fuller 
and Painter, 1988, Jones, et al., 1987, Liu, et al., 1998). Both XRCC2 and XRCC3 are 
required for the assembly and stabilisation of Rad5l foci (Bishop, et al, 1998, O'Regan, et 
al., 2001) and cells lacking XRCC2 and XRCC3 show low levels of homologous 
recombination (Brenneman, et al., 2000, Johnson, eta!., 1999, Liu, et al., 1998, Pierce, et 
al., 1999). 
A number of SNPs have been identified in genes of HRR pathway, including the XRCC2, 
XRCC3, BRCA2 and RAD51 genes, and these can be used for generating association 
studies. As DNA repair genes contribute to the prevention of tumour development, the 
study of their genetic variants whose effect could lead to inefficient repair capacity, provide 
a means of identifying a population that may be at particular risk of developing tumour due 
to an environmental exposure (e. g. radiation). 
Genetic association studies provide enough power for identifying low-penetrance alleles 
(See section 1.4.11). In association studies, genotype frequencies of three possible 
genotypes of a SNP are compared between cases and controls. The approximate relative 
risk of disease for each genotype can then be estimated relative to the group carrying 
common homozygote allele (Dunning, eta!., 1999). This approach allows estimation of the 
risk according to the number of copies of the risk allele. 
We therefore hypothesized that single nucleotide polymorphisms of HRR genes which are 
responsible for repair of DSBs could be associated with breast cancer by alteration of DNA 
repair capacity or fidelity. In addition, as a consequence of the complex physical interaction 
of the proteins, combinations of variant forms of these recombination repair genes may 
have more dramatic effects on overall DNA repair capacity than expected from the effects 
of single genes in isolation. We therefore tested the association of polymorphisms of these 
genes in association with breast cancer. We chose coding SNPs in XRCC2 and XRCC3 
genes that change an amino acid. The polymorphisms of these genes had already 
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suggested as low penetrance candidate genes for breast cancer susceptibility in the 
literature (Roberts, et al., 1999). Various BRCA2 polymorphisms have already studied in 
association with breast cancer and only a weak effect have been observed for the BRCA2 
N372H polymorphisms (Healey, et al., 2000). To the best of our knowledge no coding 
RAD51 SNP in a high frequency has been identified in the population so far, and only a 5' 
UTR polymorphism has suggested to act as a modifier of risk in BRCA2 mutation carriers 
(Levy-Lahad, et al., 2001). We therefore tested whether this polymorphism could act as a 
breast cancer predisposing allele in sporadic breast cancer patients. 
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3.2. Materials and methods 
3.2.1. Patients and controls 
The patient cohort comprised 522 Caucasian breast cancer patients, from South Yorkshire, 
UK who were diagnosed and treated for breast cancer at the Royal Hallamshire and 
Rotherham District General Hospitals between November 1998 and June 2000. Less than 
5% of patients at these clinics are secondary referrals; thus the cases are reasonably 
representative of the populations of South Sheffield and Rotherham. Women were 
included in the study if they had a diagnosis of breast cancer for which they had undergone 
surgery, so that pathology data were available. The histo-pathologic diagnosis was 
confirmed for all breast cancer cases (BCC) by a pathologist*. Demographic, family 
history, clinical and histo-pathologic data were collected for all patents. The control 
populations comprised 399 anonymous female healthy blood donors and 500 females from 
amongst those attending the Sheffield mammography screening programme from October 
2000 to February 2001. Women in the latter group were included only if they had no 
mammographic evidence of breast lesion at the time of screening. All women on the 
community health index between the ages of 50 and 65 are invited for screening, and the 
uptake rate in Sheffield is on average 80%. Demographic data, environmental risk factors 
and family history data were collected from mammography screening controls (MSC) by a 
research nurse* using the same questionnaire as used for the cases (see appendix). Age 
and sex were recorded for the blood donor controls (BDC). This study was approved by the 
South Sheffield Research Ethics Committee and informed written consent was obtained 
from all subjects (See appendix). 
3.2.2. DNA variants 
The polymorphism in exon 3 of the XRCC2 gene at nucleotide position 31479 (Genbank 
accession number A0003109) is aG to A substitution which changes arginine 188 to 
histidine. This variant was identified by sequencing polymerase chain reaction (PCR) 
products amplified from the genomic DNA of primary human fibroblast cultures from 
`See appendix for list of collaborators 
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several different individuals by our collaborators Paul O'Regan and John Thacker*. The 
polymorphism in exon 7 of the XRCC3 gene is a CIT substitution at nucleotide position 
18067 (Genbank accession number AF037222) which changes a threonine 241 to 
methionine (Shen, et al., 1998). The polymorphism in exon 10 of the BRCA2 gene at 
nucleotide position 1342 (Genbank accession number NM_000059) is an A to C 
substitution which changes asparagine 372 to histidine (Healey, et al., 2000). The 
polymorphism in 5' UTR of the RAD51 gene at nucleotide position 135 (Genbank 
accession number D14134) is aG to C substitution (Wang, et al., 2001). 
3.2.3. DNA extraction 
Genomic DNA was extracted from peripheral blood lymphocytes using 20ml of whole blood 
as described in section 2.3.1.1. The DNA concentration of all samples was then quantified 
(See section 2.3.2) and all samples were diluted to 100ng/pl for general PCR amplification 
and 5ng/pl for 5' nuclease PCR (TagManTm) assays. 
3.2.4. Genotyping techniques 
3.2.4.1. PCR-SSCP 
PCR-SSCP was used for genotyping all cases and controls for the XRCC3 T241 M 
polymorphism. PCR amplification for XRCC3 exon 7 was carried out as described in 
section 2.3.3 except that 6 pmol of forward and reverse primers (Table 1) was used. The 
amplification condition was 95°C for 3 minutes, followed by 35 cycles of 94°C for 35 sec, 
61T for 25 sec and 72°C for 25 sec. A final extension of 72°C for 5 minutes was also 
applied. 
SSCP genotyping of the XRCC3 exon 7 was also performed as described in section 
2.3.5.1. A 12% polyacrylamide gel and 5500 volt hours were used for electrophoresis. DNA 
bands were then visualised by silver staining (see section 2.3.5.1). PCR-SSCP was also 
used for re-genotyping 15% of the samples that had already genotyped for the XRCC2 
* See appendix for list of collaborators 
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R188H polymorphism by TagManTM as described below. For PCR amplification, 100ng 
genomic DNA was mixed with 10pmol each forward and reverse primers (Table 1) and 
18NI 1.1X PCR master mix. The amplification conditions consisted of 3 minutes at 94°C 
followed by 35 cycles of 30 sec at 95°C, 20 sec at 56°C and 20 sec at 72°C. Final 
extension was for 5 minutes at 72°C. SSCP genotyping was carried out as described 
above with electrophoresis for 3000 volt hours on 10% non-denaturing polyacrylamide gel. 
3.2.4.2. Fluorescent 5' nuclease PCR assay (TagManTM) 
The TagManN assay system was used for genotyping of 3 SNPs in the XRCC2, BRCA2 
and Rad5l genes. It was also used for re-genotyping 15% of samples for XRCC3 T241 M 
variants which had already been genotyped using PCR-SSCP. 
Primers and probes for TagManTM' assays were designed using Primer Express v1.5 
software (ABI) and were made by MWG (Table 1). The required amount of primers and 
probes for each experiment was adjusted as described in section 2.3.5.3. All DNA samples 
were diluted to 5ng/NI. 
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PCR-SSCP primers 
XRCC2 Forward: 5' ACT CTG AGG AAA TGT TCT CA 3' 
exon 3 Reverse: 5' AGT TGC TGC CAT GCC TTA CA 3' 
XRCC3 Forward: 5' CCA CAG GAC ACC TTG TTG GA 3' 
exon 7 Reverse: 5' AAA TAC GAG CTC AGG GGT GC 3' 
XRCC2 
R188H 
Primers Forward: 5' CTG AGG AAA TGT TCT CAG TGC TTA GA 3' 
Reverse: 5' TGA TGA GCT CGA GGC TTT CTG 3' 
Probes Detecting XRCC2 R188: 
5' FAM- TGT AAA TGA CTA TCG CCT GGT TCT M TGC -TAMPA 3' 
Detecting XRCC2 188H: 
5' TET- TTG TAA ATG ACT ATC ACC TGG TTC TTT TTG CAA C -TAMPA 3' 
XRCC3 
T241M 
Primers Forward: 5' GGC CAG GCA TCT GCA GTC 3' 
Reverse: 5' CTT GGT GCT CAC CTG GTT GAT 3' 
Probes* Detecting XRCC3 T241: 
5' FAM- ACG CAG CGT GGC CCC C -TAMRA 3' 
Detecting XRCC3 241 M: 
5' TET- CAC GCA GCA TGG CCC CC -TAMRA 3' 
BRCA2 
N372H 
Primers Forward: 5' CTG AAG TGG AAC CAA ATG ATA CTG A 3' 
Reverse: 5' AGA CGG TAC AAC TTC CTT GGA GAT 3' 
Probes Detecting BRCA2 N372: 
5' FAM- ATT CAA ATG TAG CAA ATC AGA AGC CCT TTG A -TAMRA 3' 
Detecting BRCA2 372H: 
5' TET- TCA AAT GTA GCA CAT CAG AAG CCC TTT GA -TAMRA 3' 
RAD51 135GIC 
Primers Forward: 5' AGC TGG GAA CTG CAA CTC ATC T 3' 
Reverse: 5' CCG CGC TCC GAC TTC A 3' 
Probes* Detecting RAD51 135C: 
5' FAM- CAA CGC CCC TGG CTT ACG CTC -TAMRA 3' 
Detecting RAD51 135G: 
5' TET- CAA CGC CCG TGG CTT ACG CT -TAMRA 3' 
Table 1: Primers and probes used for PCR-SSCP and TagManTM genotyping 
Underlined base pairs indicate site of polymorphisms. 
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PCR amplification for TaqMan assays was carried out as described in section 2.3.5.3. The 
amount of forward and reverse primers and probes, were different in each assay, and are 
shown in table 2. The final reaction volume was adjusted to 25NI with ddH2O. All reactions 
were prepared in 96 well PCR plates (AB gene). Six wells each of wild type, heterozygous 
and homozygous positive control and negative (no DNA) controls were included for each 
plate. PCR amplification conditions were 50°C for 2 minutes and 95°C for 10 minutes, 
followed by cycling conditions which generally consisted of 40 cycles of 95°C for 15 
seconds and 61-63°C for 1 minute (see table 2 for exact annealing temperature for each 
assay). All amplified samples were analyzed using ABI sequence detection system 7200 
(PE Biosystems) under allelic discrimination mode. 
Primers Probes Annealing 
concentration (nM) concentration (nM) temperature 
Forward Reverse FAM TET 
XRCC2 R188H 300 300 25 50 63°C 
XRCC3 T241 M 300 300 50 100 62°C 
BRCA2 N372H 300 300 25 100 62°C 
RAD51 G135C 900 900 50 150 61 °C 
Table 2: TaqMan probe and primer concentrations. 
Probes and primers concentration and annealing temperature for 5' nuclease PCR (TagManTm) for 
XRCC2, XRCC3, BRCA2 and RAD51 genotyping. 
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3.2.5. DNA Sequencing 
DNA sequencing was used to confirm sequence variants in the XRCC2 and XRCC3 genes 
following PCR-SSCP. PCR for sequencing reactions was carried out in a 5Opl volume 
using the same conditions and primers as described in sections 3.2.4.1 and 2.3.6. 
3.2.6. Statistical analysis 
All data were entered into a Microsoft Access database and exported to Stata version 6.0 
for the statistical analyses. DNA was available for 522 breast cancer cases, 496 
mammography screening controls, and 399 blood donor controls. The power of study for 
each SNP was calculated by using Stata software version 6.0 using Sampsi command 
(Stata, 2000). Chi-squared tests on 2x2 contingency tables and the Wilcoxon rank sum test 
was used for comparison of variables between BCC and MSC (Kirkwood, 1988). The Odds 
ratios and 95% confidence intervals were determined for the genotype comparisons. Odds 
ratio was calculated by standard method (Bland and Altman, 2000). Confidence interval for 
the odds ratio was estimated by Woolf method (Woolf, 1955). Cases and mammography 
screening controls were matched for by age restricting analysis to those cases and 
controls diagnosed/recruited between ages 50-65 years. This is the age range of women 
routinely invited for mammography screening. Only 64 out of 496 controls in this study 
were outside this range, insufficient for analysis of other age strata. We also used extreme 
sampling, which has been shown to increase efficiency for genes involved in complex 
inheritance (Morton and Collins, 1998). The comparison groups for this analysis were 
defined as cases with age at diagnosis below the median age 57 years, with a positive 
family history (n=88), versus controls aged over 57 years with no family history of breast 
cancer (n= 181). Mantel-Haenszel test of homogeneity was used to calculate the 
significance of difference between the odds ratios for one SNP in the presence and 
absence of other HRR variant allele using Stata version 6.0 (Stata, 2000). Since data on 
exposure to X-Ray and ionising radiation was not available we were unable to analyse our 
data for the effect of gene-exposure interactions. 
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3.3. Results 
3.3.1. Characteristics of patients and controls 
Summary statistics for the risk factor variables for the BCC and MSC groups are shown in 
Table 3. Only age and sex data were available for the BDC group. Their age range was 
significantly lower than the BCC group (median 39, range 20-64; p<10-12). There were no 
significant differences between the breast cancer cases and mammography screening 
controls for age at diagnosis/sampling (p=0.31), body mass index (p=0.14), or age at 
menarche (p=0.33). However, the breast cancer cases had fewer children (p=0.0009), a 
higher age at first pregnancy (p=0.0021), a higher age at menopause (p=0.0069) and a 
higher proportion of them had no children (p=3.9x10-6). In addition, a higher proportion of 
breast cancer cases had at least one first or second degree relative with breast cancer 
(p=0.00074). Although there was no significant difference in median age between the 
breast cancer cases and mammography screening controls, the age range of the controls 
was narrower. This difference in age ranges probably accounts for the much higher 
proportion of controls who had received HRT and OCP (p<10-12 and p=2.3x10-11 
respectively). HRT and OCP were not available to the older cases. For example, amongst 
those individuals born after 1940, for whom OCP would have been available during their 
reproductive years, there was no significant difference in OCP use between cases and 
controls (69.7% vs 71.9%; p=0.58). 
3.3.2. The XRCC2, XRCC3, BRCA2 and RAD51 genotyping 
To determine whether there is any association between carriage of variant alleles of DNA 
repair genes and susceptibility to breast cancer, we genotyped 522 independent breast 
cancer cases, 496 healthy women from mammography screening and 399 healthy female 
blood donors controls for four single nucleotide polymorphisms in XRCC2, XRCC3, BRCA2 
and RAD51 genes using PCR-SSCP and TagManTM as described in section 3.2.4.2 
(Figure 1). The different band patterns on the SSCP gel and genotype categories on the 
TagManTM analysis were clearly distinguishable between different genotypes and were 
confirmed by direct sequencing (Fig 1). To ensure the accuracy of the genotyping results 
from SSCP, 150 samples (15%) were also selected randomly and genotyped by 
TagManTM. The result of genotyping with TagManTM was more than 99% in agreement with 
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the result of genotyping obtained by SSCP. Also 25 samples from different band categories 
were randomly selected and subjected to direct sequencing that confirmed the result of 
both genotyping techniques. The result of TagManT"' genotyping of the XRCC2, BRCA2 
and RAD51 was also confirmed by SSCP and direct sequencing as described above. 
BCC MSC 
continuous variables n median range n median range pa 
Age at diagnosis (yr) 522 57 28-89 494 57 45-77 0.31 
BMI 498 25.9 9.2-44.2 493 26.2 18.7-52.9 0.14 
Age at first 419 24 16-41 447 23 16-40 0.0021 
pregnancy (yr) 
number of children 486 2 0-8 460 2 0-8 0.0009 
Age at menarche (yr) 508 13 9-18 493 13 9-18 0.33 
Age at menopause (yr) 420 50 29-61 416 49 24-59 0.0069 
binary variables n frequency % n frequency % Pb 
Children 486 434 89.3% 460 446 97.0% 3.85x10-6 
HRT 521 103 19.8% 496 220 44.4% <10-12 
OCP 521 209 40.1% 496 303 61.1% 2.28x10.11 
BrCaFH 521 168 32.3% 496 113 22.8% 0.00074 
Table 3: Characteristics of breast cancer patients and controls. 
a Wilcoxon rank sum test. b Chi-squared test. Age at diagnosis indicates age at diagnosis for cases 
and age at blood sampling for controls. BCC: breast cancer cases, MSC: mammography 
screening controls. n indicates number of observations available for that variable. BM I: body mass 
index. HRT: hormone replacement therapy, OCP: oral contrceptive pill. BrCaFH: breast cancer 
family history (at least one first or second degree relative with breast cancer). 
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Figure 1: PCR-SSCP and TaqMan genotyping. 
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A; Image of SSCP assay for XRCC3 T241M genotyping carried out on 12% non-denaturing 
polyacrylamide gel. Chromatogram of DNA sequencing has also shown under each relevant 
genotype. Arrows indicate different band patterns related to each genotype (arrows indicates sites 
of polymorphisms). B; Image of TagManTM assay for XRCC2 R188H genotyping. X axis: detects 
allelel (wild type) and labelled with FAM, Y axis: detects allele 2 (variant allele) and labelled with 
TET, Red dots: samples with wild type sequence, green dots: heterozygote samples and blue dots: 
rare homozygote samples. The result of sequencing for each genotype has also shown (arrows 
indicates sites of polymorphisms). 
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3.3.3. Analysis of genotyping data 
For XRCC3 and BRCA2 our association study with sample size of 522 cases and 500 
controls was powerful enough (83%, 88% respectively) to detect an OR of 1.5 for carriage 
of at least one copy of variant allele. For XRCC2 and RAD51, however, the power of the 
study was lower, 65% and 64% respectively, due to the lower rare allele frequency of these 
SNPs. 
The genotype frequency counts for the BCC, MSC and BDC groups are shown in Table 4. 
Genotype distributions at each locus for both control groups were consistent with the 
Hardy-Weinberg equilibrium. Expected genotype frequencies for each locus were 
calculated according to the Hardy-Weinberg equilibrium and the difference between 
observed and expected frequencies was calculated by Chi-squared test, We did not detect 
any statistically significant differences between observed genotype frequencies and what 
we expected under the Hardy-Weinberg equilibrium (Table 4). The odds ratios for the 
various genotype comparisons between cases and controls for the whole data set are 
shown in Table 5. We did not observe any statistically significant differences in variant 
allele frequencies in XRCC3 when cases were compared to either the MSC or BDC control 
groups (Table 5). Although not statistically significant, the frequency of the rare allele of the 
RAD51 was lower in the BCC than the MSC genotypes (Table 5); this would need to be 
confirmed in a larger dataset. Therefore this study does not support that XRCC3 or RAD51 
genotypes affect the risk of breast cancer. The presence of the rare homozygous genotype 
of BRCA2 shows a weak positive association with breast cancer, although not statistically 
significant possibly due to small sample size. We also did not observe any significant 
difference in the frequency of BRCA2 heterozygote allele when cases were compared to 
either of MSC or BDC controls (Table 5). The presence of the A allele of XRCC2 was 
associated with the increased risk of breast cancer when cases were compared to the BDC 
controls (odds ratio 1.58 (1.07,2.34)). There is some evidence that carriage of the XRCC2 
HH genotype is more associated (2.43 (0.48,12.14)) with an increased risk of breast 
cancer than carrying one variant allele 1.59 (1.06,2.36)), although this does not reach 
statistical significance probably due to small size sample. This positive association was 
reduced in the comparison between BCC and MSC controls (odds ratio 1.15 (0.82,1.62)), 
and fell just short of statistical significance when the two control groups were combined 
(odds ratio 1.32 (0.98,1.79)) (Table 5). 
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Case/ control Odds ratio (95% Cl) 
w/w vs w/v 
Odds ratio (95% Cl) 
w/w vs v/v 
Odds ratio (95% Cl) 
w/w vs w/v+v/v 
XRCC2 
BCC N/A N/A N/A 
MSC 1.12 (0.79,1.58) 1.94 (0.48,7.84) 1.15 (0.82,1.62) 
BDC 1.59 (1.06,2.36) 2.43 (0.48,12.14) 1.58 (1.07,2.34) 
MSC+BDC a 1.29 (0.95,1.76) 2.14 (0.65,7.06) 1.32 (0.98,1.79) 
XRCC3 
BCC N/A N/A N/A 
MSC 1.06 (0.81,1.38) 1.05 (0.71,1.54) 1.05 (0.82,1.36) 
BDC 0.94 (0.7,1.25) 0.9 (0.6,1.35) 0.93 (0.71,1.22) 
MSC+BDC 1.00 (0.79,1.27) 0.98 (0.7,1.37) 1.00 (0.80,1.25) 
BRCA2 
BCC N/A N/A N/A 
MSC 1.07 (0.83,1.40) 1.15 (0.72,1.85) 1.09 (0.85,1.40) 
BDC 0.91 (0.69,1.20) 1.29 (0.76,2.19) 0.96 (0.74,1.25) 
MSC+BDC 1.00 (0.79,1.25) 1.21 (0.80,1.84) 1.03 (0.83,1.28) 
RAD51 
BCC N/A N/A N/A 
MSC 0.85 (0.59,1.22) 0.30 (0.03,2.94) 0.82 (0.57,1.18) 
BDC 0.74 (0.51,1.08) 0.36 (0.032,4.00) 0.73 (0.5,1.06) 
MSC+BDC 0.80 (0.58,1.10) 0.32 (0.04,2.81) 0.82 (0.6,1.13) 
Table 5: Odds ratios and 95% Cl between cases and controls 
Odds ratios and 95% confidence interval (CI) between cases and controls for XRCC2, XRCC3, 
BRCA2 and RAD51. 
a Combined mammography screening controls and blood donor controls. Other abbreviations as 
table 4. 
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3.3.4. Relationship between genotype and age of diagnosis 
Data on age at diagnosis, family history of breast cancer, tumour histology types, tumour 
grade, and vascular invasion were available for 500 cases. We examined the significance of 
each polymorphism related to some of these variables. 
Age is one of the important risk factors for breast cancer. We therefore performed a number 
of analyses to study whether carriage of these variant alleles conferred increased risk of 
breast cancer in a specific age group. Since 87.4% of women in MSC were in age group of 
50-65 years, the age range for which women routinely attend mammography screening, we 
compared breast cancer cases of 50-65 years old with the age matched group from MSC. 
No significant differences in variant allele frequency were observed when carriage of at 
least one variant allele of XRCC2, XRCC3, BRCA2 and RAD51 was compared between 
cases and controls, and the size of the odds ratios were consistent with the whole dataset 
analysis (Table 6). The median value of age for both BCC and MSC was 57 years, therefore 
we analysed the genotyping results from BCC and MSC below 57 years and also BCC and 
MDC above 57 years. However no difference between cases and controls was observed for 
carriage of rare allele frequency in both age groups (Table 6). 
3.3.5. Relationship between genotype and family history 
The effect of some variants is only seen in those with positive family history of breast cancer 
(eg. CHEK2 1100deIC, (Meijers-Heijboer, et al., 2002). To determine the effect of these 
sequence variants in combination with family history in association with breast cancer, we 
selected cases with a positive family history of breast cancer and compared them to MSC 
with no family history of breast cancer. As shown in table 7, we did not observe any 
difference for the effect of the variant alleles compared to the analysis of the whole dataset. 
Although not statistically significant, the odds of having breast cancer were higher in cases 
with positive family history for carriers of BRCA2 variants relative to odds of having cancer 
from comparison of BCC and MSC in whole data set. 
To increase power to detect weak genetic effects, it has been proposed that extreme 
sampling may be useful (Morton and Collins, 1998). Therefore we selected cases of 
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younger onset (below the median value of 57 years) with a positive family history of breast 
cancer and compared them with older controls (above 57 years) that had no family history 
of breast cancer. The odds ratios of having breast cancer in cases carrying at least one 
variant allele in XRCC2, XRCC3, BRCA2 or RAD51 genes are all slightly increased relative 
to the whole dataset comparison of BCC with MSC (Table 8). In particular, there was a 
suggestive effect for carriage of the XRCC2 A allele when younger onset cases with a 
positive family history were compared to older controls with no family history, (odds ratio 
1.82 (0.91,3.64); Table 8). Although not statistically significant these results are consistent 
with the idea that in familial cases a combination of factors may act together to increase the 
effect of a particular allele. 
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Chapter 3- The association between SNPs of HRR genes and breast cancer susceptibility 
3.3.6. Relationship between genotype and histopathological markers 
Histopathological data was available on 493 tumours from our data set. The majority (294; 
59.6%) of tumours were of the ductal NOS type, 49 (9.9%) were lobular, 102 (20.6%) were 
ductal special types and the remaining 49 (9.9%) were other types. The rate of carriage of 
the XRCC2 H allele was 32.7% in the lobular type, compared to 16% in the ductal NOS type 
and 14% in the ductal special types (p=0.001). Although this preliminary result suggests that 
the XRCC2 rare allele is significantly associated with the lobular carcinoma of breast, 
however due to small sample size (n=49), this should be repeated in a bigger dataset. We 
however could not find any association between rare variants of the other genes and breast 
tumour histology. No significant association was observed between the site of tumour and 
carrying variant alleles in any of the genes (Table 9). Carriage of the RAD51 rare allele 
seems to have a preventive role against vascular invasion (OR: 0.36 (0,14,0.95), p=0.03), 
although this also needs to be confirmed in a bigger data set (Table 9). 
3.3.7. Preliminary analysis of interaction between variant alleles of HRR in 
association with breast cancer 
Given our hypothesis that the effects of variation in several proteins involved in homologous 
recombination repair may combine to produce susceptibility to cancer, we also tested for 
interaction between the XRCC2, XRCC3, BRCA2 and RAD51 polymorphisms. All possible 
pairwise interactions were tested in which the odds of cancer for carriage of at least one 
rare allele were calculated at the presence and absence of the other three variants. As 
shown in table 10, XRCC2 A allele is associated with a more increased risk of cancer in the 
presence of XRCC3 T allele (1.50 (0.97,2.31), p=0.063) and absence of BRCA2 C allele 
(1.60 (0.98,2.60), p=0.065). Our data also show that the effect of XRCC3 T allele increases in 
the presence of XRCC2 A allele (1.86 (0.97,3.55), p=0.063) and BRCA2 C allele (1.35 
(0.93,1.96), p=0.068). Also for BRCA2 rare allele the association with breast cancer is more 
evident at presence of XRCC3 T allele than in its absence (1.32 (0.96,1.82), p= 0.068), 
however the association of BRCA2 C allele with breast cancer increase in the absence of 
XRCC2 A allele (1.21 (0.92,1.59), p=0.065). The odds of having cancer for RAD51 C allele 
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shows more of a protection effect in the presence of rare XRCC2 and XRCC3 alleles (Table 
10). The results suggest that the interaction of XRCC2 and XRCC3 genes is associated with 
increased susceptibility to breast cancer. Also the present study suggests that XRCC3 and 
BRCA2 interaction is more associated with breast cancer risk. However the association of 
XRCC2 polymorphism with breast cancer increased in the absence of BRCA2 and the effect 
of BRCA2 on breast cancer susceptibility was more evident in the absence of XRCC2. 
Although all of the above results of interaction analysis are not statistically significant, they 
suggest hypothesis that could be tested in an independent dataset. 
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w/w w/v + v/v Total P 
XRCC2 
Tumour histology Lobular 33 (67.3%) 16 (32.7%) 49 0.001a 
Ductal specified 84 (84%) 16(16%) 100 
Ductal NOS 252 (86%) 41(14%) 293 
Tumour site Right-sided 202(81.7%) 45(18.3%) 247 
Left-sided 212 (84.4%) 39 (15.6%) 251 0.42 
Bilateral 16(80%) 4 (20%) 20 0.71 
Vascular invasion Yes 75 11 0.11 
No 273 69 
XRCC3 
Tumour histology Lobular 17 (34.6%) 32(65.4%) 49 0.531, 
Ductal specified 42(41.5%) 59(58.4%) 101 
Ductal NOS 113(38.4%) 181(61.6%) 294 
Tumour site Right-sided 91(36.7%) 157(63.3%) 248 
Left-sided 106 (42%) 146 (58%) 252 0.21 
Bilateral 4 (20%) 16 (80%) 20 0.08 
Vascular invasion Yes 34 52 0.88 
No 133 211 
BRCA2 
Tumour histology Lobular 30(61.3%) 19(38.7%) 49 0.148 
Ductal specified 53(53%) 47 (47%) 100 
Ductal NOS 144 (49.3°/x) 148 (50.7%) 292 
Tumour site Right-sided 117 (47.5%) 129 (52.5%) 246 
Left-sided 134 (53.6%) 116(46.4%) 250 0.17 
Bilateral 9(45%) 11 (55%) 20 0.62 
Vascular invasion Yes 44 42 0.86 
No 171 170 
RAD51 
Tumour histology Lobular 42(85.71%) 7 (14.29%) 49 0.898 
Ductal specified 90(91.83%) 8(8.17%) 98 
Ductal NOS 246 (84.53%) 45(15.47%) 291 
Tumour site Right-sided 209 (85%) 37 (15%) 246 
Left-sided 223 (90%) 25 (10%) 248 0.09 
Bilateral 16 (80%) 4 (20%) 20 0.32 
Vascular invasion Yes 80(94.11%) 5 (5.89%) 0.03 
No 290 (85.45%) 49(14.45%) 
Table 9: The association between HRR gene SNPs and histopathologic characteristics. 
Comparison of genotype frequencies and histopathologic characteristics of breast tumours. NOS: 
not otherwise specified, Ductal specified includes: tubular, mucinous, medullary, papillary 
carcinomas. w/w: wild type/wild type; w/v+ v/v: carriage of at least one variant allele. ap calculated 
by comparison of lobular carcinoma and ductal carcinoma (ductal NOS+ ductal specified together). 
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MSC Test of homogeneity 
OR (95% CI)a P 
XRCC2 T present 1.50 (0.97,2.31) 0.063 
1.32 (0.98,1.79) XRCC3 CIT T absent 0.77 (0.44,1.33) 
C present 0.84 (0.51,1.36) 0.065 
BRCA2 A/C C absent 1.60 (0.98,2.60) 
C present 0.60 (0.22,1.63) 0.16 
RAD51 G/C C absent 1.28 (0.89,1.84) 
XRCC3 A present 1.86 (0.97,3.55) 0.063 
1.00 (0.80,1.25) XRCC2 G/A A absent 0.95 (0.72,1.26) 
C present 1.35 (0.93,1.96) 0.068 
BRCA2 A/C C absent 0.84 (0.59,1.19) 
C present 0.62 (0.31,1.25) 0.11 
RAD51 GIC C absent 1.14 (0.87,1.50) 
BRCA2 A present 0.63 (0.33,1.19) 0.065 
1.03 (0.83,1.28) XRCC2 G/A A absent 1.21(0.92,1.59) 
T present 1.32 (0.96,1.82) 0.068 
XRCC3 C/T T absent 0.82 (0.55,1.22) 
C present 1.26 (0.64,2.46) 0.62 
RAD51 G/C C absent 1.05 (0.80,1.37) 
RAD51 A present 0.43 (0.16,1.16) 0.16 
0.82 (0.60,1.13) XRCC2 G/A A absent 0.91 (0.62,1.35) 
T present 0.65 (0.41,1.03) 0.11 
XRCC3 C/T T absent 1.20 (0.66,2.17) 
C present 0.911 (0.54,1.51) 0.62 
BRCA2 A/C C absent 0.76 (0.45,1.26) 
Table 10: Gene-gene interaction between HRR gene SNPs in breast cancer. 
Studying interaction between XRCC2, XRCC3, BRCA2 and RAD51genes. 
a Odds ratios and 95% confidence interval (CI) were calculated for carriage of at least one variant (v) 
allele of each gene between breast cancer cases (BCC) and mammography screening controls 
(MSC) at the presence and absence of rare variants of other genes. 
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3.4. Discussion 
Deficient DNA repair has been reported in breast cancer patients and healthy women with a 
family history of breast cancer (Parshad, et al., 1996, Patel, et al., 1997, Roberts, et al., 
1999, Scott, et al., 1999). Thus hereditary genetic defects in DNA repair capacity arising 
from genetic polymorphisms may be associated with breast cancer. We have used a case 
control series of 1416 individuals to determine whether there is any association between 
genotype of polymorphisms at HRR genes XRCC2, XRCC3, BRCA2 and RAD51 and breast 
cancer. 
We observed a suggestive association between carriage of XRCC2 GA/AA genotype and 
breast cancer (odds ratio for combined control groups 1.32 (0.98,1.79)). Although not 
statistically significant, the carriage of XRCC2 AA genotype was more associated with 
increased risk of breast cancer (2.14 (0.65,7.06)). These results need to be confirmed in a 
larger study. Whilst we found no significant effect for age and family history per se, our 
results show that the association is greater in the selected cases and controls when 
younger cases with positive family history compared to older controls without family history 
of breast cancer (odds ratio 1.82 (0.91,3.64)). Most of malignant breast tumours are ductal 
carcinoma; our data, however, indicate that carriage of XRCC2 rare allele is more 
associated with lobular breast carcinoma (p=0.001). There is also some evidence on 
combinatory effect of XRCC2 and XRCC3 polymorphisms, as we detected that the 
association of XRCC2 GA/AA genotype with breast cancer is higher at the presence of 
XRCC3 rare allele (p=0.06). Our case-control study had 65% and 35% statistical power (a= 
0.05) to detect odds ratio of 1.5 and 1.3 for carriage of the rare XRCC2 allele (using BCC 
and MSC). If we suppose that the real odds ratio for carriage of rare XRCC2 allele is 1.32 
as we found in our study, a bigger case-control study consisting of at least 1600 cases and 
1600 controls is needed to have enough power (80%) to detect this OR. Coincidentally and 
consistent with the present study, a significant positive association was also reported 
between the XRCC2 AA genotype and breast cancer (Kuschel, et al., 2002), thus providing 
confirmation of XRCC2 AA as a risk factor for breast cancer. One of a few studies on the 
functional aspect of SNPs of DNA repair genes has been carried out on the XRCC2 R188H 
polymorphism. Although the functional effect for R188H substitution is weak, our 
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collaborators showed that non-conservative substitution or deletion of amino acid position 
188 causes significant deleterious effect on cell survival following DNA damage (Rafii, et al., 
2002). The small association between carriage of rare allele and breast cancer can reflect 
the small functional effect of this variant on the protein function. 
We however did not find any association between carriage of rare alleles of XRCC3, 
BRCA2 and RAD51 and breast cancer. Although our study had 83% statistical power to 
detect odds ratio of 1.5, we did not detect any association between carriage of the XRCC3 
rare allele and breast cancer. The association of XRCC3 T241 M polymorphism with cancer 
has been studied in number of experiments and produced rather conflicting results. A 
positive association was reported between carriage of rare allele and malignant melanoma, 
bladder cancer and breast cancer (Kuschel, et al., 2002, Matullo, et al., 2001, Winsey, et al., 
2000). Malignant melanoma and bladder cancer studies were carried out using a relatively 
small sample size (Table 11). Furthermore in a relatively larger study, the malignant 
melanoma association was not replicated (Duan, et al., 2002) and the association with 
bladder cancer did not produce the same result and fell short of statistical significance 
(Stern, et al., 2002). In a small study no association was found between carriage of XRCC3 
T allele and breast cancer (Smith, et al., 2003). No association was also found between 
carriage of XRCC3 rare allele and lung cancer (Butkiewicz, et al., 2001, David-Beabes, et 
aL, 2001, Misra, et al., 2003, Smith, et al., 2003) and a weak association with squamous cell 
carcinoma of head and neck (SCCHN) was statistically insignificant (Shen, et al., 2002). 
Despite having over 99% statistical power to detect an odds ratio of 2.36 (as in the 
melanoma study) or 2.77 (as in the bladder cancer study), our study did not have good 
power (49%) to exclude an effect of XRCC3 if the true odds ratio were close to 1.3 as it is 
seen in most of other studies (breast cancer, SCCHN and bladder cancer; Table 11). Thus 
the lack of association in our dataset may be partly due to lack of power. 
We observed a weak association between carriage of BRCA2 372HH genotype and breast 
cancer that is statistically non-significant. We also identified that the association between 
carriage of H genotype and breast cancer is statistically higher at the presence of XRCC3 M 
allele than in its absence. The results from other independent studies show that there is 
weak effect for BRCA2 372HH variant in association with breast cancer and ovarian cancer, 
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In one relatively large study using five independent data sets, a weak association was 
reported with breast cancer (OR=1.31 (1.07,1.61)), although this effect was not statistically 
significant in all data sets analysed (Healey, et at, 2000). A suggestive weak association 
was also reported with ovarian cancer in UK population (OR=1.25 (0.89,1.74)) (Auranen, et 
at, 2003). Two other studies using Australian populations also reported OR= 1.47 and 1.51 
for breast and ovarian cancer respectively (Auranen, et aL, 2003, Spurdle, et al., 2002). 
Thus our data on BRCA2 N372H polymorphism is consistent with these published results. 
Cancer Cases Controls OR (95% Cl) Reference 
Breast cancer 2205 1826 1.30 (1.1,1.6) Kuschel B, 2002 
Breast cancer 162 302 0.95 (0.64,1.40) Smith TR, 2003 
Bladder cancer 124 85 2.77 (1.55,4.93) Matullo G, 2001 
Bladder cancer 233 209 1.30 (0.9,1.9) Stern MC, 2002 
Lung cancer 313 306 0.96 (0.69,1.34) Misra RR, 2003 
Lung cancer 331 687 0.92 (0.67,1.28) David-Beabes GL, 2001 
Lung cancer 96 96 N/A a Butkiewicz D, 2001 
Malignant Melanoma 125 211 2.36 (1.44,3.86) Winsey SL, 2000 
Malignant Melanoma 305 319 0.89 (0.65,1.24) Duan Z, 2002 
SCCHN 367 354 1.36 (0.89,2.08) Shen H, 2002 
Table 11: Studies on association between the XRCC3 T241 M SNP and cancer. 
a No difference was observed in genotype frequencies between cases and controls 
No association was identified between carriage of the rare RAD51 allele and breast cancer. 
Although carriage of the rare allele showed more protection against breast cancer, 
comparison of BCC with either of the controls could not reach any statistically significant 
association. Association of this polymorphism with breast cancer has been considered in 
few studies. Consistent with our result, in a large study no association was found for 
carriage of the heterozygous allele and the overall OR for carriage of the RAD51 C allele 
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was 0.86 (0.68,1.08) (Kuschel, et al., 2002). However the rare RAD51 allele appeared to be 
associated with increased risk of breast cancer in BRCA1 and BRCA2 mutation carriers 
(Levy-Lahad, et al., 2001, Wang, et al., 2001). We did not observe any evidence indicating 
that presence or absence of rare XRCC2, XRCC3 or BRCA2 alleles affect the association of 
the rare RAD51 allele with breast cancer. 
In conclusion the present study suggests that common SNPs of DNA repair genes may 
contribute to breast cancer susceptibility. The observed weak associations of XRCC2 
R188H and BRCA2 N372H are consistent with the published studies. Due to the small 
effect of these polymorphisms, no single SNP is sufficient on its own to predict occurrence 
of a clinical phenotype with acceptable accuracy. Furthermore as our data suggest the 
effect of a specific SNP might not be apparent unless in the presence or absence of others. 
Therefore to explain the genetic basis of breast cancer a polygenic approach in which the 
combinatory effect of several common low-penetrant genes with each other and also with 
the environment seems to be needed (Pharoah, et aL, 2002). 
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4. The effect of rare sequence variants on the DNA 
repair activity of XRCC3 
4.1. Introduction 
It is important for cells to have the capacity to correct DNA damage and maintain genome 
stability. This ability is lost in most cancer cells. DNA Double Strand Breaks (DSBs), 
caused by ionizing radiation and other forms of DNA damages are lethal if unrepaired. 
Cells, however, can repair DSBs through Homologous Recombination (HR) or Non 
Homologous End Joining (NHEJ) repair. HRR is an accurate and high- fidelity repair 
mechanism, whereas NHEJ repair is more error-prone (Khanna and Jackson, 2001) 
Defects in the process of HRR can cause mutations, chromosomal breakage, 
translocations and cancer, in part by shifting the repair of DSBs toward NHEJ 
(Brenneman, et al., 2002). Therefore HR is necessary for maintaining genome stability and 
cells deficient in this repair pathway show high levels of chromosomal aberrations (Cui, et 
a!., 1999, Thacker, 1999). 
Rad5l, a eukaryotic homologue of E coli RecA, is believed to play a central role in HR. 
Following DNA damage Rad5l forms nuclear foci, where HR and DSBs repair are 
presumably taking place. Two other proteins, Rad55 and Rad57, have been identified in 
yeast and form a heterodimer which interacts with Rad5l and dramatically enhance 
homologous pairing catalyzed by Rad5l (Sung and Stratton, 1996). No direct human 
homologues for Rad55 and Rad57 have been identified. However five genes (Rad51 L1 
(Rad51 B), RAD51 L2 (Rad51 C), RAD51 L3 (Rad51 D), XRCC2 and XRCC3) with 20-30% 
sequence identity to Rad5l have been identified. This homology is mostly confined to two 
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highly conserved ATP binding sites termed Walker Boxes (Thacker, 1999). Very little is 
known about the precise function of these genes, however, it has been shown that Rad5l 
family members interact with each other and with Rad5l and facilitate the assembly of 
Rad51 at site of DSBs (Masson, et at, 2001). XRCC3 interacts with both Rad5l and 
Rad51C and is required for the formation of damage-induced Rad5l sub-nuclear foci 
(Bishop, et at, 1998, Kurumizaka, et al., 2001, Masson, et at, 2001) . Cells lacking 
XRCC3, in particular, show an elevated number of spontaneous and radiation induced 
chromosomal breaks and rearrangements (Cui, et at, 1999, Fuller and Painter, 1988). 
These defects can be fully corrected by XRCC3 transfection (Tebbs, et at, 1995), 
suggesting the importance of XRCC3 in maintaining genomic instability. Cell lines lacking 
XRCC3 such as irs1SF are also significantly sensitive to ionizing radiation and the DNA 
cross-linking agents cisplatin and Mitomycin-C (Cui, et al., 1999, Tebbs, et al., 1995). 
Moreover, irs1SF cells exhibit a 25-fold decrease in levels of homologous recombination 
(Pierce, et al., 1999). Although XRCC3 was believed to act as an accessory to Rad5l for 
initiating HR, recent findings indicate that deficiency in the function of XRCC3 can affect 
both initiation and progression of HRR, and could result in chromosomal rearrangement/ 
instability by shifting DSBs repair from HR to error prone NHEJ repair (Brenneman, et al., 
2002). Chromosomal rearrangements, long gene conversion tracts and unstable 
heteroduplex DNA structure have been reported in XRCC3 deficient cells (Brenneman, et 
al., 2002), suggesting a more important role for XRCC3 in maintaining genome stability. 
XRCC3 is also important for precise chromosome segregation at mitosis and preventing 
centrosome fragmentation (Griffin, et al., 2000). 
Given the importance of BRCAI and BRCA2 in the prevention of breast cancer and the 
importance of Rad5l paralogues in the maintenance of chromosome stability, there has 
been considerable interest in the effect of mutations of these genes on cancer 
predisposition. Several single nucleotide polymorphisms in HRR genes including XRCC3 
have been identified and a number of studies have focussed on the potential role of these 
common polymorphisms as low-penetrance cancer susceptibility alleles (Healey, et al., 
2000, Matullo, et al., 2001, Stern, et ah, 2002, Stem, of ah, 2002, Winsey, et al., 2000), but 
thus far only limited information is available on the functional effects of such alleles. 
Although the functional significance of most of these polymorphisms has not yet been 
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determined, In vitro studies on some of them are suggestive of weak effect on the DNA 
repair capacity (Rafli, et al., 2002), which needs further investigation. 
In this study we report four novel single nucleotide polymorphisms in XRCC3 gene. 
Although in rare frequency, one of them can drastically affect the function of the protein. 
We also investigated whether carrying this allele was associated with increased 
susceptibility to cancer. 
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4.2. Materials and methods 
4.2.1. Cancer patients and controls 
Genomic DNA was extracted from venous blood samples from subjects recruited as 
follows. Unrelated breast cancer patients were recruited from surgical outpatient clinics at 
the Royal Hallamshire Hospital, Sheffield, UK between November 1998 and June 2001. 
Healthy women attending mammography screening in Sheffield were recruited 
concurrently. This is the same cohort of patents and controls described in chapter 3. DNA 
samples from Swedish women with breast cancer and a family history of breast cancer 
were obtained by Annika Lindblom*. Healthy males and females were recruited from 
amongst blood donors in Sheffield. Patients with bladder and prostate cancer were 
recruited from urology clinics at the Royal Hallamshire Hospital Sheffield, and colorectal 
cancer patients were recruited from those receiving surgery in Sheffield or neighbouring 
hospitals. Multi-case cancer families were recruited from regional oncology clinics at 
Weston Park Hospital, Sheffield. Ethical committee approval was obtained from South 
Sheffield Research Ethics Committee and informed consent was obtained from all subjects 
(See appendix 1). 
4.2.2. PCR amplification for SSCP genotyping 
DNA amplifications were carried out using 100ng genomic DNA, 6pmol of each primer 
(Table 1), and 18.2N1 1.1xPCR master mix (AB gene) in final volume of 20pl. Cycling 
conditions were 5 minutes at 95°C followed by 35 cycles of 95°C for 35 seconds, 61 °C for 
25 seconds and 72°C for 25 seconds. A final extension of 5 minutes at 72°C was also 
applied after cycles were finished. 
4.2.3. SSCP screening 
SSCP screening of sample was performed as described in section 2.3.5.1. A 12% 
Polyacrylamide gel and 5500 volt hours were used for electrophoresis. 
* see appendix for list and address of collaborators 
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4.2.4. TaqManTM genotyping 
DNA amplifications for 5'nuclease PCR were carried out using 12.5 NI 2X qPCR mastermix 
(Eurogentec), 20ng genomic DNA template, 5OnM of forward and 300nM of reverse 
primers, 5OnM FAM-labelled probe and 125nM TET-labelled probe (Table 1) in a final 
volume of 25pl. The cycling conditions were 50°C for 2 minutes, 95°C for 10 minutes, 
followed by 40 cycles of 95°C for 15 seconds and 63°C for 1 minute. Samples were then 
analysed using the ABI 7200 Sequence Detector to determine levels of FAM and TET. 
4.2.5. Mammalian Cell Culture 
Wild-type Chinese Hamster Ovary (CHO) XRCC3 proficient (AAB) and XRCC3-deficient 
(irslSF) cells, human colorectal carcinoma (SW480) and human skin fibroblast cells 
(LM217E) were cultured in monolayer in Dulbecco's modified eagle's medium (Life 
Technologies Inc. ) supplemented with 9% foetal calf serum. Cells were grown at 37°C in 
5% CO2 humidified incubator. 
4.2.6. Site-directed Mutagenesis 
Human XRCC3 mRNA was extracted from the LM217E cell line as described in section 
2.3.7 and was reverse transcribed to cDNA, amplified using Pfu Turbo polymerase 
(Stratagene) as described in section 2.3.8. The XRCC3 cDNA was then cloned into 
mammalian expression vector pcDNA 3.1Ns-His Topo TA (Invitrogen) as stated in section 
2.3.9. The mutagenic polymerase chain reaction was carried out using QuikChange site- 
directed mutagenesis kit (Stratagene) with mutagenic primers (Table 1) designed to create 
changes at desired positions (Also see section 2.3.10). All created mutations were 
confirmed by direct sequencing. 
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4.2.7. Transfection of mutant constructs into mammalian cell line 
Approximately 15Ng of plasmids carrying wild type and each mutant DNA were transfected 
into irs1SF cells by electroporation (Bio-Rad Gene Pulser at 400V and 125 pF) as 
described in section 2.3.12.1. A total of 5X105 cells were seeded into 100mm plates and 
incubated for 14 days in 100 Ng/ml of G418. 
4.2.8. RNA extraction and RT-PCR 
Messenger RNA was extracted from the same clones for which drug sensitivity had already 
been determined using Oligotex Direct mRNA micro kit (QIAGEN) according to the 
manufacturer instructions. Since the hamster XRCC3 sequence was not available on the 
database, mouse and human XRCC3 sequence were aligned and RT- PCR primer 
designed to only amplify the human sequence (Table 1). RT-PCR was performed 
according to the condition described in section 2.3.14.2. A negative control (excluding 
reverse transcriptase) was used for each sample to eliminate the possibility that any PCR 
products originated from contaminating DNA. 
4.2.9. Drug toxicity assay 
Cell survival assays were performed by exposing cells from individual variant or wild type 
clones to the DNA cross-linking agent Mitomycin-C (MMC), Topo isomerase inhibitor 
Camptothecine (CPT) and Thymidine as described in section 2.3.17. Plating efficiency was 
assessed in triplicate for each clone. 
4.2.10. Western Blotting 
Cells were grown to sub-confluent levels in tissue culture plates; total protein was extracted 
and quantified using the coomasie plus protein assay (Pierce) as described in sections 
2.3.15.1 and 2.3.15.2. A 20pg protein for each sample was subjected to electrophoresis on 
a 10% SDS-polyacrylamide gel. Following electrophoresis, the proteins were transferred 
onto polyvinylidene difluoride membrane (Bio-Rad) as described in sections 2.3.15.4 and 
2.4.4. XRCC3 protein was detected using the XRCC3 antibody at a dilution of 1: 200 in 
PBST, 3% non fat dried milk. Anti-goat IgG/ horseradish peroxidase conjugate was used as 
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the secondary antibody (Santa Cruz Biotechnology) at a dilution of 1: 5000, and bands were 
visualized using ECL reagents (Amersham pharmacia biotech) and Kodak film (Kodak) 
according to the manufacturer's protocols. 
4.2.11.2-D gel electrophoresis 
Proteins were extracted from irs1 SF (XRCC3 deficient) and transfectant D213N irs1 SF 
cells, quantified (Pierce) and passed through 5K Dalton centrifugal filter tubes at 12000 
rpm for 20 minutes to filter larger proteins. To spread proteins according to their isoelectric 
point on horizontal direction, IPG strips were rehydrated with equal amount of protein in 
sample buffer for 12-16 hours at 50 volts at room temperature under active condition 
following by another 40000 volt hours (Bio-Rad) as described in section 2.3.16. The IPG 
strips were then loaded onto 14% SDS acrylamide gel and vertical electrophoresis was 
performed at 16 mAl gel for 30 minutes and 24mA/gel for 5 hours. After electrophoresis 
was completed gels were stained as described in section 2.3.16. Western blotting was 
performed on gels before they stained (see sections 2.3.15.4-7). 
4.2.12. Restriction Fragment Length Polymorphism (RFLP) Analysis 
RFLP was carried out as described in section 2.3.5.2 using primers and conditions which 
were described at "PCR amplification" section 4.2.2. 
4.2.13. DNA Sequencing 
Genomic or plasmid DNA was amplified in volume of 50pl and was subjected to 2% 
agarose gel electrophoresis. The correct band was excised and the DNA was gel purified 
using DNA gel purification kit (Qiagen). Sequencing reaction was performed using human 
or vector-specific primers. For sequencing reactions, the SequiTherm EXCELTMII DNA 
Sequencing Kit-LC (Epicentre Technologies) was utilized as described in section 2.3.6.2. 
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PCR primers for Forward: 5' CCA CAG GACACC TTG TTG GA 3' 
SSCP Reverse: 5' AAA TAC GAG CTC AGG GGT GC 3' 
RT"PCR Primers Forward: 5' ATG GAT TTG GAT CTA CTG GA 3' 
Reverse: 5' CAC CGT GTC AGT GGG ACT 3' 
Mutagenic P199L 
Primers Forward: 5'GTG AAT AAG AAG GTC CTC GTA CTG CTG TCT CGG 3' 
Reverse: 5' CCG AGA CAG CAG TAC GAG GAC CTT CTT ATT CAC 3' 
D213N 
Forward: 5'CGC CTG GTG GTC ATC AAC TCG GTG GCA GC 3' 
Reverse: 5'GCT GCC ACC GAG TTG ATG ACC ACC AGG CG 3' 
T2411 
Forward: 5'GGG GGC CAT TCT GCG TGA GCT GAG CAG TGA 3' 
Reverse: 5'GCA CTG CTC AGC TCA CGC AGA ATG GCC CCC 3' 
T241 M 
Forward: 5'GGG GGC CAT GCT GCG TGA GCT GAG CAG TGA 3' 
Reverse: 5'GCA CTG CTC AGC TCA CGC AGC ATG GCC CCC 3' 
TaqMan primers Primers 
and probes Forward: 5'AGG TCC CCG TAC TGC TGT CTC 3' 
Reverse: 5' CTG TCA AAT TCA CAG CGG AAT G 3' 
Probes 
Detecting XRCC3 D213: 
5' FAM- CCA CCG AGT CGA TGA CCA CCA G-TAMARA 3' 
Detecting XRCC3 N213: 
5' TET- CCA CCG AGT TGA TGA CCA CCA GG-TAMARA3' 
Vector-specific T7: 5' TAA TAC GAC TCA CTA TAG GG 3' 
primers BGH Reverse: 5' TAG AAG GCA CAG TCG AGG 3' 
Table 1: Probes and primers for the XRCC3 functional study. 
SSCP, RT-PCR, and mutagenic primers for XRCC3, primers and probes for the D213N TagmanTM 
assay, and vector-specific (pcDNA 3.1) sequencing primers. Bold underlined nucleotides indicate 
the site of induced mutations. 
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4.3. Results 
4.3.1. Four novel polymorphisms were identified in XRCC3 exon 7 
As part of routine genotyping of the XRCC3 T241M polymorphism, we carried out PCR- 
SSCP analysis of exon 7 of the XRCC3 gene using genomic DNA from 1416 women (526 
breast cancer cases, 491 healthy women attending mammography screening and 399 
healthy female blood donors). In addition to the published T241 M variant, we found four 
novel variants in this exon, as indicated by extra bands not presented in the wild type 
samples (Fig. 1A). DNA sequence analysis of these variants revealed three heterozygous 
non-synonymous alterations; CIT (P199L), GIA (D213N), GIT (12411) and a synonymous 
alteration CIT (L201L) (at position 17941,17982,18068 and 17946 respectively in 
GenBank accession no. AF037222) (Fig. 1B). We were not able to differentiate the extra 
sequencing band from sequencing artefact for P199L alteration by direct sequencing of 
genomic DNA. Therefore to confirm the sequencing results obtained from the PCR 
products, the amplification product of exon 7 was cloned into the pCR2.1-TOPO vector, 
transformed and cultured in E. coli. Seven colonies were selected; the plasmids were 
extracted and sequenced using vector-specific primers (M13 and T7 primers). Two of the 
colonies carried the variant copy of XRCC3 (T) and five showed the wild type (C) sequence 
at position 17941(See appendix 3). 
4.3.2. The D213N substitution occurs in a highly conserved region 
Alignment of XRCC3 protein with some other members of Rad5l family included hsRad5l, 
hsXRCC2 and also mouse XRCC3 revealed that the XRCC3 D213N variant occurs in a 
highly conserved region of the protein, the ATP binding domain, known as the Walker box 
B (Walker, et aL, 1982). The XRCC3 P199L and T241M/I variants fall close to this region 
and are conserved between human and mouse (Fig. 2). Further alignments of XRCC3 with 
23 other proteins of Rad5l family from different species also showed that D213 is 
conserved in species such as Arabidopsis thaliana, fission yeast, Drosophila melanogaster 
and mouse, suggesting that this site may be important in the function of the protein. 
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Figure 1: Novel variants in exon 7 of XRCC3. 
Genomic DNA was amplified for XRCC3 exon 7. The resulting PCR products were denatured and 
subjected to electrophoresis on 12% non denaturing polyacrylamide gel (SSCP). A shows the 
results of SSCP analysis comparing band pattern identified in the novel variants and the wild type 
samples. B DNA sequences of novel variants were obtained by direct sequencing of amplified 
XRCC3 exon 7 in both forward and reverse directions using the primers listed in table 1. Arrows 
indicate site of novel variants. 
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HsRad5l 1 ----------------------------------------------------------MA 
HsXRCC3 1 ------------------------------------------------------------ 
MouseXRCC3 1 ----- ------------------------------------------------ 
HsXRCC2 1 ------------------------------------------------------------ 
HsRad5l 3 MQMQLEANADTSVEEESFGPQPISRLEQCGINANDVKKLEEAGFHTVEAVAYAPKKELIN 
HsXRCC3 1 ------------MDLDLLDLNPRIIAAIKKAKLKSVKEVLHFSGPDLKRLTNLSSPEVWH 
MouseXRCC3 1 ------------MDLDQLDLNPRITAAVKRGRLKSVKEILCYSGPDLQRLTGLPSHDVQC 
HsXRCC2 1 ---------------------------------------MCSAFHRAESGTELLAR---- 
HsRad5l 63 IKGISEAKADKILAEAAKL PMGFTTATEFHQRRSEIIQITTGSKELDKLLQ GIETGS 
HsXRCC3 49 LLRTASLHLRGSSILTALQ HQQKERFPTQHQR------LSLGCPVLDALL G GLPLD 
MouseXRCC3 49 LLRAASLHLRGSRVLSALH FQQKESFPEQHQR------ LSLGCPVLDQFLG G GLPLEG 
HsXRCC2 18 ------ LEGRSSLKEIEPNIFAD------------------ EDSPVH----- ----- 
Walker Box A 
HsRad5l 123 TEM E: -HT VTCQL ID GKA-v, ,, G' RPE LF. 
AERYGLSG 
HsXRCC3 103 TEL RR 1 ALQ CLAVQ RQH L GF! 
' PH Q. MAQQPRLR 
MouseXRCC3 103 TGL C: L CLAVQ RQY L GF., S. ý, IAQQRRLR 
HsXRCC2 44 LEFH F: AYH TARCIL rKSE L 'E` ML LEHRLSQS 
Walker Roy R 
HsRad5l 183 S VLDNVAYAR NTDHQTQLLYQASAMMVES-----------R: LRT 
HsXRCC3 163 T PGELLQKL GSQIFIEHVADVDTLLECVNKKVPVLLSRGM! 
I 
RC 
MouseXRCC3 163 T PEELIEKI SNHIFIEHAADVDTLLECVSKKVPILLSRGf1;. P RC 
HsXRCC2 104 S EIIKYCLGRF LVYCSSSTHLLLTLYSLES----ýMFCSHPS: F WI 
PI'9)L D213N 
HsRad5l 232 YSGRG-ELSARQMH RFLR L DE GV ITN VAQVDG-----------AAMF 
HsXRCC3 223 FDSQ--ASAPRARH QSLGAT RE SS QSP LCIN TEAMEEQGA-----AHGPLGF 
MouseXRCC3 223 FHLQ--ASAIRAK LSLGAT R SST RSP LCIN TDMVEDQQS-----VSRSLGA 
HsXRCC2 159 RVNGGESVNLQEST RKCSQC EN RLV. FATT TIMQKASSSSEEPSHASRRLCD 
T 
T241 Mi I 
HsRad5l 280 AADPK IGGNIIAHASTT YLRgGR------GET----RICQIYDSPC PEAEAMFAI 
HsXRCC3 276 WDERVS LGITWANQLLV LAD`LREEEAALGCP---ARTLRVLSAPH PPSSCSYTI 
MouseXRCC3 276 SEERLS LGITWANQLL VD THEDDVTTGLPRSPVRTLRVLFAPH PLSSCCYTV 
HsXRCC2 219 VDIDY YLCKAWQQLVKH FFS QD------ DSQ---SSNQFSLVSRC KSNSLKKHF 
HSRad51 330 NA GDAKD---- 
HsXRCC3 333 SAE RGTPGTQSH 
MouseXRCC3 336 SGE IRGMPGTQSY 
HSXRCC2 270 FII ESGVEFC--- 
Figure 2: Amino acid sequence alignment 
Amino acid sequences of the relevant regions of human RAD51, human XRCC3, mouse XRCC3 and human XRCC2 
are shown. Black boxes indicate amino acid identity and grey boxes indicate conservation of charge. The positions 
of the Walker A and B boxes are shown by a horizontal line and the positions of the amino acid variants investigated 
are indicated by vertical arrows 
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4.3.3. Cloning and site-directed mutagenesis of the human XRCC3 gene 
To assess the effect of these novel variants on the function of XRCC3, we determined the 
ability of the variant alleles to correct the phenotype exhibited by the XRCC3 deficient 
hamster cell line, irsl SF. We first extracted wild type XRCC3 mRNA from human skin 
fibroblast cell line LM217E as described in section 2.3.7. The human XRCC3 mRNA was 
then reverse transcribed to cDNA and amplified as described in section 2.3.8. We then 
cloned the human XRCC3 cDNA into the pcDNA 3.1 expression vector under the control of 
the human cytomegalovirus promoter (Fig. 3). The variant alleles were then re-created by 
site-directed mutagenesis as previously stated in section 4.2.6. In addition, a C/T (7241 M) 
substitution at position 18087 (GenBank accession no. AF037222), which is already 
reported to have a role in predisposition to malignant melanoma and bladder cancer, was 
created by site-directed mutagenesis. Each substitution was verified by sequencing to 
confirm the presence of desired mutation and rule out the presence of any PCR-generated 
mutations (Fig. 4). 
4.3.4. Transfection of XRCC3 constructs into XRCC3-'- mammalian cell line 
The expression constructs for the wild type and variant XRCC3 alleles were then 
transfected into irs1SF cells by electroporation as described in section 2.3.12.1. Clones 
containing the transfected DNA were selected on the basis of their resistance to the 
antibiotic G418. Depending in different experiments about 50 colonies were obtained out 
of 500,000 plated cells. Six separate clones for each construct were picked, expanded and 
tested with cellular toxicity assays. 
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Figure 3: Schematic Map of pcDNA 3.1 
Adopted from pcDNA3.1N5-His© TOPO® TA Expression kit catalog supplied by Invitrogen. 
D213N P199L 
TCRTC H 
Forward 
RI GTTi 
Reverse 1 
YE TC6 
tý1 
F AC GAGG 
RC GR6GI 
T241 M 
CRTGC 
aTHaa 
1 
AGCRTGG 
R6 C RT66 
1 
T2411 
HT TiT 
11 
T 
T 
Figure 4: cDNA sequence of cloned XRCC3 after site directed mutagenesis 
Human XRCC3 cDNA was cloned into pcDNA 3.1 expression vector. Novel mutations were created 
at desired positions using site directed mutagenesis. Created mutations were confirmed by 
sequencing using vector specific primers. 
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4.3.5. Expression of the mutant and wild type alleles in irslSF cell line 
For the D213N variant, four independent transfectants were isolated and two independent 
transfectants were isolated for each of the other constructs. Expression of the isolates was 
tested for the wild type and variants human XRCC3 gene. These clones were expanded 
and poly-A+ mRNA was then extracted from cells of each independent clone. Poly-A+ 
mRNA was then reverse transcribed and PCR amplified using XRCC3 human specific 
primers (Table 1). Poly-A+ mRNA was also extracted from the human cell line LM217E that 
expresses functional XRCC3, to be used as a positive control. For each reverse 
transcription, a second reaction was carried out in parallel, omitting the reverse 
transcriptase enzyme. Any PCR product resulting from these negative control reactions 
would indicate possible DNA contamination of reaction components. The results of the RT- 
PCR reactions show that human primers have amplified the XRCC3 mRNA from the 
positive control and the transfected cell lines but not from the non-transfected hamster cell 
line (Fig. 5A). Expression of the correct alleles was also confirmed by sequencing of whole 
length of XRCC3 cDNA for each amplified product using the same primers used for RT- 
PCR (Table 1). The result of sequencing confirmed the presence of variant XRCC3 for 
each transfectant and absence of any other mutation (Fig 5B). We extracted total protein 
from non-transfected irs1 SF cell lines and individual clones carrying wild type and variant 
XRCC3. Western blotting of these samples was performed using positive (LM217E) and 
negative (irslSF) controls. Goat polyclonal anti-XRCC3 antibody* was used for detection 
of XRCC3 protein. The XRCC3 protein (37.8 KD) was detected at the correct location in 
samples from tranfectants as well as non transfected irslSF. No difference in strength of 
protein bands was observed between XRCC3 deficient irsl SF and cell lines carrying 
variant copies of human XRCC3 (Fig 6). This could be due to the presence of a mutant 
copy of XRCC3 in the hamster irs1SF cells which produces a non functional protein that 
still can be detected by the polyclonal antibody. Since the human XRCC3 protein would be 
likely to differ from the hamster protein on the basis of their isoelectric points and molecular 
weight, we tried to separate human XRCC3 from CHO cell XRCC3 using 2D gel 
electrophoresis followed by western blotting as described in sections 2.3.16 and 2.3.15.4- 
7. Although distribution of protein in samples from human was different from CHO on the 
gel (Fig. 7), we did not detect any differences between two samples when XRCC3 was 
* This antibody detects a peptide mapping near the amino terminus domain of XRCC3 of the human origin 
(Sanata Cruz Biotechnology, Inc. ) 
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detected using polyclonal XRCC3 antibody which was the only commercially available 
antibody at the time of experiment. This also could be the result of the low specificity of the 
antibody for human protein. Therefore we did not have any means of showing the 
presence of the XRCC3 protein in the transfected and absence of it in the non-transfected 
XRCC3 deficient cells. However results from RT-PCR of XRCC3 mRNA clearly show that 
the human XRCC3 mRNA is not being made in the untransfected irs1SF. Therefore it is 
extremely unlikely that XRCC3 band in irs1 SF detected on the western blotting have 
stemmed from any human source, and all transfected variants are expressed well at the 
RNA level (Fig. 5) 
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Figure 5: Transfected clones express variant and wild-type XRCC3 
A: To confirm expression of the transfected wild-type or mutant genes, polyA+ mRNA was 
extracted from each transfected irslSF clone and subjected to RT-PCR. The resulting RT-PCR gel 
image for one representative clone from each transfection is shown (lanes 2,4,6,8,10), together 
with RT-PCR products from the LM 217E human cell line as a positive control (lane 12) and non- 
transfected irs1SF as a negative control (lane 14). Negative controls for each RT-PCR reaction, 
lacking reverse transcriptase, were also included (lanes 3,5,7,9,11, and 13). Lane 1 contains a 
DNA size marker. 
B: DNA sequence chromatograms derived from sequencing the 4 mutant RT-PCR products shown 
in A. The RT-PCR products were sequenced completely in both directions, to confirm the 
expression of the correct human allele and the absence of extraneous mutations. The position of 
the relevant base change is indicated with an arrow. 
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Figure 6: Western blot image of XRCC3 protein 
XRCC3 protein bands (- 37 KD) in irs1SF and transfected cell lines were visualized by exposing to 
goat polyclonal anti XRCC3 antibody. Human XRCC3 protein from LM217E cell line was used as 
positive control. 
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4.3.6. The XRCC3 D213N variant is not functional 
4.3.6.1. Determining sensitivity of transfectants to Mitomycin-C 
To assess whether the variant alleles retained XRCC3 function, we determined the ability of 
the expression constructs to correct the sensitivity of the XRCC3 deficient cells, irsl SF, to 
the DNA cross-linking agent Mitomycin-C (MMC). We measured the relative sensitivity of 
the transfectants to the drug, using a colony formation assay (Fig. 8). Strains expressing the 
wild type allele showed correction of the sensitivity to all these agents similar to that 
reported previously (Arnaudeau, at al., 2001, Lundin, at al., 2002). Correction was not 
complete and the cell survival was not restored to the level of the parental cell line, AAB. 
However this could be a consequence of inappropriate levels of expression or a result of 
using the human allele to complement the defect in hamster cells. Cells expressing T2411 
variant did not show any significant difference in cell survival relative to those expressing 
the wild type allele. The T241M variant exhibited higher resistance to MMC relative to the 
wild type strains, albeit slight but statistically significant (p=0.02 at the highest dose of drug) 
consistent with results previously reported by (Araujo, at al., 2002). The P199L variant was 
also less sensitive to MMC compared to the wild type (p=0.05 at the highest dose of drug). 
The results of this assay also revealed that D213N variant was unable to complement the 
sensitivity of irs1 SF to MMC. Survival of cells expressing this allele was indistinguishable 
from that of non-transfected irs1 SF cells. The result was the same for all 4 independent 
clones isolated for this variant (See table 2 for data on cell survival assays). 
4.3.6.2. Determining sensitivity of transfectants to Camptothecin 
The XRCC3 deficient cell line irsl SF is also sensitive to The Topo isomerase I inhibitor 
camptothecin (CPT). We therefore determined the sensitivity of wild type and variant 
transfectants to this agent (Fig. 9). XRCC3 deficient cells (irslSF) cells were the most 
sensitive and XRCC3 proficient cells (AA8) cells were the least sensitive to the drug. 
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Figure 1: the effect of sequence variants on XRCC3 on cell survival following exposure to 
Mitomycin-C. 
Mitomycin-C survival curves for XRCC3-deficient irs1SF cells, irs1SF cells stably transfected with wild- 
type or variant (D213N, T241M, T2411, P199L) XRCC3 cDNA, and parental AA8 cells. Data are shown 
as mean and standard deviation of 12 experiments (3 experiments on each of 4 independent cloned 
transfectants) for D213N and 6 experiments (3 experiments on each of 2 independent clones) for all 
other transfectants. For some points the standard deviation is very low and thus error bars are not 
visible. Plot symbols: ®- AA8, i- wild type XRCC3, I] - irs1SF, 0- D213N, 0- T241M, A- P199L, Qt 
- T2411 
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Wild type human XRCC3 complemented the sensitivity of irs1 SF to camptothecin, however, as 
for the MMC and in agreement with other observations, the complementation was not full 
(Arnaudeau, et al., 2001, Hinz, et al., 2003). The CPT sensitivity of cells expressing T241M 
was the same as those expressing the wild type. However both T2411 and P199L strains were 
statistically less sensitive to the drug relative to the strains expressing the wild type. As for 
MMC, The most interesting finding was the extreme sensitivity of cells expressing the D213N 
variant to the drug. Colony forming ability of D213N strains was very close to XRCC3 deficient 
cells, irs1SF, suggesting that expression of this variant was not able to rescue the sensitive 
phenotype of irs1SF to camptothecin. 
4.3.6.3. Determining sensitivity of transfectants to Thymidine 
The S-phase synchronising agent thymidine causes replication fork arrest, and cells exposed 
to thymidine show increased in levels of homologous recombination (Lundin, et al., 2002). 
XRCC3 deficient cells are also sensitive to this drug (Lundin, of al., 2002). We therefore 
determined whether strains expressing D213N variant can complement the sensitivity of irsl SF 
cells to thymidine (Fig. 10). AA8 cell lines were the most resistant cells and although not 
complete, strains expressing the wild type XRCC3 restored the sensitivity of irs1SF to 
thymidine. Strikingly we observed that the cells expressing the D213N variant were as 
sensitive to the drug as the untransfected irsl SF cells. 
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Drug dose AA8 irs1SF IrslSF+ irs1SF+ irs1SF+ irs1SF+ irslSF+ 
WT D213N T241 M T2411 P199L 
MMC 
0 100 100 100 100 100 100 100 
(0) (0) (0) (0) (0) (0) (0) 5 100.1 0.82 71.24 1.81 84.17 78 91.32 
0.469 (0.084) (6.617) (0.0019) (6.385) (11.174) (14.437) 
10 96.75 0 57.72 0 58.7 60.2 77.21 
1.558 (5.531) (11.053) (7.48) 12.47 
25 86.16 0 29.87 0 36.32 27.5 42.35 
(7.87) (6.589) (9.699) (6.928) (4.832) 
50 85.21 0 3.39 0 10.64 2.11 15.98 
(7.311) (1.813) (2.82) (0.763) (5.44) 
100 73.01 0 0 0 0 
4.1 
CPT 
0 100 100 100 100 100 100 100 
(0) (0) (0) (0) (0) (0) (0) 
5 99.125 1 73.45 2.25 72.8 89 96.25 
(1.2374) (0) (11.407) (0.037) (3.741) (7.211) (13.585) 
10 98.8 0 42.675 0 44.3 84.41 77.58 
(0.420) (0) (13.154) (1.453) (6.531) (8.703) 
25 83.4 0 17.85 0 14.46 33.29 38.26 
(4.242) (0) (5.36) (0.012) (5.907) (9.402) 
50 71.675 0 0.94 0 0.81 8.1 21.37 
(1.944) (0) (0.301) (0.213) (2.851) (3.107) 
75 29.68 0 0 0 0 0 0 
(3.365) 
Thymidine 
0 100 100 100 100 - - - (0) (0) (0) (0) 
0.5 97.45 35.62 92.08 41.5 - - 2.192 (6.187) (0.123) (13.152) 
1 82.75 6.25 82.25 10.25 - - - 10.253 1.06 (3.889) (1.033) 
2 66.75 0 63 0 - - 8.738 (24.041) 
5 16.63 0 10.03 0 - - - 3.667 (4.442) 
10 6.45 0 1.48 0 - - - (2.020) 1 0.452 
Table 2: Raw data for MMC, CPT and thymidne sensitivity of AA8 and irs1SF transfectant. 
Average of colony survival % (Standard deviation). 
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Figure 9: the effect of sequence variants on XRCC3 on cell survival following exposure to 
camptothecin. 
Colony outgrowth assay in CHO-based irs1SFcell line, irs1SF transfected with wild type and variant 
human XRCC3 (D213N, T241M, T2411, P199L) and parental CHO XRCC3 proficient AA8 cell lines 
following CPT treatment. Data are shown as mean and standard deviation of 12 experiments (3 
experiments on each of 4 independent cloned transfectants) for D213N and 6 experiments (3 
experiments on each of 2 independent clones) for all other transfectants. For some points the 
standard deviation is very low and thus error bars are not visible. Plot symbols: ®- AA8, : i- wild 
type XRCC3, N- irsl SF, 0- D213N, 0- T241 M, A- P199L, - T241 I. 
135 
o000000 00 
Chapter 4- The effect of rare sequence variants on the DNA repair activity of XRCC3 
\° o_ 
M 
0) 
O 
0 
8 
Thymidine (mM) 
Figure 10: the effect of sequence variants on XRCC3 on cell survival following exposure to 
Thymidine. 
Thymidine survival curves for XRCC3-deficient irs1SF cells, irs1SF cells stably transfected with wild- 
type or mutant (D213N) XRCC3 cDNA, and parental AA8 cells. Data are shown as mean and 
standard deviation of 6 experiments (3 experiments on each of 2 independent cloned transfectants) 
for D213N. Plot symbols: ®- AA8, i I- wild type XRCC3, Mx - irslSF, 0- D213N. 
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4.3.7. The effect of the XRCC3 D213N variant in the presence of wild type 
XRCC3 
Given that survival in strains transfected with D213N was significantly lower than the wild 
type, we next determined whether this allele could exert a dominant negative phenotype. To 
accomplish this, the D213N variant and wild type XRCC3 were transfected into the CHO 
XRCC3 proficient cell line AA8, and the human colorectal carcinoma cell line SW480, both 
of which contain a functional copy of XRCC3. Expression of the wild type and variant alleles 
was determined by RT-PCR of poly-A+ mRNA extracted from independent transfectant and 
verified by sequencing as described in section 4.3.5. (Fig. 1 1). Transfected cell lines were 
then tested for sensitivity to Mitomycin-C. However, there were no significant differences in 
sensitivity to MMC in strains expressing wild type or mutant allele (Fig. 12). The raw data for 
dominant negative survival assays has shown in table 3. 
MMC dose irslSF AA8 AA8+WT AA8+D213N SW480 SW480+WT SW480+D213N 
0 100 100 100 100 100 100 100 
(0) (0) (0) (0) (0) 0 (0) 
5 1.5 100 100 100 47.40 48.2 58.33 
(0) (0) (0) (0) (3.333) (10.75) 
10 0 97.16 98.85 90 45.30 19.34 52.85 
(4.009) (1.626) (7.071) (2.465) (4.103) (9.27) 
25 0 93.93 97.95 82.65 3.48 4.61 3.55(1.12) 
(6.314) (2.899) (5.020) (1.366) (1.40) 
50 0 87.2 81.3 69.95 2.12 1.79 1.25 
(4.242) (7.071) (2.333) (0.851) (0.86) (0.53) 
100 0 43.09 25.82 26.49 0 0.62 0 
(8.329) (0.954) (6.943) (0.25) 
150 0 3.83 0.4 0 0 0 0 
0.947 0.081 
200 0 0 0 0 0 0 0 
Table 3: Raw data for MMC sensitivity of AA8 and SW480 transfectants. 
Average of colony survival % (Standard deviation). 
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Figure 11: Transfected AA8 and SW480 clones express D213N variant and wild-type XRCC3 
A: RT-PCR gel image following the extraction of polyA+ mRNA from the wild type and D213N 
transfected AA8 and SW480 cell lines. The result of RT-PCR of wild type and D213N transfection in 
AA8 (lanes 2 and 4) and SW480 (lanes 8 and 10) is shown, together with RT-PCR products from the 
non-transfected SW480 (lane 6) and non-transfected AA8 (lane 12) and irslSF as a negative control 
(lane 13). Negative controls for each RT-PCR reaction, lacking reverse transcriptase, were also 
included (lanes 3,5,7,9 and 11). DNA amplification occurred by using non-transfected SW480 mRNA 
due to presence of human XRCC3 gene. Lane 1 contains a DNA size marker. 
B: DNA sequence chromatograms derived from sequencing the D213N variant RT-PCR products 
shown in A. DNA sequence of D213N variant extracted from AA8 (i) cell line and from SW480 (ii). The 
RT-PCR products were sequenced completely in both directions, to confirm the expression of the 
correct human allele and the absence of extraneous mutations. The position of the relevant base 
change is indicated with an arrow, Heterozygous pattern is observed in samples extracted from SW480 
transfected with XRCC3 D213N variant due to presence of human XRCC3 in SW480 cell lines. 
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Figure 12: Determination of the dominant negative effect of D213N variant following exposure 
to MMC. 
Mitomycin-C survival curves for the parental cell line (A) AA8 and (B) SW480, (containing 
endogenous functional XRCC3) and AA8 transfected with wild-type or mutant XRCC3 D213N cDNA. 
Data are shown as mean and standard deviation of 6 experiments (3 experiments on each of 2 
independent cloned transfectants) for D213N. For some points the standard deviation is very low 
and thus error bars are not visible. Plot symbols: ®- AA8, - wild type XRCC3, II - irs1SF, 0- 
D213N. 
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4.3.8. XRCC3 D213N is an infrequent variant and is not associated with sporadic 
or familial breast cancer 
Initial screening of 1416 female individuals for exon 7 of XRCC3 gene had resulted in 
identification of one heterozygote individual carrying D213N variant (See section 4.3.1). To 
determine whether this defective allele was associated with the development of breast or some 
other common cancers, a further 393 breast cancer cases, 93 breast cancer from low risk 
families (<2 breast cancer in family), 94 breast cancer from high risk families (? 3 breast cancer 
in family), 131 colorectal cancer, 47 HNPCC cases, 58 familial cancer cases, 345 healthy 
female controls and 338 healthy male controls were recruited reaching a total of 2763 female 
and 338 male individuals screened for this variant (table 4). All individuals specifically 
screened for XRCC3 D213N variant using 5' nuclease PCR (TagManTM) assay (Fig. 13) and 
probes and primers listed in table 1. Two further heterozygote individuals were identified 
carrying the D213N variant, making a total of 3 individuals from a total of 3101 screened. Two 
of individuals expressing this allele were healthy women attending the mammography 
screening clinic and one was a male from the blood donor control group. The variant allele was 
not found in any cancer cases. The D213N variant generates a distinct Hin fl restriction 
enzyme site in which the wild type 259bp fragment is cleaved to 177bp and 82bp fragments, 
and the N allele remains as an un-cleaved 259bp fragment. Therefore we also confirmed the 
genotype of these individuals by RFLP analysis (Fig. 14). 
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Figure 13: Allelic discrimination result of D213N screening 
Genomic DNA from cancer patients and healthy individuals were amplified in 96 well plates using 
primers and Fam and Tet-bounded probes. The level of fluorescent for each allele was measured for 
each sample by Sequence Detector 7200 allelic discrimination mode and compared with the level of 
fluorescent from control samples. Red dots (1) indicate samples with wild type sequence, green dots 
denote (1 and 2) samples with heterozygous sequence, black squares (No Amp) indicate samples that 
did not amplify and X (??? ) indicates samples with undetermined sequence. Arrow shows identification 
of one D213N heterozygous carrier. 
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Figure 14: The result of Hin fl restriction digest of D213N heterozygous carries 
The presence of the D213N variant in the 3 individuals was confirmed using a Hin ti PCR-restriction 
fragment length polymorphism assay. Hin fl cleaves the wild type allele but not the D213N allele. The 
cleavage results visualisation of three bands in the heterozygous samples and two bands in the wild 
type samples on 2% agarose gel. Samples 1 and 2 are from two females from mammography 
screening group and sample 3 is from an anonymous blood donor male. 
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Number Number of D213N Age of D213N Carrier's family 
screened variant carriers carriers history of cancer 
Mammography screening 54 mother 
control a 840 2 62 2x 2° relatives 
Male blood donor control 8 338 1 34 unknown 
Female blood donor control a 399 - 
Unrelated breast cancer 
Cases a 915 - 
High risk breast cancer 
families (? 3x1st degree 93 - 
relatives with breast cancer)b 
Low risk breast cancer 
families (< 2x1 st or 2nd degree 94 
relatives with breast cancer)b 
Unrelated colorectal cancer 
casese 131 - 
Unrelated bladder cancer 
cases a 98 - 
Unrelated prostate 
cancer cases 8 156 - 
Multi-case cancer 
families (> 3x1st or 2^d 37 - 
degree relatives with cancer) a 
Total 3101 3 
Table 4: The result of screening for D213N variant in cancer patients and normal controls. 
DNA extracted from blood lymphocytes of cancer patients and normal individuals was screened for 
XRCC3 D213N by 5' nuclease PCR. Three individuals carrying D213N variant were identified 
amongst the normal individuals. a Individuals from South Yorkshire, UK; b individuals from Sweden. 
Relevant ethical committee approval was obtained for each cohort, and informed consent was 
obtained from all subjects. 
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4.4. Discussion 
Four novel rare single base pair variants of XRCC3 were identified using PCR-SSCP. All of 
them fall in exon 7. Three of these variants change the amino acid while the fourth is a 
synonymous single nucleotide polymorphism. We investigated the effects of the non- 
synonymous changes on XRCC3 function. In addition to these novel variants we also 
investigated the function of the previously known XRCC3 T241 M polymorphism on XRCC3 
function. This polymorphism has already reported to increase the risk of malignant 
melanoma, bladder and breast cancer and occurs at a frequency of about 30% in the 
population (Kuschel, at al., 2002, Matullo, at al., 2001, Stern, et al., 2002a, Stern, et al., 
2002b, Winsey, at aL, 2000). 
One of three non-synonymous novel variants, D213N is highly conserved between different 
species and is located in the putative ATP-binding domain of the protein, the Walker Box B. 
Little is known about the exact role of different regions of the XRCC3 protein due to lack of 
extensive functional and structural studies. E. coli RecA, human Rad5l and Rad5l 
paralogues share similar overall structure including two ATP-binding domains, the Walker A 
and B boxes which are highly conserved from bacteria to man. These motifs are believed to 
be required for ATP hydrolysis (Brocchieri and Karlin, 1998, Roca and Cox, 1997). The role 
of ATP binding and hydrolysis in recombination and repair is not well understood, however it 
has been shown in E coli that cells with mutated RecA walker box A or B proteins have 
reduced level of homologous recombination and increased sensitivity to ionising radiation 
(Konola, eta!., 1994). RecA homologues in yeast and human, hsRad5l and ScRad5l, also 
exhibit ATP hydrolysis activity (Benson, eta!., 1994, Sung, 1994). Mutation in the Walker A 
motif of ScRad5l eliminates the strand exchange activity of the protein and results in 
sensitivity to methylmethane sulphonate (MMS) (Shinohara, eta!., 1992, Sung and Stratton, 
1996). Mutation in a conserved residue in the Walker box A of ScRad55 also resulted in 
sensitivity to ionising radiation and defects in DNA repair (Johnson and Symington, 1995). 
In contrast, similar mutations of Rad57 Walker A motif do not display radiation sensitivity 
(Johnson and Symington, 1995). Mutations in both Walker A and B motifs of Rhp5l (Rad5l 
homologue in Schizosacchromyces pombe) also resulted in extreme cellular sensitivity to 
MMS and radiation which were indistinguishable from those found in a Rhp5l deficient cell 
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line (Kim, et al., 2002). Interestingly the substitution that was used to study the effect of 
Walker B motif mutation of Rhp5l in the latter study (D244Q) is at the same position as the 
novel naturally occurring substitution in XRCC3 (D213N) in our study. There have been 
more limited studies of the effects of mutations of these domains in the human RecA 
paralogues. The mutant allele of the Rad5l paralogue XRCC2 carrying a site specific 
substitution of the Walker A box that eliminated ATP binding activity were able to correct the 
radiation and MMC sensitive phenotype of hamster XRCC2 deficient cells (O'Regan, et al., 
2001). Also, non viability of chicken DT40 B-cells deficient in Rad5l was rescued by over- 
expression of hsRad5l mutant in Walker A/B box that reduced ATP hydrolysis but not ATP 
binding (Morrison, et aL, 1999). In the present study, the D213N change substitutes the 
highly conserved acidic aspartate residue with the uncharged polar residue asparagine in 
the Walker B box, which could potentially disrupt the ATP-binding activity. This substitution 
results in a dramatic reduction in resistance to DNA damaging drugs that could be explained 
by deficient HRR as a result of loss of XRCC3 function. We could not observe any dominant 
negative phenotype for this mutation unlike the Walker A/B motif mutations in ScRad5l and 
Rhp5l (Donovan, et a!., 1994, Kim, et aL, 2002). It is known that not all mutations of Walker 
ANB motifs in RecANRad51 paralogues confer a dominant negative phenotype (Johnson and 
Symington, 1995). This may suggest that RAD51 paralogues may have different roles in 
HRR and response to DNA damage. Further biochemical studies are required to determine 
the effect of this substitution on ATP-binding and hydrolysis in HRR. 
No adverse effect on the function of XRCC3 was observed for P199L and T2411 
substitutions. Cells carrying these variant alleles exhibited more resistance to MMC relative 
to those carrying the wild type allele. Since XRCC3 protein structure is not yet known, it is 
difficult to predict whether this slight increased resistance to MMC is related to better 
expression or stability of variant protein relative to the wild-type protein. Nevertheless these 
sites are less well conserved amongst RAD51 paralogues than the Walker Box regions and 
it is likely that they do not confer the same effect as those in highly conserved region. 
Different sensitivity to MMC and CPT for cells carrying the T241I variant is also not 
unexpected, since it has been shown that different cellular response to drugs could be the 
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result of differences in the genetic make of individuals as a result of genetic polymorphisms 
(Stoehlmacher, et al., 2001). 
The T241M variant did not have any adverse effect on the normal function of XRCC3 and 
corrected the sensitivity of irs1 SF as well as the wild type XRCC3, consistent with the result 
of another report (Araujo, et al., 2002). However association studies have shown that this 
allele is associated with increased risk of melanoma, bladder and breast cancer (Kuschel, et 
aL, 2002, Matullo, et aL, 2001, Stern, et aL, 2002b, Winsey, et al., 2000). There are several 
possible reasons to explain why the results of association studies were not confirmed in the 
functional assays. Firstly, the original melanoma and bladder cancer associations have not 
been replicated (Duan, at al., 2002). Secondly, the XRCC3 T241 M itself may not be disease 
causing, but in linkage disequilibrium with other closely linked variants that cause disease. 
One study has shown that a rare haplotype containing the XRCC3 T241M variant was more 
strongly associated with breast cancer than T241M itself (Kuschel, et aL, 2002). Thirdly, the 
lack of any apparent functional effect may be due to subtle differences between species, 
since we have used the human gene to complement the deficiency in hamster cells. 
Alternatively, more sensitive assays might be needed to detect any subtle effect of this 
variant. More investigation at both the epidemiological level, using larger sample size 
studies and at the functional level using more accurate assays, are required to study the 
effect of this variant in cancer predisposition. 
We screened a large number of cancer cases and high risk families; however we did not 
find any carriers of the D213N variant amongst individuals with cancer. All three individuals 
carrying this variant were from control populations. Two of them were women aged 54 and 
62 from the breast cancer screening group with no mammographic evidence of breast 
cancer at the time of screening. The other individual was an anonymous 34 years old male 
blood donor. We do not have detailed family history data, but there is no evidence that 
these individuals come from high risk families. Although it is possible that they develop 
cancer later in their lifetime, our current data does not provide us enough evidence to 
classify XRCC3 gene as tumour suppressor gene on the basis of its contribution to the HRR 
pathway. 
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5. Mutation analysis of XRCC2 and XRCC3 genes in 
breast tumours 
5.1. Introduction 
A large body of evidence indicates that cancers arise as a result of cumulative genetic 
changes in somatic cells (Vogelstein and Kinzler 2002). The accumulation of genetic 
changes in cells during cancer development and progression has most comprehensively 
been described for colorectal cancer (Kinzler and Vogelstein 1996). In colorectal cancer, 
inactivation of the tumour suppressor gene APC is subsequently followed by mutations in 
other tumour suppressor genes, such as P53 leading to carcinoma. In tumours that have 
inactivation of the mismatch-repair genes the rate at which these mutations occur is 
accelerated by the genetic instability. Although for most other human tumours, such 
detailed knowledge of early genetic events is lacking, it is obvious that mutation in 
caretaker genes such as DNA repair genes can lead to high rate of mutations in the 
gatekeeper genes whose inactivation is required for carcinogenesis. Since one of the 
factors influencing somatic mutation rate is number of cell divisions, the rapid proliferation 
of breast epithelial cells during puberty and pregnancy offer the ideal opportunity for 
somatic mutation, including mutation in DNA repair genes. On the other hand, genomic 
instability is a common denominator in the vast majority of human cancers (Tlsty, Briot et 
al. 1995) and the connection between DNA damage and genomic instability in cancer cells 
has been well established. 
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The involvement of the BRCAI and BRCA2 genes in complexes that activate double- 
strand break repair and initiate homologous recombination links the maintenance of 
genomic integrity to tumour suppression (Scully, Chen et al. 1997; Sharan, Morimatsu et 
al. 1997). 
The connection between radiation-induced DNA damage and carcinogenesis is reinforced 
by studies that have shown homozygous mutation of most of the genes involved in repair 
of DSBs by HRR is often associated with embryonic lethality, or cancer predisposition 
where the knockout animals survive the loss of repair capacity (Hakem, de la Pompa et al. 
1996; Lim and Hasty 1996; Liu, Flesken-Nikitin et al. 1996; Xu, Wagner et al. 1999; Deans, 
Griffin et al. 2000). There is also convincing evidence that show cells from breast cancer 
patients are more sensitive to irradiation and this "radiation hypersensitivity" is heritable 
amongst breast cancer families (Scott, Barber et al. 1999). Taken these with evidence of 
involvement of BRCA1/2 in HRR together, it seems plausible to assume that other genes 
that are involved in the processing of DNA damage and act in the same pathway as 
BRCAI and BRCA2 could be among the list of candidate genes for breast cancer 
susceptibility. 
More than 10 genes have been identified so far that participate in the repair of DSB by 
homologous recombination. It has shown that certain naturally occurring mutations in some 
of the genes of this pathway could abrogate the repair capacity of the cell following DNA 
damage (See chapter 4). It has also been shown that SNPs in XRCC2 and XRCC3 genes 
can act as low penetrance susceptibility alleles for breast cancer (Kuschel, Auranen et al. 
2002; Rafii, O'Regan et al. 2002). To further investigate whether XRCC2 and XRCC3 
genes play a role in carcinogenesis, we searched for mutations in these genes in breast 
cancer tumours. 
XRCC3 (Accession number NM_005432) has been localized to 14q32.3, has 9 exons with 
exons 1,2 and part of exons 3 and 9 being untranslated, and encodes a protein of 346 
amino acids. It is a member of the Rad5l DNA repair gene family and is required for 
assembly and stabilisation of Rad5l foci which accumulates following DNA damage. Cells 
lacking XRCC3 have low levels of homologous recombination (Liu, Lamerdin et al. 1998; 
Pierce, Johnson et al. 1999). XRCC2 (Accession number NM_005431) is located on 
7g36.1, consists of 3 exons and encodes a protein of 280 amino acids. XRCC2 is also a 
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member of Rad5l family and intereacts with other members of this family Rad5l B, 
Rad5lC and Rad5lD (Masson, Tarsounas et al. 2001). It is required for genetic stability 
and embryonic viability and its disruption results in early embryonic lethality and (Deans, 
Griffin et al. 2000). XRCC2 deficient cell lines also show increased sensitivity to ionising 
radiation and Mitomycin-C (Jones, Cox et al. 1987) and decreased in homologous 
recombination (Pierce, Johnson et al. 1999). We screened the coding exons of these two 
genes for mutations in breast tumour material. 
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5.2. Materials and methods 
5.2.1. Subjects 
Sixty seven paraffin-embedded breast tumour tissues from unrelated breast cancer 
patients were used for mutation analysis. Tumour specimens from patients who had 
undergone surgery for breast cancer at the Royal Hallamshire Hospital, Sheffield between 
1996 and 1998 were retrieved from the histopathology archive of the Hospital. All tissues 
were from white Caucasian individuals and were collected without bias for age. H&E slides 
of all samples were reviewed by a histopathologist* to exclude contamination by normal 
tissue. In the cases for which tumour tissue formed less than 90% of whole specimen, the 
tumour borders were marked on slides which were subsequently used for tumour micro- 
dissection. Histopathologic data for all tumours were also collected for all samples. Ethical 
committee approval for the study was obtained from South Sheffield Research Ethics 
Committee and informed written consent was obtained from all subjects (See appendix 1). 
5.2.2. DNA extraction 
Paraffin embedded breast tumour material was provided as 2-3 sections of 5Nm for each 
specimen or as 5-10 slides if less than 90% of the tissue comprised tumour. Paraffin was 
removed from tumour sections and the tumour area was excised from breast tissue slides 
and collected in eppendorf tubes as described in section 2.3.1.2. Samples prepared by 
these methods were used for DNA extraction using QlAamp® DNA Mini Kit (QIAGEN) 
according to the manufacturer's instructions as stated in section 2.3.1.2. The concentration 
of all extracted DNA was quantified as explained in section 2.3.2 and samples were kept at 
-20°C until use. 
5.2.3. DNA amplification 
PCR amplification of samples was performed in 20pl final reaction using 1.1X PCR 
mastermix as described in section 2.3.3. Primer sequences are shown in table 1 and 
primer concentrations are shown in table 2. Negative controls were included in each 
experiment in which the DNA template was replaced with 1 NI of ddH2O. Amplification 
* See appendix for list of collaborators 
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conditions were for 40 cycles following a denaturing step of 95°C for 3 minutes (See table 
2 for cycling conditions). A final extension step of 72°C for 5 minutes was also applied after 
the cycles were finished. To confirm amplification of the correctly-sized product, 5pI of 
PCR product was mixed with 1NI of loading dye, loaded on 1.5% agarose gel along with 
DNA size marker and electrophoresed at 70 volts for 30 minutes. Correct amplification of 
product was confirmed by comparison of the amplified DNA band and DNA size marker. 
5.2.4. SSCP analysis 
Mutation analysis of XRCC2 and XRCC3 by SSCP was carried out as described in section 
2.3.5.1. A 24cm pre-prepared non-denaturing polyacrylamide gel (see table 2 for 
percentage, also see section 2.3.5.1) used for electrophoresis. Gel electrophoresis 
conditions are shown in table 2. DNA bands were then visualised by silver staining as 
described in section 2.3.5.1. 
5.2.5. Sequencing 
Exons to be sequenced were amplified in a similar fashion as described in section 5.2.3, 
except using 50pl reaction volumes. The PCR products were then electrophoresed on 
1.5% agarose gel and isolated from the gel using the Qiagen gel extraction kit. 
Approximately 5ng of PCR products were then used in sequencing amplification reactions 
using fluorescent primers. Amplified reactions were then sequenced with an automated Li- 
COR sequencer as stated in section 2.3.6.2. 
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Primers Melting temperature (°C) 
XRCC2 
Exon 1 Forward: 5' GTT GGT GGC GGG AAA GTT 3' 56 
Reverse: 5' TCT CCC TCA CTC CCA ACC 3' 58 
Exon 2 Forward: 5' TGA GTT TTC CTT CTC TCT TC 3' 56 
Reverse: 5' CTC TTG TGA GGA GTA TGT GT 3' 58 
Exon 3-Fl Forward: 5' GAG CTA CTG CAT TU GAC TG 3' 58 
Reverse: 5' CTT TGG GAT AGT TCT GTG CTC 3' 60 
Exon 3-F2 Forward: 5' TGA TAT GCT CCG GCT AGT T 3' 56 
Reverse: 5' AGT TCA CAC TTT CTC CTC CA 3' 58 
Exon 3-F3 Forward: 5' GGA TAG CCT GTC AGC TTT TT 3' 58 
Reverse: 5' GCC ATG CCT TAC AGA GAT AA 3' 58 
Exon 3-F4 Forward: 5' TGC CTC TCG ACG ACT GTG 3' 64 
Reverse: 5' CGT AGT ACC CTG CAA AAG AC 3' 60 
XRCC3 
Exon 3 Forward: 5' TGG GAA GTT ATT CAT CCT TGG T 3' 60 
Reverse: 5' GGT AGG CAA AGG AAG GAA GG 3' 62 
Exon 4 Forward: 5' GCA CCT TU GTC ACT GTG TTG 3' 62 
Reverse: 5' GGG ACC ATG ATG CTG GAG 3' 58 
Exon 5 Forward: 5' TGA CAC TAT CCC TGC CCT TT 3' 60 
Reverse: 5' GCC CAG ACC CCA CGG AAC 3' 60 
Exon 6 Forward: 5' GTT AGA AAT GGC GGG AGA CA 3' 60 
Reverse: 5' GGC TTC TCC CAC ACT CAC 3' 58 
Exon 7 Forward: 5' GAC AGT CCA AAC GGG GTC T 3' 60 
Reverse: 5' TGC AAC CCT GCC TTG GTG 3' 58 
Exon 8 Forward: 5' GCT GAC CTG GAC TGT GCT CT 3' 64 
Reverse: 5' CAG AAC CTG AGA AAC AGG AA 3' 62 
Exon 9 Forward: 5' TGC CTG CTT CCT GTT TCT C 3' 58 
Reverse: 5' TCT CAG GCA GGG CTG TTG T 3' 60 
Table 1: XRCC2 and XRCC3 PCR primers. 
Forward and reverse primers used for amplification of different exons of XRCC2 and XRCC3 
genes. 
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5.3. Results 
5.3.1. Mutation analysis of XRCC2 in human breast tumours 
All 3 coding exons of the XRCC2 gene from 67 primary breast carcinomas were analyzed 
by the single-strand conformational polymorphism method using the primer pairs listed in 
Tablel. The primers were designed so as the flanking introns could also be amplified. No 
band alterations suggestive of mutation were detected on SSCP analysis for samples which 
were amplified for exons 1 and 2 and fragments 1,2 and 4 of exon 3 (Figure 1). However 
band alterations were observed in 11 (16.4%) samples for which fragment 3 of exon 3 had 
been amplified. Subsequent direct sequence analysis of the samples confirmed the 
presence of the GlA substitution in exon 3 of the XRCC2 (Figure 2). The substitution is a 
non-synonymous coding polymorphism that changes arginine to histidine at position 188 of 
XRCC2 protein as described in chapter 3. The frequency of G/A genotype in the healthy 
population obtained from genotyping of 493 healthy female (see section 3.3.3) was 14.4%. 
The frequency of heterozygous genotype in the tumour samples is 16.4%. We therefore did 
not find any significant difference between the G/A genotype frequency in the tumour 
samples relative to healthy population (p=0.71). 
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Exon 1 
60 64 *0 44 64 *0 
Exon 3-Fragment 1 
Exon 2 
Exon 3-Fragment 2 
Exon 3-Fragment 4 
Figure 1: SSCP gel images for XRCC2 exons 1,2 and 3. 
SSCP gel images for XRCC2 exons 1 and 2 and fragments 1,2 and 4 of exon 3. No band alteration 
is seen in SSCP analysis. 
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A 
B 
CGCC 
t 
Figure 2: SSCP and sequencing images for exon3-3 of XRCC2 gene. 
A; Gel image of SSCP analysis for fragment 3 of XRCC2 exon 3 showing band shift in number of 
samples. Arrows show altered SSCP bands. B; Direct sequencing of the PCR products shows the 
G/A heterozygous genotype. Arrow indicates the site of polymorphism 
5.3.2. Mutation analysis of XRCC3 in human breast tumours 
A total of 67 breast carcinomas were analyzed by PCR-SSCP to screen for the presence of 
mutations within exons 3-9 of the XRCC3 gene, which cover the entire coding region of the 
gene. Cases with altered SSCP profile suggestive of mutation were then re-amplified using 
the primers listed in Table 1 and subjected to direct sequencing to confirm the presence of 
any sequence alteration. No band pattern alterations suggestive of mutation were found in 
exons 3,5,6,8 and 9 (Figure 3). However we observed band alterations in 5 (7.5%) samples 
for which exon 4 and its flanking introns had been amplified. Direct sequencing of the 
samples confirmed the presence of a C/T polymorphism in intron V (Figure 4). This is 
known polymorphism and has already reported to the SNP database (GeneSNPs*). We 
* See appendix for website address 
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also detected a band pattern alteration in 13 (19.4°/x) of samples for which exon 7 had been 
amplified. Direct sequencing of the samples showed a coding non-synonymous C/T 
polymorphism that changes threonine to methionine at amino acid position 241 of the 
XRCC3 protein (Figure 4). We used a different set of primers to amplify exon 7 and its 
flanking introns from the primers that we used to genotype our case-control study (See 
Chapter 3, table 1). Therefore the band pattern that we get on the SSCP for the wild type 
genotype is different from the wild type band pattern in our previous study. The primer set 
with which XRCC3 exon 7 was amplified also amplifies the flanking intron 6 in which a 
known C/T polymorphism exists. Therefore the band alteration can not purely be related to 
the heterozygous XRCC3 T241 M polymorphism. 
Exon 3 Exon 5 
Exon 6 
t- -4 +w*4,, A*4; A" 
x 
ý: 
Exon 8 
aýNýº ise r t, X11 
Exon 9 
Figure 3: SSCP gel images of the XRCC3 exons 3,5,6,8 and 9. 
No band alteration is seen in the SSCP analysis. 
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Figure 4: SSCP and sequencing imaged of the XRCC3 exons 5 and 7 
Gel image of SSCP analysis for XRCC3 exons 4 and 7 showing band shift. Direct sequencing of 
altered SSCP bands shows the C/T heterozygous genotype in exon 7 and intron 5. Arrows show 
altered SSCP bands and site of polymorphism. 
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5.4. Discussion 
DNA repair processes have evolved to defend cells against the deleterious effects of 
damage to their genetic material. Attempts to repair DNA damage can also cause many 
types of mutation, through inability to properly restore the DNA sequence. Mutations in DNA 
repair genes may also impair the fidelity with which the repair pathway can restore 
mutations. In human cancer, many different mutations can affect the function of a gene, 
such that testing a gene for all possible or known mutations can be time-consuming and 
expensive. This fact limits the potential use of gene mutations as molecular markers in 
clinical testing; however, the study of mutations remains very important for clinical research. 
We used mutational analysis approach on 67 paraffin-embedded breast cancer tissues to 
identify somatic mutations in two HRR genes, XRCC2 and XRCC3. The PCR-SSCP 
mutation analysis technique was used to analyse three exons of XRCC2 and 7 exons of 
XRCC3. Two non-conservative coding polymorphisms were identified, in XRCC2 exon 3 
and XRCC3 exon 7. One polymorphism also identified in XRCC3 intron 5. All three 
polymorphisms are previously known and have been reported to the SNP databases 
(GeneSNPs*). 
A number of mutational analysis approaches have been used to identify mutations in some 
of the genes of the HRR pathway in breast cancer. Germline mutation of RAD51 was 
reported in two patients with bilateral breast cancer and one of them showed evidence of 
loss of heterozygosity (Kato, Yano et al. 2000). However no mutation was found in mutation 
analysis of 100 cases of early onset breast cancer (Bell, Wahrer et al. 1999). No somatic 
mutation in RAD51 was also detected in mutation analysis of 47 and 15 breast tumours 
(Bell, Wahrer et al. 1999; Schmutte, Tombline et al. 1999). Although infrequent, somatic 
mutations have also been reported for BRCA1 and BRCA2 in sporadic breast and ovarian 
tumours (Merajver, Pham et al. 1995; Weber, Brohm et at. 1996). Mutation analysis of 
RAD52 and RAD54 in breast cancer patients also did not reveal any disease-associated 
mutations (Bell, Wahrer et al. 1999). In a recent study of 105 high risk non BRCA1/2 
breast/ovarian cancer families, no mutation was identified in the XRCC2 gene (Rodriguez- 
* See appendix for website address 
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Lopez, Osorio et al. 2003). No mutation in XRCC2 and XRCC3 genes were found in tumour 
samples from 106 colorectal cancer patients using the PCR-SSCP method (Lee J, 
unpublished data). Other genes involved in the processing of DNA damage such as cell 
cycle control genes, have also been analysed for mutation in tumours. In this regard a 
recently identified truncating germline mutation in CHEK2 gene was found in 5.1% of non 
BRCA1/2 breast cancer patients (The CHEK2- Breast Cancer Consortium, 2002). 
The limiting factor in our study was the mutation detection technique. We used the PCR- 
SSCP in our study. This technique was also used for mutation detection in HRR genes in 
most of the above mentioned studies. Since the sensitivity of PCR-SSCP is about 70% 
there is always possibility that some mutations can not be detected by this method, 
particularly when small number of samples is used. Thus if a more sensitive technique and 
a larger number of samples are recruited the possibility of finding a mutation will be 
increased. However despite recent findings that the common R188H polymorphism in 
XRCC2 and T241 M polymorphism in XRCC3 are associated with increased risk of breast 
cancer (Kuschel, Auranen et al. 2002; Rafii, O'Regan et al. 2002), it seems unlikely from our 
data that either of these genes be a major tumour suppressor genes for breast cancer. 
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6. Discussion 
It is now widely accepted that cancer results from the interaction between an individual's 
genetic susceptibility and their environmental exposures. At the cellular level, cancer 
depends upon the balance between mutagen activation, detoxification and the 
effectiveness of mutagens at generating cellular damage as well as the ability of the cell to 
respond and repair potentially deleterious damage prior to cell division. Most environmental 
agents induce their effects through chemical modification of DNA. Therefore repair 
pathways that correct these types of DNA damage and prevent mutagenic events are 
directly related to cancer susceptibility (Lindahl and Wood, 1999). Some individual genetic 
variants that inactivate the gene product are associated with high individual risk of cancer 
and are known as high penetrance susceptibility alleles. However such alleles segregate in 
cancer families and contribute to only a small fraction of cancer cases. Familial history is a 
risk factor for most cancers independently of any environmental exposures, indicating that 
there is a genetic role for sporadic cancer as well. Thus identifying genetic susceptibility 
markers such as low penetrance polymorphic alleles that can be linked to disease 
proneness has become a target in recent years. 
In breast cancer, for example, only a very small fraction of cases can be related to 
mutations in BRCA1/2 and some other infrequent high penetrance alleles. Although those 
cases of breast cancers that are not related to mutations in BRCA1/2 might have a genetic 
or an environmental origin, evidence from twin studies and the frequency of breast tumours 
in the contralateral breast of affected breast cancer patients, suggests a predominant role 
for genetic factors (Balmain, et al., 2003). Identifying other genetic factors for breast cancer 
will not only help us to identify a population at higher risk, but will also reveal more detail 
about biological pathways that lead to breast cancer development. 
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Several studies have shown defects in DNA repair and increased chromosomal sensitivity 
to ionizing radiation in breast cancer patients and their healthy relatives (Helzlsouer, at al., 
1996, Kovacs and Almendral, 1987, Parshad, et al., 1996, Patel, et al., 1997, Roberts, et 
al., 1999, Scott, et aL, 1999). Breast cancer is observed in some of the DNA repair 
deficiency syndromes such as Ataxia Telangectasia. BRCA1/2 deficient mice show higher 
sensitivity to ionizing radiation and are more susceptible to breast cancer (Moynahan, et 
a!., 1999, Moynahan, at al., 2001, Ponnaiya, et al., 1997). Even the high penetrance breast 
cancer susceptibility genes such as BRCA1/2 and ATM are now known to be part of the 
DNA damage signalling and processing pathway. This convincing evidence in the literature 
lead us to hypothesize that at least a proportion of breast cancer cases could be the result 
of polymorphisms in HRR genes that alter DNA repair capacity or fidelity. 
In the present study we have tried to answer to two essential questions regarding single 
nucleotide variants of HRR genes and their possible role in breast cancer susceptibility. 
Firstly, could genetic polymorphisms of HRR pathway be propounded as low penetrance 
breast cancer susceptibility alleles? And secondly, what is the effect of rare single base 
substitutions in one of the genes of HRR pathway on DNA repair capacity and cancer 
susceptibility? In addition, we looked for mutation of HRR genes in tumours. 
A genetic association study was used to investigate the role of four SNPs in four HRR 
genes in predisposition to breast cancer. We also cloned and expressed four naturally 
occurring sequence variants in the XRCC3 gene to investigate their effect on DNA repair 
phenotype. 
6.1. Methodological considerations in case-control studies 
Case-control studies are the most commonly used method to seek potential associations 
between genetic polymorphisms and the risk of common diseases in the population, and 
interactions between genetic and environmental risk factors. To be able to detect moderate 
to large genetic effects (OR > 2.0) with an 80% power, at least 200 cases and 200 controls 
are usually needed (Garcia-Closas, et al., 2000). The assessment of gene-gene or gene- 
environment interactions requires larger studies, especially when the factors under study 
are very rare or very common, or when the magnitude of the interaction is modest (Hwang, 
et aL, 1994). The power of our study to detect a moderate to large genetic effect was over 
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80% for all genotypes. This figure, however, only applies to the total study population and 
was not achieved in many of the subgroup analyses. 
Concern has been raised that population stratification (i. e., inclusion of individuals from a 
heterogeneous genetic background) may often explain the observed associations between 
genotypes and disease, rather than the physiological effect of the genetic variant 
(Altshuler, et aL, 1998). Any genetic (or environmental) factor, the distribution of which 
differs between ethnic groups, may falsely appear to be related to the disease, simply 
because the ethnic groups are distributed differently between cases and controls. Inclusion 
of only white Caucasian women, who have a genetically homogenous origin, is therefore 
considered to be a point of strength for the present study. All women participating in the 
study provided background information on reproductive factors, family history of breast 
cancer, previous cancers and smoking, etc. Tumour Histpathological data was also 
collected for breast cancer cases. This enabled us to assess the interaction of genotypes 
with these factors. 
We used, as controls, women who attended mammography screening programme and did 
not have any mammographic evidence of breast lesion at the time of screening. The 
mammography screening controls were representative sample of the age matched 
population from which the cases arose. The uptake rate for our mammography screening 
controls living in the catchment area was 81.2%, however a possibility of some selection 
bias cannot be ruled out as highly educated women with a possibility of breast cancer in 
their family and friends may be more likely to volunteer for mammography screening. 
It is nowadays acknowledged that the age distribution in controls should represent that of 
the cases; if controls are significantly younger than cases they may include several future 
cases (i. e. they will develop cancer at a later age) (Fryer and Jones, 1999). This could 
mask the possible associations. This potential source of bias can be overcome by 
matching the controls to the cases by age (Breslow and Day, 1980). In this study, 
mammography screening controls were used because they were better age-matched with 
the cases, but the study also included some controls (BDC) whose age range was younger 
than the cases. 
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At least one HRR gene polymorphisms has reported to increase the risk of breast cancer in 
mutation carriers of BRCA2 (Levy-Lahad, et al., 2001, Wang, et al., 2001). We did not have 
data on other susceptibility genes, such as BRCAI and BRCA2 to study the effect of these 
polymorphisms as modifiers of breast cancer risk. However, in a recent study these 
mutations were shown to only account for a small number of hereditary breast cancer 
cases in British women (Peto, et at, 1999). Therefore, the lack of information on these 
genes is not considered to have influenced the present results. 
A potential weakness of our study is that the information on exposure to radiation and DNA 
damaging agent was unavailable for our patients and controls. Since ionizing radiation is a 
risk factor for breast cancer and a major cause of DSBs, analysis of our genotyping data in 
the presence of radiation exposure could have provided some result in favour of gene- 
environment interaction in susceptibility to breast cancer. 
6.2. Polymorphisms in HRR genes and susceptibility to breast 
cancer 
To answer the first question, regarding the association of genetic polymorphisms in HRR 
genes and breast cancer, we examined XRCC2, XRCC3, BRCA2 and RAD51 as 
candidate susceptibility genes for breast cancer in a population-based case-control study of 
white Caucasian women of North European descent. We found a suggestive association 
between XRCC2 188 His and increased susceptibility to breast cancer (OR: 1.32,95% Cl 
(0.98,1.79)). Although the association fell out of statistical significance possibly due to the 
small number of homozygous individuals, we observed a dose effect for this variant allele 
as His/His genotypes (OR: 2.14,95% Cl (0.65,7.06)) were more associated with breast 
cancer than Arg/His genotypes (OR: 1.29,95% Cl (0.95,1.76)). 
No association was found for carriage of XRCC3 (OR: 1.00,95% Cl (0.80,1.25)) and 
RAD51 (OR: 0.82,95% Cl (0.6,1.13)) rare alleles and a weak statistically insignificant 
association was observed between BRCA2 His allele (OR: 1.21,95% Cl (0.80,1.84)) and 
breast cancer. Consistent with this study, a positive association was reported for the 
XRCC2 His/His genotype and no effect was found for the RAD51 C genotype in 
association with breast cancer in a bigger data set (Kuschel, et al., 2002). In agreement 
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with the present study, a weak association has also been reported between BRCA2 rare 
allele and breast cancer in two independent studies (Healey, et al., 2000, Spurdle, et aL, 
2002). In contrast to our finding, however, Kuschel et al (2002) reported that the XRCC3 
Met/Met genotype (and not the Thr/Met allele) was associated with increased risk of breast 
cancer (1.3 (1.1,1.6)). Since the sample size in Kuschel et al study was bigger than the 
present study, they had more statistical power to detect even a small association (See 
section 3.3.3 for the power of present study). The studies investigating association 
between common cancers and SNPs of XRCC2, XRCC3, BRCA2 and RAD51 have been 
summarized in table 1. 
Age and family history are two risk factors for breast cancer. However we did not observe 
any association between these polymorphisms and breast cancer in the age or family 
history subgroups. Although statistically insignificant due to small number of samples in 
subgroup analysis, we observed that carriage of the rare allele of XRCC2, XRCC3 and 
BRCA2 were more associated with breast cancer susceptibility when younger age breast 
cancer patients with positive history of breast cancer were compared to older age controls 
with no family history of breast cancer. This result suggests that other unknown genetic 
and environmental factors that are responsible for familial clustering of breast cancer may 
interact with these low penetrance genes. 
Given the moderate increase in the risk associated with these low penetrance genes and 
the complex nature of breast cancer, studying the effects in relation to certain types of 
cancer is anticipated to be important. We therefore evaluated the effect of these 
polymorphisms in relation to tumour histopathologic characteristics such as tumour types, 
histology grades, vascular invasion and oestrogen receptor status. Despite the majority of 
breast tumours being of ductal type, we detected a significant positive association between 
the XRCC2 His allele and lobular breast carcinoma (p=0.001). This data needs 
confirmation in a bigger dataset but may indicate a relationship with cancer subtypes. 
However no association was detected between rare allele of either of the polymorphisms 
and the histology grades, vascular invasion and oestrogen receptor status. In a big 
association study Goode et al (2002) tried to identify whether rare alleles of DNA DSBs 
repair genes can be used as predictive biomarkers of survival after breast cancer. Rare 
homozygous allele of a silent polymorphism in codon 501 (D501 D) of the Ligase IV gene 
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(LIG4) which is involved in NHEJ repair of DSBs was found to be associated with 
decreased survival in breast cancer patents (Goode, et al., 2002). 
A growing number of molecular epidemiological studies have tried to associate variations 
at a number of repair genes with cancer risk. For example, an additive effect of the XRCCI 
variants 194Trp and 399GIn has been associated with smoking-related squamous cell 
carcinoma of the head and neck (Sturgis, et at, 1999). Other studies associate variations 
in XRCCI, XPD, XRCC3, XPA, excision repair cross-complementing rodent repair 
deficiency, complementation group 1 (ERCCI), and apuriniclapyrimidinic endonuclease 1 
(APE1) with elevated risk of several cancers, including lung, colon, bladder, and breast 
(Butkiewicz, et al., 2001, Chen, 2000, Divine, et al., 2001, Duell, et al., 2001, Ratnasinghe, 
et al., 2001, Stern, et al., 2002a, Stern, et al., 2002b, Sturgis, et al., 1999, Tomescu, et al., 
2001, Winsey, et al., 2000). The odds ratios for the individual variants range from 1.3 to 
2.0, and not all of the studies report consistent risk association. 
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Cancer Cases Controls OR (95% Cl) Reference 
XRCC2 R188H 
Breast cancer 2205 1826 2.60 (1.0,6.7) Kuschel et al, 2002 
Breast cancer 519 891 1.30 (0.96,1.75) Rafii et at, 2002 
XRCC3 T241M 
Breast cancer 2205 1826 1.30 (1.1,1.6) Kuschel et al, 2002 
Breast cancer 162 302 0.95 (0.64,1.40) Smith et at, 2003 
Bladder cancer 124 85 2.77 (1.55,4.93) Matullo et at, 2001 
Bladder cancer 233 209 1.30 (0.9,1.9) Stern et at, 2002 
Lung cancer 331 687 0.92 (0.67,1.28) David-Beabes et al, 2001 
Lung cancer 96 96 N/A a Butkiewicz et al, 2001 
Malignant Melanoma 125 211 2.36 (1.44,3.86) Winsey et al, 2000 
Malignant Melanoma 305 319 0.89 (0.65,1.24) Duan et al, 2002 
SCCHN 367 354 1.36 (0.89,2.08) Shen et at, 2002 
BRCA2 N372H 
Breast cancer 2775 2326 1.31 (1.07,1.61) Healey et al, 2000 
Breast cancer 1397 755 1.47 (1.05,2.07) Spurdle et alB, 2002 
Ovarian cancer 1121 2643 1.36 (1.04,1.77) Auranen et at, 2003 
RAD51 C135G 
Breast cancer 164 93 p= 0.07 Levy-Lahad eta at, 2000 
Breast cancer 216 436 3.2 (1.4,40) Wang et al, 2001 
Breast cancer 2172 840 0.86 (0.68,1.08) Kuschel et al, 2002 
Table 1: Association between SNPs of HRR genes and common cancers 
SCCHN; squamous cell carcinoma of head and neck, OR; odds ratio, Cl; confidence interval 
a No difference was observed in genotype frequencies between cases and controls 
6.2.1. Gene-gene interaction and breast cancer risk 
SNPs do not act in isolation, but against the background of thousands of other SNPs, and 
environmental factors. Therefore assessment of single polymorphic genotypes is not 
expected to be sufficient for evaluating individual susceptibility to the various endogenous 
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or exogenous harmful agents (Hirvonen, 1997). The study of interactions between different 
polymorphic genes should, however, be based on biologically plausible hypotheses. For 
instance simultaneous examination of genes for enzymes with overlapping substrate 
specificity for a given exposure or separate genes acting in sequence in the same 
metabolic pathway are anticipated to be well justified. Proteins in DNA repair pathways are 
often multifunctional, resulting in a variety of phenotypes. An example of this is the XPD 
protein, which has a role in both NER and basal transcription. Furthermore different repair 
pathways overlap with each other in repairing DNA damages. Therefore it is biologically 
plausible to assume that combinatory effects of polymorphisms resulting from interaction 
between different repair pathways could have an adverse effect on the capacity of the 
whole repair machinery. 
In the present study, an interaction was found between the XRCC2 and the XRCC3 
genotypes. Accordingly, the odds of breast cancer susceptibility for combination of XRCC2 
His and XRCC3 Met alleles (1.50 (0.97,2.23)) was more than the odds ratio of each of the 
XRCC2 and XRCC3 rare allele separately. Although the XRCC3 Met allele was not 
associated with breast cancer in its own, it was associated with increased risk of breast 
cancer at the presence of XRCC2 His allele (1.86 (0.97,3.55)). Furthermore, the 
combinatory effect of XRCC3 Met and BRCA2 His alleles was more associated with 
increased breast cancer risk (1.35 (0.93,1.96)). In contrast the presence of XRCC2 His 
allele together with BRCA2 His allele or RAD51 C genotype was suggestive of a protective 
rather than a predisposing role (See Table 10, Chapter 3). 
Although in small numbers, the results from present study highly suggest that the 
combinatory effect of polymorphisms of genes of HRR pathway are more associated with 
susceptibility to breast cancer than the effect of a SNP in one gene. Some studies have 
already been carried out to examine combined effects of separate polymorphic oestrogen 
metabolising genes in relation to breast cancer (Curran, et al., 2000, Helzlsouer, et al., 
1998, Matsui, et al., 2000, Millikan, et al., 2000, Millikan, 2000). However to investigate 
additive or combinatory effects of polymorphisms of genes of a pathway in association with 
a particular cancer, very large sample sizes are needed, which often requires multicentre 
or international collaborations. It should also be noted that when one considers the multi- 
dimensional implications of combinations of SNPs in profile, instead of one SNP at a time, 
the level of complexity increases dramatically. Therefore particular specialist analytical 
methods are required. 
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6.2.2. Gene-environment interaction 
The general assumption in gene-environment interaction is that if the effect of genetic 
background and environmental exposure is greater than the effect of each individual factor 
then interaction between two factors is present (Brennan, 2002). Although it has been 
suggested that the role of environmental factors in breast cancer susceptibility is not as 
important as the role of genetic factors (Balmain, et al., 2003), great effort has been 
dedicated to identifying the role of environmental exposure in breast cancer. Most of the 
environmental risk factors for breast cancer are classified in groups related to exposure to 
female sex hormones. In the present study no information on radiation exposure or known 
DNA damaging agents was available for either of study cohorts. We therefore were not 
able to study the effect of gene-environment interaction in association with breast cancer. 
The gene-environment interactions in susceptibility to cancer have been extensively 
studied. A statistically significant interaction has been reported between cumulative 
cigarette smoking and two polymorphisms in the ERCC2 gene in lung cancer patients 
(Zhou, et aL, 2002). An interaction between smoking, alcohol drinking and XPD 
polymorphisms at codon 751 has also been suggested (Sturgis, et al., 1999). One study 
also suggests an interaction between low dose X-Ray irradiation and hMSH3 
polymorphism in childhood leukaemia (Infante-Rivard, et al., 2000). Whilst the result of 
these studies should be interpreted with caution, the effect of polymorphisms in DNA repair 
genes in interaction with environmental exposure deserves further study. Refinement of 
cancer risk estimates associated with exposures will require epidemiological studies of 
large cohorts with well-documented exposures that also account for polymorphisms in the 
large number of genes determining individual susceptibility. 
6.3. Investigating the effects of sequence variants of XRCC3 on 
cellular phenotype 
Whilst several high frequency DNA repair genetic polymorphisms have been shown to 
associate with cancer risk (Goode, et al., 2002, Kuschel, et aL, 2002), the contribution of 
DNA-repair genetic variants to repair function and human cancer risk is still unclear. 
Two approaches have been used to study the effect of different genotypes of DNA-repair 
SNPs on the cellular phenotype. In one approach the associations between DNA repair 
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SNPs and damage/repair endpoints has been studied. Initial studies using lymphocyte- 
based assays associate several variants with altered DNA-repair capacity. (Spitz, et al., 
2001) reported that variant alleles at amino acid residues 312 and 751 of XPD reduced 
repair capacity in a lung cancer cohort. Being homozygous for a variant allele in either XPC 
or XPD is associated with reduced capacity to repair UV-induced DNA damage as assayed 
by the host-reactivation assay in a cohort of healthy subjects (Qiao, et al., 2002). (Hu, et 
al., 2001) report that, in cancer-free women, the APE1 148GIu allele is associated with 
prolonged mitotic delay in lymphocytes exposed to IR. In addition, women with at least 
three variant alleles of APE1 and XRCC1, two genes of the BER pathway, have increased 
IR-induced cell cycle delay (Hu, et aL, 2001). Other studies relate repair genotypes to 
exposure biomarkers, such as DNA adducts and DNA damage. Some examples of this 
approach are the association of the variant allele of XRCC1 Arg399Gln with Increase rate 
of sister chromatid exchange (SCE), DNA adducts, and hypersensitivity to IR (Abdel- 
Rahman and EI-Zein, 2000, Duell, et al., 2000, Hu, et al., 2001, Lunn, et al., 1999, Matullo, 
et al., 2001). The variant allele of ERCC21XPD Asp312Asn was also found to be 
associated with increased UV-induced apoptosis (Seker, et al., 2001). An association has 
also been reported between the variant allele of ERCC21XPD Lys715Gln and higher DNA 
adducts or lower chromatid aberrations (Lunn, et al., 2000, Pall!, et al., 2001). In one study 
DNA-repair activity measured by poly (ADP-ribose) polymerase (PARP) activity was lower 
in breast cancer cases than study controls. Also, carrying rare PARP variants were in 
association with PARP enzyme activity (Hu, et a!., 1997). Although results from most of the 
studies suggest potential functional roles of DNA-repair SNPs, association studies cannot 
provide direct evidence for a genotype/ phenotype relationship. 
The second approach is to clone and express the protein from the wild-type and the variant 
allele and study the effect of the variant allele on the function of the protein. Only a limited 
numbers of studies have used this approach. In one study of this kind on seven 
polymorphisms of APE1 gene, a gene critical to the BER pathway, functional assays 
revealed that four (L104R, E126D, R237A, and D283G) of seven amino acid substitution 
variants exhibited - 40-90% reductions in binding or incision activity (Hadi, et aL, 2000). 
Another study showed that cells expressing the XRCC3 T241 M variant allele were active 
for HRR of double-strand breaks and not more sensitive to the interstrand cross-linking 
agent mitomycin C (Araujo, et al., 2002). The authors suggest that the increased cancer 
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risk associated with XRCC3 Thr241 Met may not be due to an intrinsic homology-directed 
repair defect. Also our collaborators showed that cells expressing the XRCC2 R188H allele 
only shows small, statistically insignificant sensitivity to MMC relative to the cells 
expressing the wild type allele (Rafii, et al., 2002). In another approach, (Ellison, et al., 
2001) targeted yeast residues for alterations that would mimic variants in the human 
population in MLH1 gene. Cells expressing variant (A41 F, G64R, 165N, E99K, 1104R, 
T114R, 0552L and R672P) MLH1 proteins, exhibited 62-130 fold higher mutation 
frequencies relative to the cell expressing the wild type allele (Ellison, et al., 2001). 
In the present study we investigated the functional effect of four naturally occurring variants 
(P199L, D213N, T241 M, T2411) of XRCC3 gene, all of them conserved between human 
and mouse. One of the variants (D213N) occurs in a highly conserved region of the 
protein, the Walker box B, and is conserved between 23 orthologues and paralogues from 
different species (SIFT online sequence alignment software). To determine the functional 
significance of these variants, first human XRCC3 was cloned and then the variant bases 
were created using site-directed mutagenesis. The human XRCC3 cDNA carrying the 
variant alleles were then transfected into CHO XRCC3 deficient cell line and the effect of 
variant alleles on XRCC3 mediated HRR was measured by evaluating resistance of 
transfected cell lines to DNA damaging agents, mitomycin-c, camptothecin and thymidine. 
Mitomycin-C induces DNA double-strand breaks (DSBs) (Natarajan, et al., 1983) and 
extreme sensitivity of XRCC3 deficient cell lines (irs1SF) to MMC has already been 
established by several reports (Cui, et al., 1999, Tebbs, et al., 1995). Camptothecin is a 
plant alkaloid that can produce DNA DSBs by inhibition of topoisomerase I (Hsiang and 
Liu, 1988)( Trumberg D, 2000). Although thymidine does not generate any detectable 
DSBs, sensitivity of XRCC3 deficient cell lines to S-phase synchronising agent thymidine 
has been shown in previous reports (Lundin, et al., 2002). 
Clones expressing P199L, T2411 and T241M variants did not show significant differences 
in the sensitivity to MMC or CPT relative to the clones expressing the wild type allele. Cells 
expressing the T2411 variant were more sensitive to MMC and less sensitive to CPT. In 
contrast, cells expressing T241M were more sensitive to CPT and less sensitive to MMC. 
The differences in MMC and CPT sensitivity between T241 I and T241 M variants is not 
surprising as it has been known for a long time that the differences in genetic makeup can 
affect individual drug response. In this regard it has recently been shown that carrying 
XRCC1 399GIn variant allele was associated with increased resistance to 5-FU/oxaliplatin 
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chemotherapy in colorectal cancer patients (Stoehlmacher, et al., 2001). In fact genetic 
variants can be used as markers of prediction of response to drug therapy in cancer 
patients if an association between a particular polymorphism and clinical response to a 
certain drug is established. To our knowledge the XRCC3 protein structure is not available 
on the database. We therefore could not study the effect of these polymorphisms on the 
protein structure. However it is possible that change in protein folding resulting from SNPs 
leads to different response to different drugs. 
The most distinctive finding in this study was that all clones expressing the XRCC3 D213N 
variant showed extreme sensitivity to MMC, CPT and thymidine, which was hardly 
distinguishable from the sensitivity of the XRCC3 deficient cell lines. This finding is 
interesting because this variant occur in highly conserved putative ATP-binding domain of 
protein, Walker box B. Although a recent study has shown that the ATPase activity of 
RAD51 is necessary for HRR in mouse embryonic stem cells (Stark, et at, 2002), it is not 
clear whether this ATPase is necessary for the function of all RAD51 paralogues in vivo. 
Also, not much is known about the function of the Walker boxes. However, various studies 
have investigated the functional significance of domains of HRR proteins by targeted 
mutation of Walker box residues that are conserved between different species. Mutations 
in the Walker A motif of ScRad5l and ScRad55 resulted in sensitivity to methylmethane 
sulphonate (MMS), ionising radiation and defect in DNA repair (Johnson and Symington, 
1995, Shinohara, eta!., 1992, Sung and Stratton, 1996). An equivalent mutation to XRCC3 
D213N variant in Walker B motif of Rhp5l (Rad5l homologue in Schizosacchromyces 
pombe) (D244Q) has been shown to produce extreme cellular sensitivity to MMS and 
radiation which is indistinguishable from the deficient cell line (Kim, et al., 2002). Also 
mutation in Walker A motif of Rhp5l has produced the same result (Kim, et at, 2002). 
However targeted mutations of conserved Walker box A of the XRCC2 and Rad57 only 
had small effects on mitomycin-c and radiation resistance of mutant cell lines (Johnson and 
Symington, 1995, O'Regan, et at, 2001). To determine the effect of XRCC3 213N variant 
in the presence of wild type allele, we also carried out dominant negative assay by 
transfecting XRCC3 D213N allele into CHO cell line AA8 and human colorectal carcinoma 
cell line SW480 which both carry wild type copies of XRCC3. However we did not observe 
any significant difference in sensitivity to MMC in strains that carry D213N alleles relative to 
the strains transfected with the wild type copy of XRCC3. Lack of dominant negative effect 
has also been seen in other mutations of Walker A/B motifs in RecA/Rad51 paralogues 
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(Johnson and Symington, 1995). Although due to unavailability of proper XRCC3 antibody 
we could not prove that the level of expression of the variant allele is the same as the wild 
type allele, assuming that the variant allele was over-expressed under the viral promoter, 
the lack of dominant negative effect in the present study suggests that normal XRCC3 
protein produced by the parental gene is sufficient for cell to repair MMC induced damage. 
To determine whether the D213N variant, with such a drastic inactivation of the protein 
function could have a role in predisposition to cancer, we screened a large number of 
cancer cases and control groups for the presence of this variant. A total of 1524 patients 
with common cancer including breast, bladder, prostate and colorectal cancer and 1577 
male and female healthy individuals were screened, two further heterozygous carriers of 
the D213N variant were identified, both of them from the control population. Although 2 of 3 
D213N carriers in the control group had a weak history of cancer in their family, we did not 
identify any cancer patient carrying this variant allele. Therefore we did not find any 
evidence on the basis of the present study to propose that the XRCC3 gene could act as a 
tumour suppressor gene. 
There is some evidence that suggests that the XRCC2 and XRCC3 genes are required for 
accurate chromosome segregation during replication (Griffin, et aL, 2000). We also know 
that correct duplication of cells depends on accurate replication of genome, repair of DNA 
damages prior to replication and precise chromosome segregation during mitosis. In this 
context, genes that are involved in repair of DNA damage, fidelity of chromosomal 
segregation and accurate replication are predicted to be of crucial importance as a 
suppressor of cancer development. Therefore it has been proposed that XRCC2 and 
XRCC3 genes could act as tumour suppressor genes on the basis of their participation in 
chromosome segregation (Griffin, et al., 2000). Two other HRR genes, BRCA1 and BRCA2 
have been identified as tumour suppressor genes that predispose to breast and ovarian 
cancer. A RAD51 mutation was identified in a bilateral breast cancer patient with evidence 
of loss of heterozygosity (Kato, et al., 2000). However no human cancer has been 
associated with mutation of RAD51 päralogues so far. 
As no data on knockout XRCC3 in mice has been published, the effect of XRCC3 
disruption on cellular viability and carcinogenesis is not fully understood. However 
embryonic lethality has seen as a result of knockout of XRCC2 and some other RAD51 
paralogues (Deans, at al., 2000, Pittman and Schimenti, 2000, Shu, et al., 1999). This 
indicates that cell death rather than proliferation may be the normal outcome of loss of 
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XRCC3 in vivo. Therefore, our data suggest that mutations in genes encoding proteins that 
are involved in the same repair pathway as BRCA1 and BRCA2 may not confer the same 
risk of cancer as do mutations in the genes for BRCA1 or 2 themselves. 
Another issue that should be addressed is that despite published positive association 
between DNA repair gene polymorphisms and increased risk of cancer, the result of these 
association studies often are not supported by the functional assays. In this context we 
found that carriage of the XRCC2 R188H rare allele is associated with increased risk of 
breast cancer, however the result of mitomycin-c sensitivity of cells expressing this variant 
was weakly different from the wild type allele. Two independent studies have also showed 
that the XRCC3 Met allele is functional (Araujo, et al., 2002, Rail, et al., 2003), despite 
reports on positive association of this allele with increased risk of breast, bladder and skin 
cancer (Kuschel, et al., 2002, Matullo, et al., 2001, Winsey, et al., 2000). The reason for 
these discrepancies between the epidemiological and functional studies is not clear. 
However given the large variation and complexity of individual genotypes for each of the 
DNA-repair pathways, it is clear that the relationship among genotype, repair capacity, and, 
ultimately, individual risk will be complex. In the end, the integrated function of the genes of 
the relevant pathways, not the variation at any one gene, will determine susceptibility to an 
exposure. Therefore the relatively low impact on cancer risk associated with one variant 
allele compared to the reduced-capacity phenotype is not unexpected. The functional 
assays integrate the impact of a whole pathway, while molecular epidemiological studies 
genotype for only 1 or 2 from among lots of variants expected among the 10-20 genes in 
each repair pathway. The small adverse effect of one polymorphism on one protein of a 
repair pathway therefore can be compensated by other proteins of the pathway or the 
effect could be weak and undetectable by some assays. In addition, in the functional 
studies of XRCC2 and XRCC3 polymorphisms, due to unavailability of human XRCC2 and 
XRCC3 deficient cell lines, deficient CHO cell lines were used to study the effect of human 
XRCC2 and XRCC3 variant alleles. The interspecies differences, however small, can 
potentially mask any weak effect arising from a single base pair substitution. While we 
need more accurate assays to study the functional effect of single base substitutions, 
independent replication of association studies in bigger sample size groups is also required 
to ensure a real association between SNPs and cancer. 
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6.4. Concluding remarks and future directions 
The results from this study and other independent studies suggest that variants of HRR 
genes that are involved in repair of DNA DSBs are weakly associated with increased risk of 
breast cancer (Healey, et al., 2000, Kuschel, et al., 2002, Rafii, et al., 2002). Moreover 
when the combinatory effect of these variants is studied they may confer even greater risk 
of developing breast cancer. Although before any definite conclusion is taken, the result of 
these studies should be replicated by independent studies in different populations, more 
evidence now is in favour of participation of HRR genes as low penetrance cancer 
susceptibility genes. The present study also suggests that instead of looking at the one 
gene, one outcome hypothesis, studies should be designed to answer the question of how 
collections of genes, either alone or in combination, contribute to complex diseases like 
breast cancer. Although there are different repair pathways for repairing different types of 
DNA damage, there is no clear cut border between different repair pathways in vivo. 
Repair of DNA damage may be the result of interaction between many proteins and 
enzyme from different repair pathways. In this regard investigating pathways of genes in 
large association studies could provide invaluable information of biological pathways as 
well as estimation of penetrance or disease association. In other words, the search should 
not be confined to identifying more genetic markers, but also for the biological significance 
of the markers. No single study is definitive, each has its own limitations, and all results 
should be replicated in different population. Only the combined consideration of studies in 
different populations replicating similar data will result in the belief that a candidate gene 
polymorphism is indeed a cancer risk factor. The average sample size of most of current 
case-control studies for genetic polymorphisms is 150-350 cases and similar number of 
controls which is appropriate for detecting common (>5%) SNPs with OR of -2 (Brennan, 
2002). However this sample size does not provide enough power to detect smaller odds 
ratio or less common SNPs. Since collecting enough samples to generate big association 
studies may not be feasible particularly in less common cancer, multicentre collaborations 
will provide enough samples size and adequate power to detect weak effect that has been 
observed for these alleles. Also the results of all genetic association studies should be 
published in a format that allows pooling with similar studies. All SNPs should be publicly 
available and to avoid bias the result of negative finding should be published as well as 
positive associations. At this time positive results are more likely to be published than 
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negative findings because investigators only submit and journals are keener to accept 
positive findings. 
Collecting accurate data on environmental exposure will also allow us not only to evaluate 
the effect of gene-environment interaction in cancer predisposition, but also to find 
subgroups who are genetically more sensitive to one special environmental exposure. 
Studies that concentrate on analysis of interaction between genetic effects and particular 
exposure require significantly larger sample size to have enough power to detect such 
interactions. 
Although there is a crucial difference between looking at a SNP as a susceptibility factor in 
the general population and in a population at risk, identifying more genetic markers will 
hopefully allow medicine to specify population at risk and eventually create a profile of 
biomarkers for susceptibility to diseases. Genetic variation may even be used as a tool to 
select optimal therapy, tailor dosage regimens, and improve clinical outcomes. 
The present study suggest that ATP binding domain Walker B box may be important for 
DNA repair activity of XRCC3. Therefore the effect of XRCC3 D213N variant on the 
ATPase activity, RAD51 focus formation following DNA damage and HRR capacity may be 
considered as fields of future studies. 
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approval from the Ethics Committee. 
3. That should any untoward event occur during the-conduct of the 'study the Chairman of the 
Committee or failing this the Administrator should be informed immediately. 
4. Reports of progress shall be submitted at yearly intervals. A follow-up form will be sent to 
you annually to keep the Ethics Committee informed of the progress of the project. " 
5. The Ethics Committee is to be advised if the project has not commenced within six months. 
6. No deviations from or changes of the protocol will be initiated without prior written approval 
of an appropriate amendment, except when necessary to eliminate immediate hazards to the 
subjects or when the change(s) involve only logistical or administrative aspects of the trial. 
7. That you should promptly report any changes increasing the risk to subjects; adverse drug 
reactions or new information that may affect adversely the safety of the subjects or conduct of 
. the trial. 
8. That you familiarise yourself with the ICH Guidelines laid down for the conduct of human. 
experiments. - 
9. The Ethics Committee is to be advised when the project is completed. 
Yours sincerely 
Pete J kson 
Cha an 
C' l: laura,. 9SIet'2azmy_137. duc 31/07198 
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